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Abstract 
 
Background 
 
Systemic AL amyloidosis is a rare complication of immunoglobulin light chain 
secreting B cell clonal disorders. Much progress has been made in the recent 
years in the management of AL amyloidosis. Yet, certain patient groups 
continue to fare badly, posing a challenge to the treating physicians. 
 
Aims  
 
To describe the clinical features and outcomes of the challenging subgroups of 
patients with AL amyloidosis such as elderly patients and those with rare 
subtypes – IgD and IgM related amyloidosis. To explore the role of 99mTc-DPD 
scintigraphy in imaging soft tissue AL amyloid deposits and look at possible risk 
stratifying methods based on plasma cell phenotype and serum clonal markers 
at presentation. To evaluate the effectiveness of the novel agent, bortezomib as 
front line therapy in AL amyloidosis.   
 
Results and Conclusion 
 
Treatment of systemic AL amyloidosis in the elderly is challenging, yet, 
treatment of carefully selected older patients with novel therapies with low 
toxicity profile, results in improved survival.  
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The clinical profile of IgD amyloidosis is similar to that of AL in general 
but the long term outcome appears poor.  In contrast, IgM related amyloidosis 
has some distinct features and the underlying B cell clone needs to be 
accurately characterised to direct the choice of therapy. The adverse outcome 
in this latter group appears to be associated with cardiac, liver and nerve 
involvement.  
The role of 99mTc-DPD scintigraphy in imaging soft tissue AL amyloidosis 
is promising and requires further studies. Multicolour flow cytometry and heavy 
light chain measurement seem valuable in assessing the impact of plasma cell 
clones and degree of immunosuppression on prognosis respectively.  
Bortezomib based treatment is effective in achieving deep clonal 
response in patients without cardiac amyloidosis and those with early disease. 
Those with advanced cardiac involvement continue to pose a challenge and are 
in need of more effective therapies. 
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Chapter One: Introduction 
 
This chapter is written in the context of two of my publications:  
Imaging in systemic amyloidosis. Sachchithanantham, S., & Wechalekar, A. 
D. (2013). Review article. Br Med Bull. 2013;107:41-56. Copyright permission 
obtained from Oxford University Press, licence no. 4036760241088 for use in 
my thesis  
An evaluation of current treatment options for AL Amyloidosis - Review 
article. Sachchithanantham, S., & Wechalekar, A. D. and Hawkins, P. N. Expert 
opinion in orphan drugs. 2014:2 (3) pp. 229-244. Copyright permission obtained 
from publisher for use in my thesis.  
 
What is Amyloidosis? 
Amyloidoses are a heterogeneous group of diseases resulting from unstable 
circulating proteins which give rise to extracellular deposition of insoluble 
amyloid fibrils. The condition leads to gradual tissue destruction and eventual 
organ dysfunction.  Amyloid deposition can occur in any organ: heart, lungs, 
liver, kidneys, skin, bones, peripheral or autonomic nerves are commonly 
involved.  There are currently over 30 different proteins known to cause 
amyloidosis (Table 1.1).1  Amyloidosis can be classified in several ways; 
hereditary or acquired, by means of the precursor proteins and the distribution 
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of amyloid deposits (localised or systemic).  The natural history and outcome 
are dependent on the amyloid fibril type and anatomical distribution.  
 
Amyloid fibril and fibrilogensis 
The molecular structure of amyloid fibril and the mechanism underlying its 
formation are not completely understood. Despite having heterogeneous 
structures and functions, all amyloid proteins can generate morphologically 
indistinguishable amyloid fibrils.2  In the light-microscope amorphous and 
homogenous amyloid, irrespective of type, consists of fine, 10nm thick fibrils.3 
Other constant components include proteoglycans (especially heparin 
sulphate), the glycoprotein serum amyloid P component (SAP), apolipoprotein 
E, laminin and Collagen IV.4  The protein monomers in amyloid are bound to 
each other by hydrogen bonds to a very stable intermolecular β-sheet.  It is this 
characteristic β pleated sheet configuration that produces apple green 
birefringence under polarised light when stained with Congo red dye. The 
protein monomers are orientated perpendicularly to the fibril axis forming a thin 
filament.  Several filaments then twist around each other to form a definite 
amyloid fibril. This structure is shared by all types of amyloid despite the high 
diversity between amyloid fibril proteins.5 
In vivo there are a limited number of proteins which are able to form 
amyloid fibrils.  One crucial component is the β-structure, either present in 
normal folded state of the amyloidogenic protein or acquired during 
amyloidogenesis.  Examples of proteins with β-structure in their normal folded 
state include β-2 microglobin, immunoglobulin light chains and transthyretin.6-8 
Chapter 1 
26 
 
Other proteins such as apolipoproteins, including serum amyloid A protein 
(SAA) have comparatively little β-structure in their normal folded state and 
undergo α-helix to β sheet conversation.9  A number of factors affect the 
conformational transition from a native protein into pathological aggregates.  
The main factors include: high concentration of normal proteins such as that 
seen with SAA in chronic inflammatory conditions predisposing to AA 
amyloidosis; the protein’s intrinsic propensity to assume pathologic 
conformation that become evident with aging as seen with transthyretin in senile 
systemic amyloidosis (ATTRwt); and mutations as occurs in hereditary 
amyloidosis where the substitution of a single amino acid transforms a normal 
protein into an amyloidogenic one such as in transthyretin (ATTR), fibrinogen α 
chain (AFib), apolipoprotein A1 (AApoAI) and lysozyme amyloidosis (ALys).10  
Physiologic mutations that occur during immune response in the variable 
domains of immunoglobulin light chains can sometimes affect critical structural 
sites and destabilise the domain favouring the generation of an aggregation 
prone  state as seen in AL amyloidosis.11, 12  
 
Amyloid deposition and degradation 
The distribution of amyloid deposits in organs varies significantly between 
amyloid fibrils.  Fibrinogen α chain predominantly aggregate in the kidneys, 
transthyretin Met30 variant in peripheral nerves and β2-microglobulin in joints 
and light chain amyloidosis can involve any organ but the brain.  In hereditary 
amyloidosis, there may be further phenotypic variation within the same families 
with a specific genetic mutation.  The site of deposition may depend on the 
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coexistence of several factors favouring the formation of fibrils, such as local 
protein concentration, a low pH and other factors.13  For example, in AL 
amyloidosis, recognition of particular tissue constituents (i.e., collagen) by 
amyloidogenic light chains may determine the specificity of tissue deposition.
 The mechanism by which amyloid formation results in tissue damage 
and organ dysfunction is not well understood and is believed to be beyond 
mechanical replacement of parenchymal tissue by large amounts of amyloid 
deposits.  Some studies suggest that in ATTR amyloidosis, it is the prefibrillar 
oligomers, rather than the fibrillar form, as the major pathologic species.14, 15  
Others have demonstrated direct cytotoxicity of amyloidogenic immunoglobulin 
light chains in AL amyloidosis, especially in cardiac cells.16  This hypothesis is 
supported by improvements in cardiac function after arresting the production of 
amyloidogenic light chains with chemotherapy but before any evidence of 
improvement in myocardial amyloid deposits on echocardiogram.17  The degree 
of cytotoxicity and tissue dysfunction caused by the amyloid deposits or 
prefibrillar aggregates may vary between types of amyloidosis and involved 
organs.  
Amyloid formation, deposition and tissue damage occurs in the presence 
of high levels of circulating amyloidogenic proteins.  Organ dysfunction can be 
halted or reversed if the production of the precursor protein is suppressed.18, 19  
This is based on the principle that oligomers form at a certain threshold and that 
reducing the concentration of the amyloidogenic protein without the need to 
eliminate it, will promote the resorption of amyloid deposits.  The exact 
mechanism of amyloid resorption is still unclear.  It has been postulated that 
macrophages may have a role in amyloid regression.  Studies of Amyloid-β 
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immunotherapy suggest phagocytosis may have a role but that only when 
additional production of Aβ is arrested can it make an impact on amyloid 
burden.20  The heterogeneity in the rate of regression of amyloid amongst 
patients despite complete suppression of amyloidogenic precursor protein may 
be explained by variation in phenotype and function of macrophages and 
monocytes.   
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Table 1.1 Classification of Amyloidosis by implicated precursor proteins and 
distribution  
Amyloid type / 
Fibril protein 
Precursor Acquired 
or 
Hereditary 
Systemic / 
Localised 
Clinical Syndrome 
Immunoglobulin 
light chain (AL) 
Monoclonal 
immunoglobulin 
light chains 
A S, L Associated with 
monoclonal plasma 
cell dyscrasias 
Immunoglobulin 
heavy chain (AH) 
Monoclonal 
immunoglobulin 
heavy chains 
A S, L Associated with 
monoclonal plasma 
cell dyscrasias 
Reactive 
amyloidosis (AA) 
Serum amyloid A A S Associated with 
chronic inflammation, 
infection, or certain 
neoplasia 
Β2-microglobulin 
(Aβ2M) 
Β2-microglobulin, 
wild type 
A L Associated with 
chronic 
haemodialysis 
(affects 
Musculoskeletal 
system) 
Senile systemic 
amyloidosis 
(ATTRwt) 
Transthyretin, wild 
type 
A S Age-related, usually 
males (primarily 
cardiac involvement) 
Transthyretin 
amyloidosis 
(ATTR) 
Transthyretin, 
Variant, > 100 
amyloidogenic 
mutations 
H S PNS, ANS, Heart, 
eye, leptomen 
Fibrinogen 
amyloidosis (AFib) 
Fibrinogen  α 
chain, variant 
H S Primarily kidneys  
Apolipoprotein A-I 
(AApoAI) 
Amyloidosis 
Apolipoprotein A-I, 
variants 
H S 
 
Heart, liver, kidneys, 
skin, 
larynx, testes 
Apolipoprotein A-II 
(AApoAII) 
Apolipoprotein A-
II, variants 
H S Kidneys 
ALys Lysozyme, variant H S Kidney, liver, spleen 
AGel Gelsolin, variant H S Cranial nerve 
involvement with 
lattice corneal 
dystrophy 
ACys Cystatin C, variant H S Icelandic hereditary 
cerebral amyloid 
angiopathy 
ALect 2 Leukocyte 
chemotactic factor 
2 
H S Slowly progressive 
with kidney and liver 
involvement 
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Types of Amyloidosis  
Systemic amyloidosis  
The systemic amyloidoses affect various organ systems and are caused by a 
number of precursor proteins as listed on Table 1.2.  
Table 1.2 Typical organ involvement in various types of systemic amyloidosis.21 
Type of 
amyloidosis 
Cardiac Renal Liver/GI 
tract 
PNS Soft tissue 
AL      
Hereditary ATTR  Uncommon     
ATTRwt      
AA Uncommon     
AFib Uncommon     
AApoA1      
ALys     Uncommon 
AGel  Uncommon    
 
The International Society of Amyloidosis has devised a nomenclature 
based on the nature of the main protein that constitutes the amyloid fibril.  The 
fibril proteins involved in the main forms of systemic amyloidosis are designed 
as follows: AL is the protein derived from immunoglobulin light (L) chains; AA 
the fibril protein derived from the acute phase protein SAA; and ATTR the fibril 
protein derived from the plasma protein transthyretin. Systemic light chain (AL) 
amyloidosis is the most common of these conditions, but ATTRwt cardiac 
amyloidosis is increasingly being diagnosed. 
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AL Amyloidosis 
Immunoglobulin light chain (AL) amyloidosis is the most common of the 
systemic amyloidosis. It is characterised by the deposition of amyloid fibrils 
derived from the aggregation of misfolded, kappa or lambda monoclonal 
immunoglobulin light chains.22  The abnormal folding results from either a 
proteolytic event or an amino acid sequence which renders a light chain 
thermodynamically unstable and prone to self-aggregation. The aggregates 
form protofilaments that associate into amyloid fibrils.23  The light chains are 
produced by a B-cell clone, which in the majority of cases is a plasma cell 
clone. In a few patients, however, the amyloid deposits have been reported to 
contain immunoglobulin heavy chains and are therefore termed H chain type 
amyloidosis (AH).  It is the toxic products of the B-cell clone rather than its 
malignant behaviour that are thought to be responsible for the fatal 
consequences of AL amyloidosis.  The actual mechanism whereby amyloid 
deposits produce organ dysfunction remains unclear but theories include two 
main mechanisms, firstly via disruption of tissue architecture from the 
accumulation of amyloid fibrils and secondly through direct toxicity of the pre-
fibril oligomers.24  
The incidence of AL amyloidosis is around five to twelve people per 
million person-years, although autopsy studies suggest that the actual 
occurrence might be higher.25  The median age at diagnosis is 63 years, and 
median survival if left untreated is 12 months.26  
AL amyloidosis can affect any organs apart from the central nervous 
system.  Patients usually present with a wide range of symptoms that are often 
mimicked by more common disorders, which, inevitably leads to delayed 
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diagnosis in the absence of high grade of suspicion.  Kidneys and the heart are 
the most commonly affected organs.27, 28  Amyloid deposits in the heart result in 
restrictive cardiomyopathy. Heart failure is a rapidly progressive complication.28  
Symptoms are those of congestive cardiac failure, most commonly 
breathlessness.29  Renal involvement usually presents with nephrotic syndrome 
and worsening renal function. Severe cases of amyloid infiltration of the liver 
sinusoids result in liver failure. AL amyloidosis also affects both the autonomic 
and peripheral nervous system.  Involvement of the former results in orthostatic 
hypotension and symptoms due to delayed gastric emptying and impaired 
intestinal motility.  Patients also suffer from erectile dysfunction. Peripheral 
nervous system involvement causes bilateral, distal, symmetrical, painful 
sensory symptoms before progressing to motor neuropathy.  Orthostatic 
hypotension can also be secondary to intravascular depletion in nephrotic 
syndrome and is a common feature in cardiac amyloidosis.  Soft tissue 
infiltration may manifest in a number of ways, including macroglossia, carpal 
tunnel syndrome, skin nodules, arthropathy, alopecia, nail dystrophy, 
submandibular gland enlargement, periorbital purpura and hoarseness of voice.  
Macroglossia and periorbital bruising are hallmarks features of AL amyloidosis, 
although rare.  Amyloid infiltration of the thyroid and adrenal glands are rare and 
result in hypothyroidism and hypoadrenalism respectively.27  Patients can also 
develop acquired factor X deficiency30, 31 which can be a hindrance to 
performing biopsies necessary to confirm the diagnosis.  The exact mechanism 
of factor X deficiency is unclear but include adsorption on amyloid fibrils, 
synthetic dysfunction due to liver involvement and vitamin K deficiency.32, 33  
Although baseline factor X levels are not predictive of bleeding risks34, factor X 
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assays are important in patients with abnormal clotting at baseline and for 
monitoring response to replacement and treatment of AL amyloidosis. 
The survival of AL amyloidosis has improved over time, with maximum 
improvement over the last decade attributable to better supportive care and 
novel chemotherapeutic agents.  Mayo clinic reported an improvement in the 
four year overall survival (OS) from diagnosis during each decade between 
1977 and 2006.  The four year survival between 2003-2006 was 42% compared 
to 30% between 2000-2002 and 21% between 1977-1986.  Interestingly, the 
one year mortality during this 30 year period remained high.35 
 
IgM-related AL amyloidosis 
The majority of patients with AL amyloidosis have an underlying plasma cell 
dyscrasia (PCD), but in 5-6% of patients, the underlying clone is of 
lymphoplasmacytic (LPL) origin producing an IgM paraprotein.  The level of 
bone marrow infiltrate can be very subtle in these patients, making the detection 
of the underlying clone challenging at times.  Traditionally patients with IgM-
related AL amyloidosis have been treated similarly to those with underlying 
PCD, but in recent years, treatment has been tailored to the differing nature of 
the underlying B cell disorder.  Currently, patients with IgM-related AL 
amyloidosis on a background of an underlying LPL, are treated with a rituximab 
based therapies similar to those use in low grade non-Hodgkin’s lymphomas. 
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AA Amyloidosis 
The amyloid fibrils of AA amyloidosis are composed mainly of the serum 
amyloid A (SAA) protein.  SAA is usually present at low levels in serum and is 
synthesised by hepatocytes in response to various pro-inflammatory 
cytokines.36  Persistently elevated levels of SAA is essential for the 
development of AA amyloidosis but only a small number of patients with 
inflammatory conditions eventually develop amyloidosis.37  The estimated global 
incidence of AA amyloidosis in the UK is one case per million person-years.38 
AA amyloidosis most commonly affects the kidneys. The earliest clinical 
manifestation is proteinuria, which eventually leads to nephrotic syndrome and 
renal insufficiency.  Proteinuria may be present in up to 95% of patients and 
determines prognosis.39  Other commonly affected organs are liver, spleen and 
gastrointestinal tract, usually without any clinical significance in the early stages.  
Splenic involvement is demonstrable on SAP scintigraphy in almost all patients 
with AA amyloidosis.  AA amyloidosis is rarely known to affect the heart, cause 
soft tissue infiltration or peripheral neuropathy.  
Common therapeutic approaches are limited in AA amyloidosis due to 
the diversity of the underlying conditions that can cause the disease.  Complete 
suppression of inflammation with SAA concentration persistently <5mg/L, can 
lead to regression of amyloid deposits and preservation of renal function.   
The use of intensive treatment protocols and the availability of biologics 
have essentially modified the natural history of inflammatory joint disease in 
developed countries. 
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Wild type transthyretin amyloidosis or Senile Systemic Amyloidosis 
Wild-type transthyretin amyloidosis invariably affects older patients. Hence, it is 
also known as senile systemic amyloidosis and is a slowly progressive disease. 
The amyloid fibril is composed of normal wild-type transthyretin.40  The true 
incidence of clinically significant myocardial deposits of ATTRwt remains 
unknown.  Its prevalence increases with age and has a male preponderance. 
The burden of disease is likely to become an increasing problem as the 
population demographic shifts toward the elderly in the current era of 
sophisticated cardiac imaging techniques such as cardiac magnetic resonance 
(CMR).41  The heart is the most predominantly involved organ but deposits are 
also seen in other sites with limited clinical significance.42  Heart failure is the 
most predominant presenting feature.43  Patients with ATTRwt are reported to 
have greater left ventricular (LV) wall thickness than those with cardiac AL and 
hereditary TTR amyloidosis.44  99m-technetium-3,3,-diphosphono-1,2- 
propanodicarboxylic acid (99mTc-DPD) scintigraphy has been shown to be a 
sensitive imaging technique in diagnosing cardiac ATTR amyloidosis.45  
The principle of current management is mainly supportive with emphasis 
on heart failure symptoms involving meticulous fluid balance control, aided by 
heart failure team and management of arrhythmias.  
 
The Hereditary Systemic Amyloidoses  
Hereditary amyloidoses are rare and result from mutation in genes encoding 
variant proteins giving rise to new proteins with amyloidogenic properties.  All 
types of hereditary amyloidosis are dominantly inherited but many patients have 
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no obvious family history.  Age of onset, disease penetrance and phenotype 
vary between different mutations and even within families, posing a challenge 
for genetic counselling.   
Hereditary amyloidoses can be divided into neuropathic and non-
neuropathic forms.  Clinically, the syndrome maybe indistinguishable from AL 
amyloidosis. The non-neuropathic forms include AFib amyloidosis, AApoAI, 
AApoAII, and ALys amyloidosis.  This group of diseases typically present with 
renal dysfunction in association with involvement of various other organ 
systems.46-48  Other hereditary forms of amyloidosis include cystatin C (ACys) 
and β-2-microglobulin (β2M) amyloidosis. The neuropathic hereditary systemic 
amyloidoses comprise the Familial Amyloid Polyneuropathies (FAP), commonly 
caused by mutations in the transthyretin gene (ATTR) and rarely AGel 
amyloidosis. Patients with hereditary ATTR amyloidosis present with 
neuropathy and cardiomyopathy, although renal amyloid deposits occasionally 
associated with end stage renal disease (ESRD), maybe present.49  Patients 
with AGel amyloidosis present with cranial neuropathy.  
The mainstay of diagnosing the hereditary amyloidosis is DNA testing. 
The choice of the gene to sequence is guided by the clinical presentation and 
the results of histology and immunohistochemistry where available.50  The 
diagnosis of a hereditary form of amyloidosis with its implications for future 
generations can be devastating news to the patient.  Therefore, genetic 
counselling is of great importance in hereditary amyloidosis. 
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Localised AL amyloidosis 
In localised amyloidosis, the amyloid deposition is confined to a specific organ 
or site.  The commonest reported localised amyloidosis is AL type and is 
characterised by localised growth of monoclonal plasma cells.  This is not part 
of a systemic AL amyloidosis where the amyloid light chains are produced by 
bone marrow.  Infiltration of plasma cells has been observed near localised 
amyloid deposits suggesting local production of the amyloid fibril precursor 
protein.51  It can appear almost anywhere.52-56  The commonly reported sites 
include the urinary tract (bladder, urethra and ureter) and the respiratory tract 
(larynx and tracheobronchial tree).57, 58  Unlike in systemic AL amyloidosis, the 
clinical consequence of localised type is determined by the site and the extent 
to which the amyloid fibrils are deposited – typically causing problems due to 
mechanical obstruction.  Localised amyloidosis rarely progresses to become 
systemic.  It has an excellent prognosis with no apparent effect on life 
expectancy.52  The condition, may, however, cause substantial morbidity and 
affect quality of life due to complications such as haemorrhage and dyspnoea.  
The management of localised amyloidosis is determined by the site 
involved and the symptoms experienced by the patient.  Treatment is mainly 
localised and in most cases experimental due to the paucity of localised 
amyloidosis and diversity of affected sites.  It is very rarely that patients with 
localised amyloidosis require systemic chemotherapy.52 
Although, localised amyloidosis rarely evolve to a systemic form, patients 
should undergo long term follow-up in order to monitor the localised disease 
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and for the early detection of any systemic manifestations leading to prompt 
treatment.52, 58  
 
Diagnosis of AL amyloidosis  
 
Histology - Typing Amyloid deposits 
Correctly identifying the amyloid type is vital, as it has a major impact on 
prognosis and dictates treatment.  The amyloid fibril type is difficult to deduce 
clinically in any given patient as the clinical presentations are similar for the 
various types of amyloidosis.  Biopsy followed by Congo red staining under 
polarised light and immunohistochemistry is the gold standard for diagnosing 
and typing amyloid.59  Majority of patients have one or more organ involvement, 
and biopsies of clinically involved organs such as kidneys, endomyocardium 
and liver are invasive and have high risk of post procedure haemorrhage.60  The 
bleeding risk after liver biopsy is 2%.61  Biopsy proof of amyloid at an alternate 
site such as subcutaneous fat, bone marrow, rectum, labia minor, or salivary 
gland biopsy carry a lower risk and can be helpful in diagnosing amyloid.  
Amyloid deposits can be identified in 85% of patients with a combination of 
bone marrow and abdominal subcutaneous fat aspiration.62  Biopsy of the 
suspected affected organ may become necessary when both the bone marrow 
and fat biopsy fail to identify amyloid deposits. 
Fibril type is most commonly confirmed with immunohistochemistry.  
High background staining makes this unreliable in a third of patients with AL 
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amyloidosis.63  Another problem is two potential precursor proteins coexisting in 
a patient, making it clinically perplexing to elicit the type of amyloidosis present.  
This is particularly relevant in the African-American population, who have higher 
rates of monoclonal gammopathies and 4% carry a variant of transthyretin 
(Val122Ile), and in elderly men, who also have higher rates of both monoclonal 
gammopathies and can develop wild-type ATTR amyloidosis in the heart.50, 64  
In these cases, patients almost always have one type of amyloid causing the 
disease, and confluent risks exist for both doctor and patient.  A tissue biopsy, 
often endomyocardial, is critical in this situation.  It is also important to exclude 
secondary or hereditary amyloidosis as PCD maybe an incidental finding.  
Recent advances in diagnostic testing such as mass spectrometry can help 
identify the type of amyloidosis with high reliability and accuracy.  Amyloid fibril 
typing can also be performed on immune-electron microscopy which is highly 
specific but has limited availability.65 
 
Mass spectrometry 
Laser microdissection of the Congophilic deposits followed by mass 
spectrometry (LMD/MS) with customized bioinformatics assessment of the 
constituents may enable precise identification of type in over 98% of cases.66   
LMD/MS is specifically indicated for typing in any case where the 
immunohistochemistry is unrevealing and may be particularly useful in cases in 
which two potential amyloid precursor proteins are present in a patient.  A 
critical feature of LMD/MS is that it captures all of the chaperone and fellow-
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traveller elements in amyloid deposits, as well as the identity of the protein in 
the fibrils.   
 
DNA analysis 
The clinical features in hereditary systemic amyloidosis may be 
indistinguishable from those in AL amyloidosis.  DNA analysis helps 
differentiate between the two. Hereditary amyloidoses are autosomal dominant 
conditions but a family history of amyloidosis may be absent due to incomplete 
penetrance.  Consequently, occasionally, new variants and new amyloidogenic 
proteins are identified.  There should be a low threshold for sequencing the TTR 
gene in patients with polyneuropathy and/or amyloid cardiomyopathy as 
hereditary ATTR amyloidosis presents with similar phenotype.  Likewise, 
hereditary AFib amyloidosis should be considered in any patients with isolated 
renal involvement.  Once the gene defect is identified, screening and 
counselling must be offered to relatives.67  Patients with AL amyloidosis may 
occasionally have an incidental mutation therefore genetic results must be 
interpreted in the context of clinical and histological findings.50, 68  DNA analysis 
is also essential in patients with systemic amyloidosis whose fibril type cannot 
be confirmed by immunohistochemistry or mass spectrometry. 
 
Assessment of Organ Function 
Amyloidosis can be either localised or systemic; therefore, on confirming the 
presence of amyloid deposits, it is imperative to investigate the distribution of 
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the amyloid deposits and severity of organ involvement.  Assessment should 
also include prognostic stratification as this guides treatment.  Figure 1.1 shows 
an algorithm for evaluating patients with suspected amyloidosis. 
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Figure 1.1 Algorithm of investigation of patients with clinical suspicion of 
amyloidosis.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical features suspicious of 
amyloidosis 
Serum and urine immunofixation and 
serum free light chain assay 
Negative Positive 
Obtain tissue for confirmation of 
diagnosis: Fat aspirate and Bone 
marrow specimen for Congo red 
staining 
Positive Negative 
~15% likelihood of amyloidosis. 
Organ biopsy warranted if high 
clinical suspicion 
Refer to specialist centre for: 
 Assessment of distribution 
(Localised or systemic) 
 Exclusion of Non-AL 
amyloidosis 
Assess extent of organ involvement: 
 NT-proBNP, Troponin T , 
Echo, ECG +/- CMR 
 24 hour urine proteinuria, 
renal function and albumin 
 LFTs 
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Biochemical analysis  
The first international consensus opinion for the definition of organ involvement 
and response to treatment was published in 2005.69  These criteria were 
recently updated and form the basis for data collection and reporting, including 
clinical trials.70  In addition to biopsy confirmation of the suspected organs 
where necessary, clinical and biochemical evidence of organ dysfunction form 
the mainstay of definition of organ involvement. 
 The extent of cardiac involvement is the major determinant of outcome in 
AL amyloidosis.  Approximately 60% of patients with AL amyloidosis present 
with heart involvement, and about 80% die a cardiac death.71  The degree of 
cardiac damage determines survival and treatment tolerability.  The definition of 
cardiac involvement has been better defined with the introduction and wide 
availability of cardiac biomarkers: serum troponin T and N-terminal pro 
natriuretic peptide (NT-proBNP).  Troponin I or T provides a quantitative 
assessment of cardiac damage and BNP and/or NT-proBNP indicate 
cardiomyocyte stress and higher levels are independently associated with 
poorer survival.72  The Mayo staging system73  using NT-Pro BNP (0.332ng/L) 
and cardiac troponin-T (cTnT)/troponin-I (cTnT 0.035mcg/mL; cardiac troponin-
I, 0.1 ng/mL) is the most robust and widely used method for risk stratification.  
Patients are categorised into three stages.  Patients with stage III disease have 
the poorest prognosis with a median survival of 3.5 to 8 months.73-75  This 
staging system is important for clinical management, but also for stratifying 
patients enrolled on clinical trials.  As these markers are elevated in chronic 
kidney disease and other cardiac conditions, they should be interpreted with 
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caution.  In patients with renal dysfunction with eGFR <30ml/min, Mayo staging 
is not directly applicable.  
 Renal involvement and the degree of dysfunction are best evaluated by 
eGFR and albuminuria.  Disease progression can be monitored with 
quantification of 24-hour urine protein loss.  The urine protein is predominantly 
albumin, unlike in multiple myeloma (MM) where large amount of 
immunoglobulin light chains are excreted.  Other causes of albuminuria should 
be excluded and approximately 10% of patients present with renal dysfunction 
and non-nephrotic range proteinuria.76 
 In addition to non-tender hepatomegaly, liver function tests are useful to 
document involvement.  Damage due to hepatic amyloid is usually obstructive 
in nature and should be suspected in patients when serum alkaline 
phosphatase value is 1.5 times the upper limit of the institutional normal value.  
However, significant amyloid infiltration of the liver would have occurred by this 
time.  An obstructive liver dysfunction and hepatomegaly may also be due to 
right heart failure from cardiac amyloidosis. 
 
Imaging  
SAP Scintigraphy  
SAP is a non-fibrillar glycoprotein of the pentraxin family and binds amyloid 
independently of the protein of origin.  It has a specific binding motif for the 
common conformation of amyloid fibrils.  The binding of SAP is reversible and 
calcium dependent.  This property makes radiolabelled SAP a diagnostic tool 
for the imaging of amyloid deposits.77  SAP in circulating plasma is in constant 
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equilibrium with SAP in the amyloid deposits.  Pepys and Hawkins developed 
the theory of using radiolabelled (123I) SAP as a tracer imaging for amyloid 
deposits.77, 78  When injected radiolabelled SAP localises rapidly and specifically 
to amyloid deposits in proportion to the quantity of amyloid deposited.  The dose 
of radiation is small and comparable to a plain X-ray of the lumbar spine.78  A 
number of studies over the years have confirmed that this is a safe and non-
invasive technique providing information on the presence, distribution and 
extent of amyloid deposits of all types and its utility in monitoring of treatment 
responses.79  SAP scintigraphy is reported to have 90% sensitivity in AA and AL 
amyloidosis.80  
SAP scintigraphy enables identification of amyloid deposits78  in the liver, 
kidneys, spleen, adrenal glands and bones.  It is valuable in identifying amyloid 
deposits in organs that have not been suspected clinically (e.g. liver or 
adrenals) and in anatomic sites that are not available for biopsy (e.g. spleen).  
SAP scintigraphy will identify liver involvement in over 30% of cases not 
detected by standard tests of liver function or size (Figure 1.2).81  The patterns 
of organ involvement on SAP scintigraphy may give clues to, but is not 
diagnostic of, the amyloid fibril type since there is considerable overlap in the 
patterns of organ involvement.  Significant uptake in the bones is a feature 
almost unique to AL amyloidosis.78 
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Figure 1.2 Whole body 123I-SAP scintigraphy; a) Anterior and posterior whole 
body scan in a patient with AFib hereditary amyloidosis.  Amyloid deposits are 
present in the spleen (solid blue arrow) and kidneys (red dotted arrow) (seen 
more clearly on the posterior scan); b) Anterior and posterior whole body scan 
in a patient with AL amyloidosis.  Amyloid deposits are present in the liver (red 
dotted arrow) and the spleen (solid blue arrow).  There is also uptake in the 
bones which is rarely seen in other types of systemic amyloidosis.  The large 
amyloid deposits in the liver obscure the visualization of kidneys and adrenal 
glands on planar imaging.82 
a) 
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b) 
 
 
Scintigraphic estimation of whole body amyloid load can provide 
information on prognosis.83  AL amyloidosis patients with a large amyloid load 
have a higher risk of complications associated with chemotherapy, peripheral 
blood stem cell or solid organ transplantation.84, 85  
Serial SAP scintigraphy is a useful guide to monitor 
regression/progression of amyloid deposits - thereby, confirming adequacy of 
therapy or identifying the need for further therapy. This is useful in all types of 
systemic amyloidosis including patients with AA,86 AL,87 Ab2M,88 AFib89 and 
AApoA190 of amyloidosis.   
The limitations of 123Iodine labelled SAP scintigraphy include the cost of 
123I, availability of SAP (a purified virally inactivated plasma derived 
component), inability to image diffuse, hollow or small structures such as skin, 
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gastrointestinal tract or nervous system and most importantly, its inability to 
image the heart.  There are many plausible factors that may account for this 
major limitation, including movement artefact, ventricular blood-pool content, 
and possibly the most important factor being a lack of a fenestrated 
endothelium in the myocardium, hindering access of the large 127kDa SAP 
molecule to the amyloidotic interstitium within the available timescale of the 
short half-life of 123I isotope.80 
Currently, 123I-SAP-scintigraphy remains the best and only modality in 
routine clinical use for assessing the extent and distribution of amyloid 
deposition in all types of systemic amyloidosis.78  It is part of routine clinical 
practice at the UK national amyloidosis centre for in-vivo imaging of amyloid 
deposits.  It is also available in the University Medical Centre, Groningen (the 
Netherlands). 
 
Echocardiography  
Echocardiography has been used for the diagnosis of cardiac amyloidosis over 
the last few decades.  Patients with advanced cardiac amyloidosis have 
characteristic features (Figure 1.3).  Echocardiography has both diagnostic and 
prognostic significance in established disease; however, early diagnosis is 
challenging.91  There are many echocardiographic features in cardiac 
amyloidosis, including, concentric LV wall thickening with right ventricular 
involvement, impaired biventricular long-axis function and thickened valves 
(particularly in wild-type or variant ATTR amyloid).44  Impaired systolic function 
is a late feature of the disease and carries a poor prognosis.  Right ventricular 
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dilatation is associated with severe cardiac involvement and a median survival 
of only four months.44  One of the main features is diastolic dysfunction on 
echocardiography which may occur before the development of cardiac 
symptoms.92  This is one of the most typical features and maybe present in all 
patients with evidence of restrictive pattern on Doppler mitral inflow 
assessment.  In isolation, none of these are highly specific.  A combination of 
several features is usually necessary and must be interpreted in the context of 
clinical and other investigational findings.  LV wall thickening together with low 
electrocardiogram (ECG) voltage is suggestive of an infiltrative cardiomyopathy 
and amyloidosis should be suspected in patients with such combination.  This 
simple combination is reported to have high sensitivity (72-79%) and specificity 
(91-100%) for cardiac amyloidosis.93  
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Figure 1.3 Echocardiography in cardiac amyloidosis.  Two dimensional 
echocardiography in a patient with advanced cardiac amyloidosis demonstrating 
thickening of the interventricular septum, left ventricular free wall as well as the 
right ventricle (solid blue arrow).  There is bi-atrial enlargement giving an “owl’s-
eye” appearance to the images.82   
 
 
 
Longitudinal strain and strain rate analysis maybe abnormal in early 
amyloidosis94 and appear to be more sensitive than tissue Doppler, confirming 
disproportionate impairment of longitudinal contraction despite apparently 
preserved fractional shortening.94  LV longitudinal strain in particular may have 
a role in evaluating prognosis and response to treatment.95 
RA LA 
RV LV 
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Bisphosphonate bone tracers in amyloid imaging 
Studies on cardiac amyloidosis imaging using bone seeking radionuclide tracers 
were inspired following the observation of random myocardial uptake on routine 
bone scans during the 1970s and 1980s which were later confirmed to be 
cardiac amyloidosis.  A number of tracers have been used, including 99m-
technetium-methylene diphosphonate (99mTc-MDP), 99m-technetium-labeled 
pyrophosphate (99mTc-PYP), and 99mTc-DPD.  The exact mechanism of 
myocardial accumulation of bone-seeking tracers in cardiac amyloidosis is 
unclear.  The use of bone seeking tracers for amyloidosis was largely 
abandoned in the 1990’s due to conflicting results from a number of studies.96    
The interest in the use of these tracers was recently reignited following a 
report demonstrating a high sensitivity and specificity of 99mTc-DPD in imaging 
cardiac transthyretin amyloid deposits (Figure 1.4).  Perugini and colleagues 
have reported 100% sensitivity and specificity of 99mTc-DPD in imaging deposits 
in ATTR variant and ATTRwt.97  A number of centres45 have confirmed this 
finding.  99mTc-DPD is also taken up in cardiac AL amyloidosis but only in half of 
the cases with cardiac involvement and the uptake is generally low grade in 
contrast to the avid high grade uptake in ATTR.     
99mTc-DPD scintigraphy is a valuable, accurate and inexpensive 
technique allowing non-invasive identification of amyloidotic cardiomyopathy in 
ATTRwt amyloidosis in elderly patients with unexplained concentric left 
ventricular hypertrophy (LVH) and a non-dilated LV (heart failure with preserved 
ejection fraction).  Rapezzi et al demonstrated that 99mTc-DPD uptake was seen 
across a wide spectrum of cardiac involvement ranging from overt 
cardiomyopathy to cases with normal echocardiograms and normal or near-
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normal ECGs raising the intriguing possibility of using 99mTc-DPD as a 
screening test for ATTRwt amyloidosis.98   
 
Figure 1.4 99mTcDPD scintigraphy, in cardiac amyloidosis, in a patient with 
ATTRwt cardiac amyloidosis.  There is avid cardiac uptake with marked 
attenuation of the bone uptake (red dotted arrow).82  
 
 
 
In summary, 99mTcDPD scintigraphy is a useful and sensitive method of 
early identification of cardiac ATTR amyloid deposits; possibly at a stage when 
echocardiography, serum cardiac biomarkers, and perhaps even CMR remain 
normal.97  Although the sensitivity of 99mTcDPD scintigraphy opens an immense 
potential for screening and diagnosis of cardiac ATTR, it is not a diagnostic test 
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in isolation since uptake of 99mTc-DPD in the heart occurs in about half of the 
patients with cardiac AL amyloidosis.  99mTcDPD, therefore, has to be 
interpreted in context with full assessment of a patient with amyloidosis and 
integrated with CMR, echocardiography, SAP scintigraphy as well biochemical 
assessment to increase its specificity and therefore its clinical usefulness. 
 
Cardiac Magnetic Resonance imaging  
Cardiovascular magnetic resonance imaging has been found to have a vital role 
in the diagnosis and prognosis of cardiac amyloidosis.99  Gadolinium is used as 
a contrast agent to characterise cardiomyopathies including cardiac 
amyloidosis.  Extracellular space of the myocardium is hugely expanded due to 
amyloid fibril deposition into which gadolinium is distributed.  This results in 
abnormal kinetics of gadolinium and has been exploited for diagnostic use in 
amyloidosis (Figure 1.5).  Global and subendocardial late gadolinium 
enhancement occurs after gadolinium contrast injection in cardiac amyloidosis 
and has been correlated with histological proof of amyloid deposition in the 
heart.99  These features are observed in up to 80% of biopsy proven amyloid 
cases and are reported to correlate with prognosis.99  CMR can provide better 
morphological information on cardiac amyloidosis and accurately define systolic 
function than echocardiography.  CMR is especially valuable when 
echocardiography is unhelpful in the presence of other “hypertrophic” conditions 
of the heart such as severe hypertensive hypertrophy, hypertrophic 
cardiomyopathy, uremic cardiomyopathy and storage disorders.  Although CMR 
now has a defined role in the diagnosis of cardiac amyloidosis, the usefulness 
of CMR in serial monitoring remains to be established.  
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Equilibrium contrast CMR (EQ-CMR) is a quantitative technique where 
an infusion of gadolinium creates equilibrium between the amount of gadolinium 
in the myocardial interstitium and the plasma - allowing a numerical estimation 
of the myocardial interstitial volume.  Interstitial space within the heart is 
expanded by fibrosis in many types of cardiac disease, but, EQ-CMR has 
recently demonstrated a higher extracellular myocardial volume in cardiac 
amyloidosis than in any other cardiac disease.100  EQ-CMR may detect amyloid 
infiltration earlier than conventional magnetic resonance imaging (MRI) and can 
potentially provide a direct measure of the amyloid burden with scope for use in 
early diagnosis and disease monitoring.100  
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Figure 1.5 Cardiac magnetic resonance images with late gadolinium 
enhancement in long axis (vertical) (top) and short axis (horizontal planes) 
(bottom) in a normal subject and a patient with cardiac AL amyloidosis.  In a 
normal subject (left), signal from the myocardium is nulled and it appears black 
(solid red line) without areas of white contrast that would indicate myocardial 
fibrosis or amyloidosis.  In a patient with cardiac AL amyloidosis (right) using a 
similar sequence the expanded myocardial extra-cellular volume leads to nulling 
of both myocardium, blood pool and diffuse subendocardial enhancements 
(dotted blue line) – which  is characteristic of cardiac amyloid infiltration (Images 
– courtesy of Dr Marianna Fontana and Dr James Moon, Heart Hospital, UCL, 
London).82  
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Computerised Tomography  
Standard computerised tomography (CT) scanning is useful to detect and 
monitor organomegaly in systemic amyloidosis but CT features are not specific 
to amyloidosis.  CT scanning is important in patients with lymph node 
involvement (either isolated or as a part of systemic amyloidosis) to document 
extent of disease and response to treatment.  CT is the imaging method of 
choice in amyloidosis localised to the respiratory tract.  It can provide 
quantitative assessment of airway narrowing in tracheobronchial amyloidosis, at 
presentation, follow up, and establish extent of disease by identification of any 
extraluminal manifestations.  High resolution CT (HRCT) is useful in diffuse 
pulmonary amyloidosis to identify and track the disease course in combination 
with serial pulmonary function tests.  
 
Positron Emission Tomographic  in amyloid imaging  
Positron emission tomography (PET) has a better resolution than planar whole-
body imaging with standard radionuclides and has the advantage of being 
quantitative.  The role of PET radiopharmaceuticals in imaging systemic 
amyloidosis is limited.  Fluorodeoxyglucose (18F-FDG) is a standardised tracer 
in PET imaging and is widely available with excellent data on quantification.  
Standard 18F-FDG-PET has been used to detect metabolic activity in 
amyloidosis.  Amyloid deposits are metabolically inert but the infiltrating cells 
involved in amyloid formation in localised AL or macrophages involved in 
amyloid regression in both localised and systemic AL amyloidosis may have 
enough metabolic activity to be detected by 18F-FDG.  Case reports and small 
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studies suggest that patients with localised AL amyloidosis show 18F-FDG 
uptake at the sites of localised deposits allowing such deposits to be imaged for 
the first time and may provide a method for monitoring.101  Another approach 
has been to use monoclonal antibodies (mAb) to amyloid fibrils labelled with 
PET tracers.  A phase I study using murine IgG1 mAb 11-1F4 labelled with 
124Iodine was studied in 18 patients with AL amyloidosis.  50% of the patients 
showed uptake in liver, lymph nodes, bone marrow, intestine, or, spleen (but not 
kidneys or heart).  This is undergoing further studies.102 
 
Assessment for clonal disorder 
The amyloid fibril proteins in AL amyloidosis are derived from the N-terminal 
region of monoclonal light chains secreted by clonal B cells, predominantly of 
plasma cell origin.  The light chains are more commonly lambda than kappa and 
consist of whole or part of the variable (VL) domain, although occasionally intact 
light chains are present.  Monoclonal intact immunoglobulins (M-Igs) are also 
expressed in about 50-75% of patients with AL amyloidosis.83  These are 
predominantly IgG or IgA type and rarely IgM or IgD type. Patients with clinical 
features consistent with AL amyloidosis should undergo appropriate screening 
including serum and urine immunofixation and serum free light chain (SFLC).103  
Most patients will have evidence for monoclonal light chain production in the 
serum, urine, or bone marrow.  In 14% of patients with AL amyloidosis, the 
underlying gammopathy cannot be characterised. 
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Serum and urine protein electrophoresis and Immunofixation 
Serum electrophoresis (SPE) is the conventional means of identifying 
monoclonal immunoglobulin.  This method fails to identify the circulating M-
protein in more than half of all patients with AL amyloidosis at the time of 
presentation.27  In others, the levels are so low that quantification is either 
inaccurate or unattainable.  This is particularly relevant in the initial detection of 
the IgD paraprotein which can be challenging as laboratory analysis of IgD-
related PCD by SPE usually demonstrates a minimally detectable M-protein 
spike, often in the β, γ, or β-γ region.  A large percentage of cases can actually 
show hypogammaglobulinemia or a normal serum electrophoretic pattern 
making detection of the paraprotein difficult.104  This can apparently occur 
despite very high levels of IgD in the patient's serum, with some cases 
mistakenly diagnosed solely as light chain disease.105  Therefore, it is vital that 
all patients with what appears to be a light chain only secreting PCD, have IgD 
paraprotein excluded.  
Immunofixation is more sensitive and a monoclonal component is evident 
in the serum and urine (Bence Jones proteinuria) of 65% and 86% patients 
respectively using this method but the results are not quantitative and are 
dependent on renal function.106  Urine total protein electrophoresis is reported to 
have a significantly higher detection rate of the IgD myeloma paraproteins than 
SPE, with up to 96% of cases showing a detectable paraprotein in one study.104   
Thereby, reinforcing the need for both serum and urine protein electrophoretic 
analysis as standard parallel testing in all patients with suspected AL 
amyloidosis. 
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Serum free light chain estimation 
The SFLC assay is highly sensitive and quantitative nephelometric 
immunoassay.107  It enables the circulating fibril precursor protein in AL 
amyloidosis to be quantified at diagnosis and also to monitor disease 
progression or response to treatment in most patients.  Monoclonal 
immunoglobulin light chains are identifiable in 98% of patients with systemic AL 
amyloidosis using this method.  The assay, however, is not specific for AL 
amyloidosis as monoclonal SFLCs are also found in other B-cell clonal 
disorders such as MM and monoclonal gammopathy of undetermined 
significance (MGUS).  
As SFLCs are filtered by the glomerulus, the half-life of both kappa and 
lambda SFLCs is markedly prolonged in patients in chronic kidney disease with 
the absolute SFLC concentration increasing 20–fold.  The range for a normal 
SFLC ratio therefore alters with progressive renal failure.108  The ratio of the 
serum concentrations of the two light chain isotypes rather than their absolute 
concentrations should be assessed when the glomerular filtration rate is 
reduced.109, 110  In addition, the monoclonal component is estimated using the 
difference between the amyloidogenic and uninvolved SFLC concentration 
(dFLC) and is applicable to patients with renal failure.111, 112  
The identification of amyloidogenic light chains cannot rely on a single 
test and requires the combination of a commercially available SFLC assay with 
immunofixation of both serum and urine.  The association of both techniques 
has 100% sensitivity.113, 114  Bone marrow examination usually demonstrates 
clonal B cells as the source of the light chain production.115 
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Bone marrow aspirate and trephine biopsy 
A bone marrow biopsy is mandatory to assess the plasma cell burden115 and 
exclude MM and other, less common disorders that can be associated with AL 
amyloidosis, such as Waldenstrom’s macroglobulinemia.116  The tumour burden 
in AL amyloidosis is low.  About 80% of patients have ‘benign’ monoclonal 
gammopathies with average bone marrow plasma cell infiltration of around 
7%.117, 118  Fifteen percent of patients have MM and a smaller proportion have 
other B cell disorders such as lymphomas.  Half of all amyloidogenic PC clones 
produce light chains only.  The lambda clones dominate kappa ones by 4:1, 
unlike the 2:3 ratio in MM.  In addition to routine Congo red staining for amyloid, 
immunophenotyping is performed on the trephine, to establish clonality.  
 
Multicolour flow cytometry and Cytogenetic analysis  
Multicolour flow cytometry (MFC) is more sophisticated technique increasingly 
being performed on bone marrow samples of AL patients.  MFC identifies 
proportion of normal and clonal PCs.  Monoclonal plasma cells are detectable in 
97% of patients by flow cytometry immunophenotyping.  One study showed that 
quantification of bone marrow plasma cells (BMPCs) by MFC was a significant 
prognostic factor for overall survival and in the same study, detecting persistent 
normal PCs at diagnosis identified a subgroup of patients with AL with 
prolonged OS.119  Therefore, MFC immunophenotyping could be clinically 
useful for the demonstration of PC clonality and for the prognostication of 
patients with AL.119 
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Assessment of prognostic factors 
In addition to the presence and extent of cardiac involvement,73 high circulating 
levels of SFLCs were recently shown to be associated with poor outcome.120  
Kumar et al have since incorporated SFLC levels at presentation in the Mayo 
staging system but this is yet to be validated.121  
 Other factors which have been associated with prognosis but have not 
been integrated into similar staging system include supine systolic blood 
pressure, the characteristic of the plasma cell clone including percentage of 
bone marrow plasma cells, the number of organs involved, serum uric acid 
level, age, serum albumin and performance status.62, 122 
 Identification of a neoplastic plasma cell population adversely affects 
survival123, and bone marrow plasma cell infiltration above 10% has also been 
associated with poorer outcome.124  Abnormal fluorescence in situ hybridisation 
(FISH) results at diagnosis has been reported to be prognostic for poorer 
survival and advanced cardiac disease.  Particularly, trisomies and t(11;14) 
affect survival when degree of plasma cell burden is considered.125 
 Refined imaging techniques, in particular Doppler myocardial strain and 
strain rate, identify high-risk patients more accurately than standard 
echocardiographic parameters, adding prognostic information to that derived 
from cardiac biomarkers.126  A large whole body amyloid load on SAP 
scintigraphy and evidence of accumulation of amyloid on serial SAP scans are 
also poor prognostic factors.83 
 The most favourable prognostic factor is achieving an organ response 
which is dependent on gaining a deep haematological response.127  Because of 
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the frequent time lag in organ response, hematologic response has become an 
important prognostic measure.128 
 
Approach to Treatment 
Effective management of AL amyloidosis is challenging due to a combination of 
the inherent nature of the disease and treatment related complications. 
Therefore a multidisciplinary approach is essential for the prospect of optimal 
outcome. Early treatment is associated with improved survival.83 
All current strategies to manage AL amyloidosis involve systemic 
therapies designed to destroy the plasma cell responsible for the synthesis of 
the immunoglobulin light chain.129  Consequently, all such therapies have been 
derived from the encouraging results obtained in similar MM populations.  AL 
patients have distinctive organ dysfunction resulting in increased toxicity 
associated with systemic therapy making both the treatment and response 
assessment more challenging.  
 
Measuring response to treatment 
The efficacy of a treatment can be measured both in terms of reduction in the 
burden of clonal plasma cell disease (hematologic response) and by 
improvement in the organ function (organ response).69  Consensus criteria for 
hematologic and organ response have been recently developed and 
validated.130 
Chapter 1 
63 
 
 Paraproteins are measurable only in about a quarter of AL amyloidosis 
patients for monitoring purposes,83 making conventional immunochemical 
techniques insufficiently sensitive.  Quantification of SFLC allows direct 
measurement of the amyloidogenic precursor, providing a powerful means for 
hematologic response assessment.107  Moreover, SFLC are more powerful 
predictor of survival in AL amyloidosis than intact immunoglobulins.110  The 
degree of SFLC reduction directly correlates with prolonged survival.120  
Therefore, the therapeutic goal is to achieve a deep SFLC response.  Stable 
hematologic disease despite therapy is likely to result in continued effects of the 
toxic light chain.  In 10–15% of patients, the SFLC is only minimally abnormal, 
therefore, in these patients, monitoring haematological response relies on there 
being a measurable M-protein, which has been defined as >5 g/l.131  A minority 
of patients lack an adequate measurable marker of haematological response.  
 
Organ response 
Organ improvement may occur in those who achieve at least a partial 
hematologic response, with kidney and liver responses occurring most 
commonly.  Organ responses can lag 6 to 12 months behind the hematologic 
response, necessitating aggressive supportive care and collaborative 
management with other specialists, particularly in patients with advanced 
cardiac or renal involvement.  
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Types of treatment 
Alkylators and steroids 
Chemotherapy for AL amyloidosis using alkylating cytotoxic agents was 
described in 1972 with oral melphalan and prednisone (MP) being 
demonstrated to be the first effective treatment,132 but the hematologic 
response rates were not only low but delayed, allowing organ dysfunction to 
progress in the interim.  
Pulsed dexamethasone has also been shown to be active in AL 
amyloidosis but cause considerable toxicity, most commonly dose limiting fluid 
retention in patients with nephrotic syndrome and heart failure.133  Using a low 
dose, low frequency dexamethasone regimen minimises toxicity whilst providing 
similar response rates.134  This activity of single agent dexamethasone led to 
studies of it in combination with melphalan (MDex), which showed much higher 
hematologic response rates than MP, and underscores the continued use of 
MDex in patients who are not eligible for stem cell transplantation (SCT).135-138   
 
Novel agents  
Thalidomide 
Thalidomide, an immunomodulator (IMiD), was the first novel agent explored in 
AL amyloidosis due to its proven efficacy in MM.  As a single agent, thalidomide 
has limited efficacy.139  The combination of thalidomide and dexamethasone 
(ThalDex) is effective, but confers substantial toxicity resulting in poor tolerance 
and subsequent limited organ response.140, 141  
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ThalDex with cyclophosphamide, (CTD) has been shown to result in a 
high hematologic response rate.142  CTD is stem cell sparing, supporting use of 
this regimen in younger patients whom SCT might subsequently be considered.  
Nonetheless, the adverse effects of thalidomide, particularly neuropathy, 
bradycardia, and worsening congestive heart failure, remain problematic and 
dose limiting in many patients. 
 
Lenalidomide 
Lenalidomide is a second generation immunomodulatory (IMiD) agent that has 
been combined with dexamethasone (LenDex) in treatment of AL 
amyloidosis.143-145  LenDex have been combined with either melphalan 
(MRD)146, 147 or cyclophosphamide (CRD)148 but myelosuppression may be a 
limiting factor.   
 The non-hematologic toxicity is greater than reported in MM trials 
(serious adverse events (SAE) 60-86%).  The most common adverse effects 
are cytopenias, rash, fatigue and muscle cramps.  Like thalidomide, 
lenalidomide is prothrombotic, particularly in combination with corticosteroids, 
therefore, require anti-thrombotic prophylaxis.149   
 
Pomalidomide 
Pomalidomide is the newest IMiD and is structurally similar to both thalidomide 
and lenalidomide.  Pomalidomide and dexamethasone is a promising therapy 
for AL amyloidosis.150, 151   
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Bortezomib 
Bortezomib is a reversible proteasome inhibitor that triggers stress-activated 
protein kinases and mitochondrial apoptotic signalling in plasma cells.152  
Bortezomib with or without dexamethasone has been reported to have 
71% hematologic response with 25% complete response (CR) (47% CRs in 
previously untreated patients) in one study.  Notably, cardiac response was 
documented in 29% of patients, and the 1-year survival rate was 76%.153  
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) 
demonstrated significant activity in AL amyloidosis with hematologic responses 
in 93% of untreated and relapsed patients with 71% achieving CR and patients 
originally not eligible for stem cell transplantation becoming eligible.154  
The most common non-hematologic toxicities reported with bortezomib 
are fatigue, peripheral sensory neuropathy, exacerbation of orthostatic 
hypotension, peripheral oedema, and constipation or diarrhoea.155  The 
incidence of any grade of neuropathy is less than 5% when bortezomib is 
administered subcutaneously, similar to that observed with weekly intravenous 
administration.156  
Bortezomib is rapidly active in AL amyloidosis with high rates of 
hematologic and organ responses.154, 157, 158  Table 1.3 shows the clinical 
studies in AL amyloidosis. 
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Table 1.3 Clinical studies of conventional and novel chemotherapy agents in AL 
amyloidosis. 21  
Regimen (Reference) Clonal 
response 
(%) 
Overall 
Survival 
(months) 
Toxicity 
(>grade 3) 
TRM 
Melphalan     
MPC 159 ns 10.6 Non-significant Nil 
MP or MPC 160 28% 18 Non-significant ns 
Melphalan 
dexamethasone 135 
67% Not reached 11% Nil 
Intermediate dose 
melphalan (IDM) 138 
54% 44 ns 12% 
Thalidomide     
Thalidomide (standard 
dose) 139 
25% Non-significant 50% ns 
Thalidomide 
dexamethasone 141 
48% Non-significant 65% ns 
CTD 142 74% Not reached 32% 4% 
Lenalidomide     
Lenalidomide ± 
dexamethasone 143 
75% Non-significant 73% Nil 
Lenalidomide ± 
dexamethasone 144 
67% Non-significant 35% Nil 
CRD 148 63% 37 74% 9% 
CRD 161 62% 36 57% Nil 
MRD 146 53% 54% at 2 years 81% Nil 
MRD 147 44% 24 88% 13% 
Pomalidomide     
Pomalidomide ± 
dexamethasone 152 
48% 24 30% 3% 
Bortezomib     
Bortezomib ± 
dexamethasone 162 
77% 22 ns Nil 
Bortezomib 153 94% Not reached 11% Nil 
CyBorD 163 94% - 12% - 
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High dose melphalan therapy – Autologous Stem cell 
Transplantation  
The introduction of SCT in 1990’s was a major breakthrough in the treatment of 
AL amyloidosis since it held the promise of very rapid and deep haematological 
responses.  Since then, high rates of hematologic and organ response have 
been documented at many centres, with long-term data among 800 patients 
demonstrating median survival of over a decade for SCT patients who achieve 
a CR.25, 164, 165 
Amyloid-related organ disease25 and quality of life166 has been shown to 
improve in most patients who achieve a CR after SCT.  However, SCT carries 
substantial risks, with high treatment-related mortality reported in early 
studies.167  Some centres reported treatment related mortality (TRM) exceeding 
40%128 or more in those with cardiac involvement,168 reflecting high risks in 
populations that are not carefully selected.85, 169  Deaths have also been 
reported during stem cell mobilisation, reflecting the susceptibility of these 
patients to unanticipated adverse events such as dramatic fluid retention and 
pulmonary oedema.168, 170  
Cardiac staging has helped to minimise TRM by identifying patients 
susceptible to complications of SCT.  Several studies have demonstrated that 
Stage III patients should be excluded from SCT studies.171  Incorporating 
refined selection criteria, TRM can be reduced from 40 to 4%.170, 172   
SCT should remain a preferred option for patients deemed eligible to 
undergo this procedure safely.  Unfortunately, only a minority (20-25%) of 
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patients with AL amyloidosis would be eligible for safe SCT.  In practice, most 
patients require alternatives to high-dose therapy. 
 
Post-stem cell transplant consolidation therapy 
High-dose therapy does not preclude the use of highly active novel agents in 
those who do not achieve an adequate response.  Adjuvant therapy post–SCT 
improves haematological response in patients not achieving a CR.  This is 
particularly useful in those with poor response due to risk-adapted SCT.173-175 
 
Novel therapies in development 
Developments in treatment of AL amyloidosis have continued to follow those of 
MM, aiming to reduce the burden of underlying clonal cells. In AL amyloidosis, 
the light chain protein product of the plasma cells causes the disease, and is 
therefore a separate rational target for therapy.  
An alternative approach comprises the combination of a small molecule 
that depletes circulating SAP co-administered with a monoclonal antibody that 
can then target SAP associated with amyloid deposits.  The novel compound 
CPHPC ((R) -1-[6-[(R)-2- Carboxy-pyrrolidin-1yl]-6-oxo-hexanoyl] pyrrolidine-2 
carboxylic acid) cross-links pairs of SAP molecules in the plasma, triggering 
their rapid and almost complete removal by the liver.176  Whilst sustained 
depletion of circulating SAP is well tolerated and may itself be therapeutic with 
prolonged administration177, 178 this treatment does not deplete SAP from 
amyloid deposits in the very short term.  This phenomenon enables the 
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targeting of residual amyloid-associated SAP with anti-SAP antibodies.179  A 
phase I clinical trial recently reported that treatment with CPHPC followed by an 
anti-SAP antibody safely triggered clearance of amyloid deposits from the liver 
and some other tissues.180  Given the universal presence of SAP in amyloid, 
this combination therapy is potentially applicable to all types of amyloidoses.  
These various developments open up the possibility that treatment for AL 
amyloidosis in the future may involve a combination of novel approaches to 
inhibit amyloidogenic light chain production in conjunction with therapies that 
enhance clearance of existing amyloid deposits.  
 
Supportive therapy 
Patients with renal amyloidosis are usually nephrotic and therefore are 
hypoalbuminemic, with consequent oedema.  The mainstay of management is 
diuretics with occasional patients benefiting from albumin infusions.  Care must 
be taken not to prescribe overly aggressive diuretic therapy as it can result in 
hypotension, syncope, and reduced renal blood flow with a rise in creatinine.  
Dangerous electrolyte imbalance can also complicate aggressive diuresis. 
 The management of heart failure often also requires diuretic therapy and 
hemodynamic stabilisation.  Caution is required in the use of standard heart 
failure medications in patients with amyloidosis.  Angiotensin converting 
enzyme inhibitors and angiotensin receptor blockers are generally not well 
tolerated as can induce severe hypotension therefore are best avoided.  The 
impact of β blockers and calcium channel blockers on heart rate and myocardial 
contractility can exacerbate hypotension and heart failure.  
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 Arrhythmias have been reportedly treated with prophylactic amiodarone 
and have been incorporated into therapy trials of amyloidosis to reduce the risk 
of sudden cardiac death if complex ventricular arrhythmias are detected on 
Holter ECG.135  Caution needs to be exercised with the use of digoxin in cardiac 
AL patients as they can be exquisitely sensitive to AV nodal blockage and 
development of digitalis toxicity.  Implantable cardiac defibrillators have been 
used in patients with cardiac involvement because of the high incidence of 
sudden death, but strong evidence demonstrating their efficacy in this disease 
is lacking.181  Αlpha agonists such as midodrine can improve orthostatic 
hypotension due to autonomic neuropathy. 
 
Organ Transplantation 
Both cardiac and renal transplantation have been successfully carried out in AL 
amyloidosis.182-185  Positive outcomes require strict control of amyloid precursor 
protein production or recurrence amyloid deposition in the graft is inevitable.  
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Aims and Objectives 
 
AL amyloidosis is a rare and potentially devastating disease that is possibly 
under diagnosed and diagnosis is typically delayed. Advances in diagnostic 
techniques and the use of cardiac biomarkers for staging and free light 
chains to grade response to treatment have improved care.  Nonetheless, 
patients and the clinicians managing these patients continue to face many 
challenges. Much of the work within this thesis seeks to explore and 
understand these challenges. In addition, it looks at possible risk stratifying 
methods based on plasma cell phenotype and serum clonal markers at 
presentation, which may be useful in guiding management strategies to 
improve outcome in AL amyloidosis. And finally, it examines the 
effectiveness of the currently widely used novel agent, bortezomib.   
AL amyloidosis is increasingly recognized in the elderly, mirroring 
monoclonal gammopathy but very little has been reported on this subgroup 
of patients where co-morbidities and frailty may compound morbidity and 
mortality. Moreover, the treatment for AL amyloidosis has to be highly 
individualised based on age, organ dysfunction, and regimen toxicities. 
Chapter three focuses on this challenging subgroup of patients. In this 
chapter, the clinical features, treatment and outcomes in patients over the 
age of 75 years with systemic AL amyloidosis are analysed.   
The next two results chapters concentrate on the rare subtypes, IgM 
and IgD-related AL amyloidosis. Chapter four focuses on the even rarer 
subtype, IgD paraprotein-associated AL amyloidosis. The clinical phenotype 
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and outcomes are uncertain in this cohort of patients.  This chapter seeks to 
improve the understanding of the clinical features and outcomes of patients 
with IgD related AL amyloidosis.  
IgM-related AL amyloidosis, accounting for 6-10% of all AL cases, is a 
rare and poorly studied clinical entity.  Its natural history and management is 
not clearly defined.  Prognostic and response criteria for AL in general have 
not been validated in this population.  Chapter five explores and compares 
the clinical features, haematological response and overall survival of patients 
with IgM-related AL amyloidosis in three European countries to that of non-
IgM AL patients.  The staging and response criteria currently used in non-
IgM AL patients are applied and their utility evaluated in the IgM-related AL 
patients with a view to identifying more specific staging and response criteria 
in the latter group.   
Chapters six, seven and eight examine the potential novel 
investigations and prognostic markers in AL amyloidosis.  
Imaging modalities to detect and delineate soft tissue and lymph node 
amyloid deposits have not been very well established. Hence, diagnosis is 
usually based on biopsy of the suspicious lesion if this is deemed safe but 
histology alone does not provide information on the extent and distribution of 
amyloid deposits. In chapter four, the role of the bisphosphonate bone tracer, 
99mTc-DPD in detecting amyloid deposits in soft tissue, lymph nodes and lung 
parenchyma are explored.  
Cardiac involvement and presenting dFLC are independent predictors 
of outcome.  However, these markers have less predictive value in patients 
surviving the initial few months following diagnosis and markers determining 
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longer term outcomes are needed.  The role of plasma cell (PC) clones in 
determining prognosis has been of recent interest.  Multiparameter flow 
cytometry (MFC) identifies proportion of normal and clonal PCs.  Chapter five 
examines the impact of ‘normal’ plasma cells, as determined by multicolour 
flow cytometry, on the outcome of AL patients in the context of the total 
plasma cell burden as determined by standard morphological techniques. 
Chapter six explores the utility of a novel method heavy and light chain 
(HLC) immunoassay, to measure immunoparesis, as an important marker of 
prognosis in newly diagnosed patients with AL amyloidosis.  
Whilst multi-organ failure makes AL patients particularly susceptible to 
treatment toxicity, the reductions in the concentration of the circulating free 
light chain (FLC) can rapidly result in marked clinical improvement and 
prolonged survival.  The final results chapter focuses on the treatment of AL 
amyloidosis. Therapeutic options in AL have broadened in the last decade, 
mirroring that of multiple myeloma resulting in improved quality of life and 
extended survival in majority of patients with AL amyloidosis. The 
combination of cyclophosphamide, bortezomib and dexamethasone 
(CyBorD) is one of the most commonly prescribed regimens in AL 
amyloidosis with high rates of hematologic response. However, CyBorD does 
not overcome the poor prognosis of advanced cardiac amyloidosis. This 
chapter seeks to identify patients who benefit most from this regimen. The 
overall haematological response and organ response are analysed. The 
haematological responses are then determined according to the three Mayo 
stages.  
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Chapter Two: Materials and Methods 
 
Declaration 
I have designed the studies, collected and analysed the data in my role as a 
clinical research fellow at the National Amyloidosis Centre, University College 
London (Royal Free Campus).  This thesis comprises of seven studies, of which 
three are collaborative studies.  Chapter five, the IgM-related AL amyloidosis 
study was in collaboration with the Amyloidosis centres in Pavia, Italy and 
Limoges, France.  Chapter nine, the Bortezomib study was also in collaboration 
with the Amyloidosis centre in Pavia, Italy.  Chapter seven, multicolour flow 
cytometry study was in collaboration with the Haematological Malignancy 
diagnostic service, St James’s University Hospital in Leeds.  The data for the 
Italian patients in chapters five and nine were provided by Dr Giovanni Palladini, 
from the Amyloidosis Research and Treatment Centre, Fondazione IRCCS 
Policlinico San Matteo and Department of Molecular Medicine, University of 
Pavia, Pavia, Italy.  The data for the French patients in chapter five were 
provided by Dr Murielle Roussel, Department of Haematology, CHU Purpan, 
Toulouse, France.  
 
Several diagnostic methods were performed by other individuals based at the 
following sites: 
 
 National Amyloidosis Centre: 
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o Frozen serum blood samples for the NT-proBNP and Troponin 
assays for missing data were collected by Wendy Taylor and Lois 
Cook. 
o Histological and immunohistochemical analyses were performed 
by Janet Gilbertson and Karen Boniface. 
o Gene sequencing was performed by Dorota Rowczenio and 
Hadija Trojer.  
o Echocardiography was performed by Babita Pawarova, Oliver 
Manalo and Sevda Ozer.  
o 123I-SAP scintigraphy was performed by Dorothea Gopaul, David 
Hutt and McKnight. 
o 99mTcDPD scintigraphy was performed by David Hutt and 
Stephanie McKnight.  
o Multicolour flow cytometry on bone marrow aspirates of the 
patients in chapter seven were performed by Anna Baginska, 
when the bone marrow biopsies were carried out at the National 
Amyloidosis Centre. 
 
 Royal Free Hospital: 
o Royal Free Hospital laboratory services carried out the serum and 
urine biochemical investigations and performed measurements for 
haematological data.  
o Bone marrow trephine analysis for the patients in chapter seven 
was performed by Royal free Histology department, when the 
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bone marrow biopsies were carried out at the National 
Amyloidosis Centre.   
o 99mTcDPD scintigraphy was reported by Anne-Marie Quigley, 
Consultant in Nuclear medicine. 
 
 St James’s University Hospital in Leeds 
o Multicolour flow cytometry on bone marrow aspirates and 
histological analysis of bone marrow trephine for the patients in 
chapter seven were performed by the Haematological Malignancy 
diagnostic service, St James’s University Hospital in Leeds, 
overseen by Dr Roger Owen. 
 
Statistics advice was given by Catherine Klersy, from Servizio di Biometria e 
Statistica, Direzione Scientifica, Fondazione IRCCS Policlinico San Matteo, 
Pavia, Italy, for chapter five. 
  
Patients 
All of the patients, (apart from those from international collaborative studies) 
whose individual details are used in this thesis, have been seen at the UK 
National Amyloidosis Centre.  Chapters five and nine were international 
collaborative studies. Eighty one of the patients included in chapter five and one 
hundred and eighteen patients included in chapter nine were seen at 
Amyloidosis Research and Treatment Center in Pavia, Italy.  Thirty one patients 
included in chapter five were seen at the Amyloid centre in Limoges, France.  
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The National Amyloidosis centre maintains an Access database with details of 
all patients found to have amyloidosis which was available for me to utilise.  
Data on patient deaths were updated on the database based on information 
from the Office of National Statistics and deceased patients’ family members. 
All patients included in this thesis provided explicit informed consent.  
 All patients underwent systematic review at presentation and detailed 
follow up assessments at six monthly intervals or as clinically indicated.  
Assessment included clinical examination, detailed blood and urine analysis 
(including assessment of serum and urine monoclonal immunoglobulin and 
serum free light chains), serial 123I labelled SAP scintigraphy to assess whole 
body amyloid load, ECG and echocardiogram. 
 
Functional assessment 
Function assessment of patients attending clinic were assessed based on their 
performance status and heart failure symptoms.  Performance status was 
measured according to the Eastern Cooperative Oncology Group (ECOG) 
criteria (Table 2.1).186  This is one of the most widely used scales to assess how 
the disease affects the daily living abilities of cancer patients, and is a central 
factor in determining appropriate treatment and prognosis.  This criteria has 
also been used in patients with systemic AL amyloidosis.187  Heart failure 
symptoms were assessed using the New York heart association functional 
classification (NYHA) (Table 2.2).188   
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Table 2.1 Classification of Eastern Cooperative Oncology Group 
performance status186  
Grade Description 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature 
2 Ambulatory and capable of all self-care but unable to carry out any 
work activities. Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours 
4 Completely disabled.  Cannot carry on any self-care. Totally confined 
to bed or chair 
 
Table 2.2 Definition of New York heart association functional 
classification188   
NYHA 
Class 
Summary Description 
I Normal No limitation of physical activity. Ordinary physical activity 
does not cause undue fatigue, palpitation, dyspnea 
(shortness of breath) 
II Mild Slight limitation of physical activity. Comfortable at rest. 
Ordinary physical activity results in fatigue, palpitation, 
dyspnea (shortness of breath) 
III Moderate Marked limitation of physical activity. Comfortable at rest. 
Less than ordinary activity causes fatigue, palpitation, or 
dyspnea 
IV Severe Unable to carry on any physical activity without discomfort. 
Symptoms of heart failure at rest. If any physical activity is 
undertaken, discomfort increases 
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Histology 
 
Congo Red Staining  
Tissues were processed using Puchtler’s alkaline alcoholic Congo red 
method.189  Rehydrated, formalin fixed, de-paraffinised tissue sections 
measuring 6-8μg were counterstained with Mayer’s haematoxylin under running 
tap water.  Slides were then placed in ethyl alcohol before being stained in fresh 
Congo Red Working Stain solution.  Slides were then rinsed, dehydrated and 
cleared before sections were mounted in DPX mounting medium.  Stained 
sections were observed in bright-field, and cross polarised light microscopy 
using a 10x objective.  Positive controls, from a known Congo-red positive block 
validated by laser micro dissection and mass-spectrometry based proteomic 
analysis were processed in parallel.  
 
 
Immunohistochemistry  
Once the presence of amyloid deposits were confirmed, a panel of 
monospecific antibodies against known amyloid-forming proteins were used to 
identify the amyloid fibril.  Twenty-two serial sections from each biopsy were cut 
where possible.  Sections were cut into 2μm and 6μm thickness for 
immunohistochemistry and Congo Red overlay190 respectively.  
Immunohistochemistry was carried out using the Sequenza™ (Thermo 
Shandon, UK) system and antibodies were labelled using Impress™ detection 
Chapter 2 
 
81 
 
kits (Vector Laboratories UK) following the manufacturer’s recommendations.  A 
metal-enhanced DAB Substrate kit (Thermo Scientific) was used for visualising 
the immuno-compound.  After completing the immunohistochemistry, a Congo 
red method was performed over the top of the immunostain.190 
 Antibodies routinely used were: AA (Euro Diagnostica), AL lambda, AL 
kappa, P component, Lysozyme, and transthyretin (DAKO), fibrinogen Aα chain 
(Calbiochem) and Apolipoprotein AI (Genzyme Diagnostics).  All biopsies were 
also stained with anti-amyloid P component (AP) so that a comparison can be 
made with that of a negative Congo red.  A positive control section for each 
antibody used was included in every run. 
 Interpretation of all stained slides were carried out blindly by two 
experienced workers independently.  When the immunohistochemistry is non-
diagnostic of amyloid fibril type, laser microdissection of amyloid and mass 
spectrometry66 were performed in tandem.  
 
Gene sequencing  
Genetic sequencing of the genes implicated in hereditary amyloidosis were 
carried out when appropriate.  Where indicated, whole blood collected in an 
EDTA tube was frozen and stored for gene sequencing.  Genomic DNA was 
isolated by a rapid method.  The coding regions for Apolipoprotein AI (exons 3 
and 4),  Fibrinogen A α-chain (the 5’ end of exon 5) and Transthyretin (exons 2, 
3 and 4) were amplified using  PuReTaq ‘Ready-To-Go’ polymerase chain 
reaction (PCR) Beads  (GE Healthcare) with the use of primers as listed in 
Table 2.3. 
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Table 2.3 Primers Used in the PCR Process for Genotyping Hereditary 
Amyloidosis 
 
Gene  Exon Forward primer sequence Reverse primer sequence 
Apolipoprotein 
AI  
3 5’-
GGCAGAGGCAGCAGGTT
TCTCAC-3’ 
5’-
CCAGACTGGCCGAGTCCTC
ACCTA-3’ 
4 5’-
CACTGCACCTCCGCGGA
CA-3’ 
5’-
CTTCCCGGTGCTCAGAATA
AACGTT-3’ 
Fibrinogen A  5-
5’en
d 
5’-
GCTCTGTATCTGGTAGTA
CT-3’ 
5’-
ATCGGCTTCACTTCCGGC-3’ 
Transthyretin  
  
2 5’-
TTTCGCTCCAGATTTCTA
ATAC-3’ 
5’-
CAGATGATGTGAGCCTCTC
TC-3’ 
3 5’-
GGTGGGGGTGTATTACT
TTGC-3’ 
5’-
TAGGACATTTCTGTGGTACA
C-3’ 
4 5’- 
GGTGGTCAGTCATGTGT
GTC-3’ 
5’-
TGGAAGGGACAATAAGGGA
AT-3’ 
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SAP scintigraphy 
All patients underwent SAP scintigraphy at the initial visit for the assessment of 
amyloid deposits in major visceral organs (liver, kidneys, adrenals, bone and 
spleen) and at subsequent visits if clinically indicated for the monitoring of 
amyloid deposits.  
 Female patients between the ages of 12 and 55 years were asked to 
confirm that they were not pregnant and sign the pregnancy declaration form 
prior to injection.  The need for thyroid blockade and oral dosing schedule of 
potassium iodide (six doses over three days) were explained to patients.  The 
first dose (60mg) is administered to the patient prior to the injection. Following 
thyroid blockade, patients received 200μg of SAP with 190MBq of radiolabelled 
iodine (123I), the equivalent of 3.8mSV of radiation by intravenous bolus 
injection.  Six or 24 hours after injection, anterior and posterior whole-body 
images and appropriate regional views were obtained with a General Electric 
Starcam gamma camera (IGE Medical Systems, Slough, UK).  
 Amyloid load was classified as follows: ‘normal’ - no abnormal 
localisation of the tracer; ‘small’- uptake in one or more organs visible with 
normal intensity in the blood pool; ‘moderate’ - abnormal uptake within organs 
and diminished blood pool; ‘large’ - blood pool signal lost with adjustment of the 
grey scale to encompass the target organ.  
 Follow-up scans were performed, when feasible, at approximately yearly 
intervals.  Amyloid progression and regression on these scans were defined as 
follows: ‘progression’- increase in the tracer uptake within an affected organ or a 
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reduction in the background blood-pool signal in combination with a stable 
amyloid burden; ‘regression’ - reduction of the tracer within an affected organ 
and/or an increase in the background blood pool when compared with the 
previous scans. 
 
Cardiac assessment 
Patients routinely undergo a combination of blood tests (cardiac biomarkers), 
electrocardiogram, echocardiogram and most recently cardiac MRI (CMR), for 
assessment of evidence of cardiac amyloidosis.  Amyloidotic heart muscle can 
not to be visualised on 123I-SAP-scintigraphy, due to movement artefact, 
ventricular blood-pool content, and a lack of a fenestrated endothelium in the 
myocardium, hindering access of the large 127kDa SAP molecule to the 
amyloidotic interstitium within the available timescale of the short half-life of 123I 
isotope.80  
 
Cardiac biomarkers and Mayo staging 
Measurement of the cardiac biomarkers, are vital part of cardiac assessment 
and risk stratification in patients with AL amyloidosis.  All patients had blood 
tests at presentation and at each visit.  This included the measurement of 
cardiac biomarkers, N-terminus pro-B Natriuretic Peptide (NT-proBNP) and 
Troponin which were used to risk stratify patients using the Mayo staging 
system, defined as follows:73  Stage I -  NT-proBNP <332ng/L and cTnT 
<0.035mcg/L or Troponin I <0.1ng/mL, stage II – NT-proBNP >332ng/L or cTnT 
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>0.035mcg/L or Troponin I >0.1ng/mL, and stage III both NT-proBNP >332ng/L 
and cTnT >0.035mcg/L or Troponin I >0.1ng/mL.73  In chapter nine, stage III 
patients were divided in two groups based on whether they had NT-proBNP 
below (stage IIIa) or above (stage IIIb) 8500ng/L, which is known to be 
associated with a very poor prognosis.74   
 
Blood pressure and 12 lead Electrocardiogram 
All patients had lying and standing blood pressure measured by the nursing 
staff. All patients had a standard 12 lead ECG at presentation and subsequent 
visits.  The ECG was acquired using a calibration of 10 mm/mV and speed of 25 
mm/s. The presence of low voltage on 12-lead electrocardiography (ECG) (all 
limb leads less than 5 mm in height), as defined in the amyloidosis consensus 
criteria, was considered suspicious of cardiac involvement by amyloid.69  
 
Echocardiography 
All patients underwent transthoracic echocardiography at presentation and 
subsequent visits.  Parasternal long axis and apical long axis views were most 
commonly used.  Echo studies, included tissue Doppler.  Scans were performed 
and analysed by two echocardiographers experienced in scanning patients with 
cardiac amyloidosis.  Accepted markers of diastolic dysfunction i.e. isovolumic 
relaxation time (IVRT), E-deceleration time and E:E’ ratio were measured.191  In 
addition, left ventricular wall thickness, left ventricular systolic function and atrial 
diameter were measured using defined criteria from the British Society of 
Echocardiography. 
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99m-technetium-3,3,-diphosphono-1,2-propanodicarboxylic 
acid scintigraphy  
99mTcDPD scintigraphy is only performed in patients with suspected cardiac 
amyloidosis.  Patients were scanned using two General Electric (GE) Medical 
Systems hybrid SPECT-CT (single photon emission computed tomography with 
a low-dose, non-contrast CT scan) gamma cameras (Infinia Hawkeye 4 and 
Discovery 670) after intravenous injection of 700MBq of 99mTc-DPD.  Whole 
body planar images were acquired 3 hours post-injection followed by cardiac 
SPECT-CT.  The whole body sweep images were acquired using low energy, 
high-resolution collimators and a scan speed of 10cm/min. SPECT-CT 
reconstruction and image fusion were performed on the GE Xeleris workstation.  
The CT raw data were reconstructed three times using soft tissue, lung, and 
bone settings with a 512 matrix and 3.75mm slice thickness.  The soft-tissue 
reconstruction was loaded into the Myovation programme on the Xeleris to 
perform the attenuation correction on the SPECT data.  The SPECT data were 
reconstructed using filtered back projection.  Data were pre-filtered using a 
Butterworth filter with a critical frequency of 0.4 cycles/cm and a power of 10.  It 
was then reconstructed with a quantitative ramp filter.   
Cardiac retention of 99mTc-DPD was visually scored using a modification 
of the grading devised by Perugini et al.97  Grade 0 - no visible myocardial 
uptake in both the delayed planar or cardiac SPECT-CT scan; Grade 1 - cardiac 
uptake on SPECT-CT only or cardiac uptake of less intensity than the 
accompanying normal bone distribution; Grade 2 – moderate cardiac uptake 
with some attenuation of bone signal; and Grade 3 – strong cardiac uptake with 
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little or no bone uptake.  All scans were reported by two experienced clinicians 
who were blinded to all clinical data. 
 
Renal staging 
In chapters three and nine, staging of renal damage was performed according 
to recently published criteria.192  Renal stage was defined by eGFR (cut off 
50mL/min per 1.73m2) and proteinuria (cut off 5g/24h); stage I patients have 
both eGFR above and proteinuria below the cut off, stage II have either eGFR 
below or proteinuria above the cut off, and stage III patients have both eGFR 
below and proteinuria above the cut off. 
 
Criteria for diagnosis of amyloid and definition of organ 
response 
Amyloid organ involvement were defined according to the international 
consensus criteria (ICC) 2010 along with SAP scintigraphy findings.70  Cardiac 
response was assessed as per the consensus criteria published by Palladini et 
al.130 (Table 2.4) 
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Table 2.4 - Definition of Organ Involvement and Organ Response70, 130 
Organ Definition of organ involvement Definition of organ response Definition of disease progression 
Kidney - 24-hr urine protein >0.5g/day, 
predominantly albumin 
- 50% decrease (at least 0.5g/day) of 
24-hr urine protein (urine protein 
must be >0.5g/day pre-treatment) 
Creatinine and 
- Creatinine clearance must not 
worsen by 25% over baseline 
- 50% increase (at least 1g/day) of 
urine protein to greater than 
1g/day or  
- 25% worsening of serum 
creatinine or creatinine clearance 
Heart - Echo: mean wall thickness >12mm, 
no other cardiac cause 
- NT-proBNP response (>30% and 
>300ng/L decrease if baseline NT-
proBNP  ≥650ng/L)  
- Mean interventricular septal 
thickness decreased by 2mm 
- 20% improvement in ejection 
fraction 
- Improvement by 2 New York Heart 
Association classes without an 
increase in diuretic use, and 
- No increase in wall thickness 
- NT-proBNP progression (>30% 
and >300ng/L increase) 
- Interventricular septal thickness 
increased by 2mm compared with 
baseline 
- An increase in New York Heart 
Association class by 1 grade with a 
decreasing ejection fraction of 
>10% 
- EF progression (10% decrease) 
Liver - Total liver span >15cm in the 
absence of heart failure or 
- 50% decrease in abnormal alkaline 
phosphatase value 
- 50% increase of alkaline 
phosphatase above the lowest 
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- Alkaline phosphatase >1.5 times 
institutional upper limit of normal or 
- SAP scintigraphy evidence 
- Decrease in liver size 
radiographically at least 2cm 
- Regression on SAP scintigraphy 
value 
- Progression on SAP scintigraphy 
Peripheral nerve - Clinical; symmetric lower extremity 
sensorimotor peripheral neuropathy 
 
- Clinical assessment 
- Improvement in electromyogram 
nerve conduction velocity (rare) 
- Clinical assessment 
- Progressive neuropathy by 
electromyography or 
- Nerve conduction velocity 
Autonomic 
nerve 
- Gastric-emptying disorder,  
- Pseudo-obstruction, 
- Voiding dysfunction not related to 
direct organ infiltration 
- Clinical assessment - Clinical assessment 
Gastrointestinal 
Tract 
- Direct biopsy verification with 
symptoms 
- Clinical assessment - Clinical assessment 
Lung - Direct biopsy verification with 
symptoms 
- Interstitial radiographic pattern 
- Clinical assessment 
- Pulmonary function tests 
- Clinical assessment 
- Radiographic evidence 
Soft tissue - Tongue enlargement, 
- Clinical Arthropathy 
- Claudication 
- Presumed vascular amyloid 
- Skin 
- Clinical assessment - Clinical assessment 
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- Myopathy by biopsy or 
pseudohypertrophy 
- Lymph node (may be localized) 
- Carpal tunnel syndrome 
Spleen - SAP scintigraphy  - Regression on SAP scintigraphy - Progression on SAP scintigraphy 
Adrenal - SAP scintigraphy  - Regression on SAP scintigraphy - Progression on SAP scintigraphy 
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Assessment of clonal disease 
 
Total immunoglobulins, Serum protein electrophoresis and 
immunofixation electrophoresis  
All patients had total immunoglobulin levels measured on a BNTMII System 
nephelometer (Siemens, Germany).  Serum protein electrophoresis (SPE) 
and immunofixation electrophoresis (IFE) (Sebia, France) were carried out 
using standard laboratory procedures.  As, some cases can be difficult to 
diagnose, e.g. with the low concentration of monoclonal protein that is often 
typical of IgD-related plasma cell dyscrasia,105 great care is exercised in the 
interpretation of electrophoresis patterns and immunoglobulin profiles.  All 
patients seen at the centre, with suspected AL amyloidosis are routinely and 
specifically screened for the presence of IgD monoclonal protein, especially 
in cases where no M-protein is detected on SPE and the underlying clonal 
disorder appears to be of just light chain origin.  
 
Serum free light chain assay 
All patients had blood tests for kappa and lambda SFLC at presentation 
using latex-enhanced immunoassay - (The Binding Site, Birmingham, United 
Kingdom) on a Behring BNII auto-analyser (Dade Behring, Marburg, 
Germany).107  Serial measurement of SFLC were also carried out at monthly 
intervals during treatment with chemotherapy and 1-2 monthly thereafter. 
This forms a standard part of the assessments in systemic AL 
amyloidosis.110  
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The assay utilises antibodies directed against SFLC epitopes that are 
hidden in whole immunoglobulin molecules, and has a sensitivity of <5mg/l.  
The reference range was determined by testing the sera from 100 healthy blood 
donors; the mean concentrations of polyclonal free kappa and free lambda light 
chains were 11.38mg/L (95% CI, 7.41-16.77mg/L) and 17.36mh/L (95% CI, 
8.91-29.87mg/l) respectively. The mean kappa/lambda ratio was 0.70 (95% CI, 
0.37-0.95). 
 Kappa or lambda values that exceeded the respective reference ranges 
and produced an abnormal kappa to lambda ratio in the context of preserved 
renal function was considered evidence of an underlying clonal disorder.  In 
patients with renal impairment the ratio alone was used.  SFLC values were 
considered evaluable for assessing response if the pre-treatment dFLC was 
>50mg/L with an abnormal SFLC ratio.  The definitions of haematological 
response are outlined in Table 2.5. 
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Table 2.5 - Haematological Response Criteria130 
Clonal response Criteria 
Complete response - Serum and urine negative for a monoclonal protein 
by immunofixation 
- Free light chain ratio normal 
- Normalisation of both light chain classes, unless 
there is renal failure causing polyclonal retention of 
free light chain, in which case the ratio alone was 
used 
Very good partial 
response (VGPR) 
- dFLC < 40mg/L 
 
Partial response 
(PR) 
- If free light chain >10mg/dL (100mg/L) and 50% 
reduction 
- If serum M component >0.5g/dL, a 50% reduction 
- If light chain in the urine with a visible peak and 
>100mg/day and 50% reduction 
Non responder - Patients who could not be classed as achieving 
SFLC-PR or better  
Progression - From CR, any detectable monoclonal protein or 
abnormal free light chain ratio (light chain must 
double)  
- From PR or stable response, 50% increase in 
serum M protein to >0.5g/dL or 50% increase in 
urine M protein to >200 mg/day; a visible peak must 
be present 
- Free light chain increase of 50% to >10mg/dL 
(100mg/L) 
Stable - No CR, no PR, no progression 
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Haematological response criteria 
Hematological responses were assessed as per the consensus criteria 
published by Palladini et al.130  The responses were assessed as the best 
achieved response after starting chemotherapy and before any further therapy 
was given.  Those who died early prior to response assessment were 
categorised as non-responders in the intent to treat analysis (ITT). 
 
Hevylite assay 
Hevylite (The Binding Site Group Ltd, Birmingham, UK) are sheep polyclonal 
antibody-based immunoassays targeted at unique junctional epitopes between 
the heavy chain and light chain constant region of intact immunoglobulins 
(heavy and light chain, HLC).  The assays allow separate quantification of IgGλ, 
IgGκ, IgAλ, IgAκ, IgMλ and IgMκ in serum.  In patients with monoclonal 
gammopathies, Hevylite measurements give an indication of the monoclonal 
and non-clonal immunoglobulin production (e.g. in an IgGλ patient, IgGλ and 
IgGκ concentrations, respectively).  These can be measured in pairs to 
calculate HLC ratios (e.g. IgGλ/IgGκ); HLC ratios outside the reference range 
can give a sensitive indication of clonality.  Table 2.6 shows the manufacturer’s 
reference ranges for Hevylite immunoassays on the BNII  nephelometer.  
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Table 2.6 - Reference ranges for Hevylite immunoassays on the BNII 
nephelometer (as provided by manufacturer) 
 
IgGκ 4.03 – 9.78g/L 
IgGλ 1.97 – 5.71g/L 
IgGκ/IgGλ 0.98 – 2.75 
IgAκ 0.48 – 2.82g/L 
IgAλ 0.36 – 1.98g/L 
IgAκ/IgAλ 0.80 – 2.04 
IgMκ 0.29 – 1.82g/L 
IgMλ 0.17 – 0.94g/L 
IgMκ/IgMλ 0.96 – 2.30 
 
 
The results from this method were a vital part of chapter eight.  HLC 
concentrations (IgGκ, IgGλ, IgAκ, IgAλ, IgMκ and IgMλ) using Hevylite® assays 
(The Binding Site Group Ltd, UK) were measured on serum samples collected 
at the time of presentation, and stored at -80°C prior to any therapy of the 
patients in chapter eight.  
 Hevylite measurements were carried out on a BNII nephelometer 
(Siemens, Germany) using stored serum samples.  Evaluating the 
concentration of a soluble antigen by nephelometry involves the addition of the 
test sample to a solution containing the appropriate antibody in a reaction 
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vessel or cuvette.  A beam of light is passed through the cuvette and as the 
antigen-antibody reaction proceeds, the light passing through the cuvette is in 
excess so the amount of immune complex formed is proportional to the antigen 
concentration.  The light scatter is monitored by measuring the light intensity at 
an angle away from incident light.  A series of calibrators of known antigen 
concentration are assayed initially to produce a calibration curve of measured 
light scatter versus antigen concentration.  Samples of unknown antigen 
concentration can then be assayed and the results read from the calibration 
curve. 
 
Bone marrow biopsies  
All the patients in chapter seven had bone marrow biopsies performed prior to 
treatment, either at the National Amyloidosis Centre or at their local hospital.  
When the procedure was done at the centre, the trephine biopsy was sent to 
Royal Free Histopathology department for further analysis.  Bone marrow 
trephines performed outside of the centre were reviewed at the Haematological 
Malignancy diagnostic service, St James’s University Hospital in Leeds.  The 
plasma cell burden was morphologically estimated on the bone marrow trephine 
biopsy (BMT) on haematoxylin-eosin stain and by CD138 
immunohistochemistry, by an experienced haematopathologist.  Patients with 
≥10% plasma cells on BMT were classified as having AL-multiple myeloma (AL-
MM) and those with <10% plasma cells as having AL-MGUS. 
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Flow cytometry 
Flow cytometric analysis was performed at Haematological Malignancy 
Diagnostic Service, Leeds or the National Amyloidosis Centre (NAC), London, 
United Kingdom, according to the principles outlined by the European Myeloma 
Network.193  Bone marrow biopsies were performed as part of the ongoing AL 
amyloidosis bone marrow study at the National Amyloidosis Centre.  
Leukocytes were prepared by incubation of a volume of BM aspirate containing 
106 leukocytes with 5 mL of ammonium chloride (8.6g/L in distilled water) for 10 
minutes at 37°C, washed twice, and suspended in 5mL of FACS Flow (BD 
Biosciences, Oxford, United Kingdom) containing 0.3% bovine serum albumin.  
The cell pellet was re-suspended in pre-titered antibody mixtures and incubated 
for 30 minutes at 4°C in the dark, washed twice, and re-suspended in FACS 
Flow.  A minimum of 100,000 events were acquired analysed for each antibody 
combination using a Canto II flow cytometer with FACS Diva software (BD 
Biosciences).  A six-colour panel of antibodies was used: CD138 APC (B-B4; 
Miltenyi Biotec), CD45 APC-Cy7 (2D1; BD Pharmingen, Oxford, United 
Kingdom), CD38 PE-Cy7 (HIT2; BD Pharmingen), and CD19 PerCP-Cy5.5 
(HIB19; BD Pharmingen) and the eight colour panel included additionally CD81 
and CD20.  In all cases, expression of CD56 PE (MY31; BD Biosciences) and 
CD27 FITC (M-T271; BD Pharmingen) on gated plasma cells was assessed.  
An aberrant phenotype was classified as a lack of CD19 expression, strong 
CD56 expression, weak CD27 expression, and/or weak CD45 expression and 
were defined as “abnormal” plasma cells.  Plasma cells expressing CD19 and 
lacking the aberrant phenotype were defined as “normal’’ plasma cells.  
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Statistical analysis 
Statistical analysis was undertaken using the SPSS 21 software package 
(SPSS, Chicago, IL) in all the studies apart from the two international 
collaborative studies in chapters five and nine.  Stata 13.1 (StataCorp, College 
Station, TX, USA) was used in chapter five and MedCalc Statistical Software 
version 14.10.2 (MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org; 2014) was used in chapter nine.  Individual statistical 
methods are discussed separately in each results chapter. 
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Chapter Three: Clinical profile and treatment 
outcome of elderly patients with systemic AL 
amyloidosis 
 
This chapter is written in the context of my publication:  
Clinical profile and treatment outcome of older (>75 years) patients with 
systemic AL amyloidosis. Sachchithanantham S, Offer M, Venner C, 
Mahmood SA, Foard D, Rannigan L, Lane T, Gillmore JD, Lachmann HJ, 
Hawkins PN, Wechalekar AD. Haematologica. 2015 Nov;100(11):1469-76. 
Copyright permission obtained from Haematologica office for use in my thesis.  
 
Introduction 
Historically, systemic AL amyloidosis has been reported to have a very poor 
prognosis with a median survival of about 13 months194 but in the last two 
decades with the adoption of autologous stem cell transplantation and 
availability of novel therapeutic agents, improved outcomes have been reported 
with a median survival of 46 months by the Italian group195 and 3.3 years in the 
UK196.  Although, treatment of AL amyloidosis is aimed at the underlying clonal 
disorder, similar to that of multiple myeloma, patients with AL amyloidosis tend 
to experience a higher rate of treatment related toxicity due to vital organ 
involvement.  This poses a great challenge in the management of elderly 
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patients with AL amyloidosis as multiple co-morbidities and frailty further reduce 
the threshold for developing treatment related toxicity leading to premature 
termination of treatment or not being considered for therapy at all.  
Consequently, traditionally, treatment decisions in this group have not been 
straightforward and require careful risk assessment prior to embarking on a 
potentially toxic therapy.   
Anagnostopoulos reported that elderly (>70 years) patients with multiple 
myeloma have a significantly shorter survival than their younger counterparts 
with twice the risk of experiencing early death in the older age group.197  The 
increased risk has been attributed to the presence of co-morbidities and higher 
toxicity from chemotherapy, leading to poor tolerability resulting in early 
discontinuation of treatment and suboptimal response.  Subsequently, 
guidelines have been established to categorise patients into risk groups and 
tailor therapies to individual patients.198 
As the population ages and with 5% prevalence of MGUS in those aged 
over 70 years199, the incidence of AL amyloidosis in the older population is likely 
to increase.  There is very little reported on the outcome of this potentially 
growing subgroup of patients with AL amyloidosis.  The toxicity profile of novel 
therapies are promising and may be better tolerated than some of the 
conventional therapies, permitting treatment of carefully selected elderly 
patients with AL amyloidosis. 
17% of AL amyloidosis patients seen at the UK NAC are >75 years of 
age at presentation.  The aims of chapter three are to understand the outcome 
of patients over the age of 75 years with systemic AL amyloidosis, and to 
explore whether treating elderly patients translates into a better survival and 
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how it compares to the predicted life expectancy of a 75 and 80 year old person 
in the UK.  The chapter also explores risk stratification models, and studies the 
impact of treatment on survival whilst characterising the features of patients 
who received greatest benefit from treatment in terms of survival and 
improvement in amyloidotic organ function. 
 
Methods 
 
Patient selection 
A retrospective review of all the patients above the age of 75 who had been 
evaluated at the UK NAC between 2005 and 2012 were studied.  All patients 
with AL amyloidosis under the age of 75 years seen during the same study 
period, were also identified, to derive proportion of older patients and overall 
survival outcomes.     
 
Outcome measures and Statistics 
The primary outcome measures studied were haematological response to 
treatment and overall survival.  The response was assessed as the best 
achieved response after starting chemotherapy and before any further therapy 
was given.   
 Statistical analysis was undertaken using the SPSS 21 software package 
(SPSS, Chicago, IL).  Categorical variables were compared with chi-square or 
Fisher’s exact tests as appropriate.  Survival was assessed by the method of 
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Kaplan and Meier and compared by log-rank test.  All P values were 2 sided 
with a significance level of 0.05.  Multivariate analysis was by Cox or binary 
logistic regression as appropriate.  All analyses were on intent to treat basis.  
Two land mark analyses were performed: at six months and two years, the 
former time point was to evaluate the impact of presenting factors on early 
survival.  Amyloidotic organ responses are frequently delayed and only patients 
who survive long enough after treatment would benefit from these responses.  
The latter time point was chosen as this was close to the median survival of the 
whole cohort and by which time patients would have organ responses and, 
most importantly, in an elderly population, identifying patients who would 
genuinely benefit from a response to treatment is important.  
 
Results 
A total of 295 patients with AL amyloidosis older than 75 years of age were 
identified, accounting for 16% of a total of 1870 AL amyloidosis patients 
reviewed during the study period.  The proportion of patients over the age of 75 
years increased from 13% in 2005-2006, to 14% in 2007-2008, 17% in 2009-
2010 and 19% in 2011-2012.   
The presenting characteristics of the patients are detailed in Table 3.1.  
There was a male predominance (male: female ratio of 1.4:1).  65% of patients 
had a detectable M-protein.  The median paraprotein at presentation was 8g/l 
(range 1-57). 35% of patients had an isolated light chain clone.  The median 
number of organs involved was 2 (1-7).  Among the entire group, there was 
echocardiographic evidence of cardiac involvement in 51% of cases.  Of the 
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252 patients (85%) with full baseline cardiac biomarkers (both NT-proBNP and 
cardiac troponin-T) available for staging, 54% had Mayo stage III disease at 
presentation.  Among the remaining 43 patients with an incomplete set of 
biomarkers at baseline, 88% had abnormal NT-proBNP and 52% had cardiac 
involvement as defined by echocardiographic criteria.  Renal function was 
normal in only 9% and severe renal impairment (≥stage IV chronic kidney 
disease (CKD)) was seen in 30% of patients.  Ten percent of the cohort had a 
median systolic blood pressure less than 100mmHg and 24% of the cohort had 
NT-proBNP concentration ≥8500ng/L,  both cut-offs associated with a 
particularly poor prognosis.74   
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Table 3.1 Baseline characteristics of the whole patient cohort, and the survivors 
and non-survivors of the two year landmark analysis of treated patients.200  
Patient 
characteristics 
Entire cohort – 
Median (range)/ 
number of 
patients (%) 
Treated patients at 2 years - Median 
(range)/number of patients (%) 
Non 
survivors 
(n=113) 
 
Survivors 
(n=108) 
 
P value 
Age at presentation 
 - 75-80 years 
 - >80 years 
78.5 (75-94.3) 
205 (69%) 
90 (31%) 
78.4 (75-
94.3) 
78.2 (75.1-
86) 
 
0.561 
Sex (Male: Female 
ratio) 
1.4:1 1.4:1 1.6:1 0.784 
Age at death (years) 79.8(75.2-
95.2)/181 (61%) 
79 (75.7-
95.2) 
81.6 (78.4-
87.8) 
 
Monoclonal protein 
type 
    
IgG 118 (40%) 46 (41%) 39 (36%)  
IgA 39 (13%) 12 (11%) 15 (14%)  
IgM 35 (12%) 14 (12%) 13 (12%)  
Light chain only 102 (35%) 41 (36%) 40 (37%)  
Paraprotein 
concentration (g/L) 
8 (1-57) 8 (1-57) 8 (2-26)  
Involved light chain 
type 
    
Kappa (mg/L) 264 (29.1-3880)/ 
71 (25%) 
   
Lambda (mg/L)  168 (26.9-
14000)/ 211 
(74%) 
   
Baseline involved 
FLC (mg/L) 
197 (26.9-
14000) 
240 (27.2-
5631) 
143 (26.9 – 
3880) 
0.001 
Baseline dFLC (mg/L) 174.2 (0.80 – 
13990) 
224(12.2-
5594.1) 
113.6 (7.5-
3877.90) 
0.002 
Organ involvement     
No of organs involved 2 (1-7)    
1 Organ 85 (29%) 18 (16%) 
45 (40%) 
50 (44%) 
39 (36%) 
36 (33%) 
33 (31%) 
0.002 
2 Organs 106 (36%) 
3 or more Organs 105 (35%) 
Cardiac involvement 146 (51%) 73 (67%) 42 (39%)  
Systolic blood 
pressure (mmHg) 
126 (71-202),  121 (71-
192) 
132 (80-181) 0.005 
Systolic blood 
pressure <100 mmHg 
31 (10%) 16 (14%) 4 (4%) 0.006 
NT-proBNP (ng/L)  2720 (51-
112992) 
4093 (118.6-
50271.2) 
843.2 (93.2-
70144.0) 
<0.0001 
Chapter 3 
106 
 
NT-proBNP 
≥8500ng/L 
71 (24%) 33 (29%) 15 (14%) 0.006 
cTnT (ng/ml) 0.0515(0.003-
0.578) 
0.057 (0.00-
0.578) 
0.0245 (0.00 
– 0.269) 
<0.0001 
Mayo stage* n = 252 (85%) n = 98 
(87%) 
n= 92 (85%)  
I 30 (12%) 3 (3%) 
26 (27%) 
69 (70%) 
17 (18%) 
45 (49%) 
30 (33%) 
<0.0001 
II 86 (34%) 
III 136 (54%) 
Renal involvement 230 (78%) 110 (97%) 86 (80%) 0.613 
Serum creatinine 
(μmol/L) 
124 (39-1285) 126 (49-
1285) 
111 (39-612) 0.081 
24 Urine protein 
(g/24h) 
3.4 (0-20.0) 2.02 (0-11) 4.48 (0-20) 0.021 
eGFR (ml/min) 46 (>90-ESRF) 44 (>90 – 
ESRF) 
51.5 ( >90-
ESRF) 
0.076 
≥CKD stage IV 88(30%) 32 (29%) 23 (21%) 0.243 
Renal stage     
1 37 (13%) 17 (17%) 
60 (58%) 
26 (25%) 
18 (21%) 
39 (46%) 
27 (32%) 
0.844 
2 116 (39%) 
3 71 (24%) 
Liver involvement     
Consensus criteria 42 (15%) 25 (23%) 6 (6%) 0.001 
Alkaline phosphates 
(U/L) 
89 (33-1717) 93 (41-
1717) 
85 (33-902) 0.021 
SAP 93 (32%) 41 (36%) 30 (28%) 0.176 
Soft tissue 57 (20%) 24 (22%) 21 (19%) 0.665 
PNS 29 (10%) 15 (13%) 7 (7%) 0.092 
ANS 54 (19%) 26 (23%) 20 (19%) 0.411 
GI 35 (12%) 13 (12%) 8 (7%) 0.279 
NYHA class     
1 – 2 143 (79%) 47 (70%) 
20 (30%) 
58 (95%) 
3 (5%) 
<0.0001 
3-4 39 (21%) 
ECOG performance 
status 
    
0 – 1 148 (52%) 43 (40%) 
43 (40%) 
22 (20%) 
76 (72%) 
24 (23%) 
5 (5%) 
<0.0001 
2 95 (33%) 
≥ 3 43 (15%) 
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Treatment response 
238 (81%) patients were given chemotherapy, and 57 (19%) patients made an 
informed decision to continue with supportive care only.  Details of 
chemotherapy were incomplete in 19 (8.5%) patients and their data were 
excluded from the analysis of treated patients.  Patients received a median of 4 
cycles (range 1-10).  Thalidomide based combinations, mostly dose attenuated 
oral cyclophosphamide, thalidomide and dexamethasone (CTDa), were used in 
100 patients (45%), melphalan-dexamethasone were used in 63 (29%), 
bortezomib based regimens in 30 (13%), other alkylator-steroid combinations in 
7 (3%), and various regimens for lymphoplasmacytic lymphoma in 22 (10%) 
patients.  32% of patients received less than three cycles of treatment and only 
67 (35%) patients completed their planned course of six cycles of treatment.   
Evaluation of haematological response to treatment was undertaken as 
ITT analysis of all 284 (96%) patients and a separate ITT analysis of only those 
patients who actually received chemotherapy.  Five patients were excluded as 
their clonal markers were insufficiently elevated to enable assessment of 
response, and six patients did not attend follow-up.  On an entire cohort ITT 
analysis, 125 (44%) patients had a haematological response with 64 (23%) 
patients achieving a CR or VGPR (11% CR and 12% VGPR) and 61 (21%) 
attaining a PR.  On an ITT analysis of 227 patients who received chemotherapy, 
a haematological response was achieved by 125 (55%) patients with 28% 
CR/VGPR and 27% PR.  One hundred and ninety seven of 238 (83%) treated 
patients were entered in the evaluable response analysis.  This excluded 30 
Chapter 3 
108 
 
patients who died before response assessment.  Of the evaluable patients, 125 
(63%) achieved a haematological response consisting of 32% with CR or VGPR 
(15% and 17% respectively) and 31% with a PR.  Sixty nine percent of the 
patients treated with a bortezomib based regimen attained a haematological 
response, with 61% achieving a VGPR or better.  Fifty three percent of those on 
melphalan and 61% on thalidomide based regimens achieved haematological 
responses respectively (Figure 3.1).  21/197 (11%) patients in the 75-80 year 
group and 9/87(10%) patients in over 80 year age group achieved CR 
suggesting that age did not appear to substantially impact CR rates. 
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Figure 3.1 Haematological response achieved with various chemotherapy 
combinations on an ITT basis.200  The response rates were: Thalidomide based 
combinations – CR/VGPR 30(31%), PR 29(30%); Melphalan dexamethasone – 
CR/VGPR 11(18%), PR 22(35%); Bortezomib based – CR/VGPR 16(61%), PR 
2(8%); other Alkylators – CR/VGPR 3(43%), PR 0(0%); regimens for 
Lymphoplasmacytic lymphoma – CR/VGPR 3(14%), PR 8(38%).  
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Following appropriate counselling, 57 patients decided not to receive 
chemotherapy and have supportive care only.  The median age at diagnosis for 
this subgroup was 79 years (22 (39%) were over 80 years of age).  The median 
age at death was 80 years and median survival without treatment was 8 
months.  These patients had more severe disease than those who received 
chemotherapy.  Cardiac, renal and liver involvement were seen in 25 (46%), 37 
(65%) and 19 (33%) patients respectively.  67% of patients had Mayo stage III 
disease with a median NTproBNP of 6695ng/L of and 42% had NT-proBNP 
above 8500ng/L.  Thirty patients (53%) had eGFR less than 30mls/min at 
presentation and 11 (20%) had systolic blood pressure (SBP) <100mmHg.  
Twelve patients (32%) had NYHA class 3 or above and 37 (66%) had ECOG 
≥2.  
Toxicity data was recorded in detail from 2009 as a part of a prospective 
observational study (ALCHemy) at the National Amyloidosis Centre.  This was 
available for 147 patients of whom 113 (77%) experienced grade three or 
greater toxicity.  Fluid retention in 32% of patients was the most commonly 
reported adverse event followed by infection or sepsis in 17%.  Thalidomide 
based regimens were associated with the greatest toxicity (84%) and 
bortezomib based regimens had the least (70%), but was not statistically 
significant (Fisher’s exact p=0.141). 
 
Survival analysis 
The median overall survival (OS) of the entire cohort was 20.9 months and OS 
at 1, 2 and 5 years were 59%, 47% and 26% respectively, which is inferior to 
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the outcome for AL amyloidosis patients aged <75 years seen at the NAC 
during the same period (median OS 6.1 years) (Figure 3.2a).  Early deaths at 2, 
3 and 6 months were seen in 4%, 9% and 22% of patients respectively.  The 
OS of patients aged between 75 to 80 years was 24.2 months and of those over 
80 years of age was 13.5 months (Figure 3.2a).  Figure 3.2b-f shows the 
survival of the whole cohort and risk factors adversely impacting survival.   
 
Figure 3.2: Kaplan-Meir analysis of survival of the whole cohort and risk factors 
adversely impacting survival.  a) This shows overall survival by age groups 75-
80 years and >80 year old patients with AL amyloidosis compared with those 
presenting at age <75 years.  The median OS of the two older age cohorts is 
24.2 months and 13.5 months, respectively, compared to 73 months in the 
younger patient cohort;  b) This shows OS for patients presenting with 
performance status ECOG 0-1 vs.  ECOG 2 vs ECOG 3-4 - median OS 45.6, 
10.4 and 8.7 months respectively (log rank p <0.0001); c) This shows OS 
stratified by presenting dFLC <180mg/L vs ≥180mg/L  - median OS 33.9 and 
14.3 months respectively (log rank p =0.001); d) This shows OS by presenting 
NYHA class 1-2 vs. NYHA >2 - median OS 37.6 and 8.7 months respectively 
(log rank p<0.0001); e) This shows OS by Mayo stage I, II and III  - median OS 
64, 52.5 and 9.9 months respectively(log rank p<0.0001); f) This shows OS by 
presenting NTproBNP ≥8500ng/L vs <8500ng/L - median OS 8.7 and 30 
months respectively (log rank p<0.0001).200 
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The median OS over 2005-2006, 2007-2008, 2009-2010 and 2011-
2012 were 19.6, 18.5, 14.4 and 52.5 months respectively; showing an 
improvement in survival since 2011, perhaps due to the availability and use 
of novel therapeutic agents (36% of patients were treated with bortezomib 
based therapy during 2011-2012 period compared to only 6% in 2009-2010 
and none prior to 2009) and better supportive care.  Patients who received 
treatment had a median OS of 24.7 months compared to 8.4 months for 
those who chose  supportive care only; p <0.0001.   
A CR or VGPR was associated with better median OS than a PR 
(74.7 months vs. 52.5 months respectively; p = 0.037 both on an ITT analysis 
and of the evaluable patients) (Figure 3.3a).  The estimated five year survival 
in those who achieved a CR was 68% in patients aged up to 80 years and 
89% in those over 80 years of age.  For patients with cardiac involvement, 
those achieving a VGPR or CR had a median OS of 55.6 months compared 
to only 20.2 months for those with PR (p=0.002) and 6.4 months for the non-
responders (p<0.0001) (Figure 3.3b).  The survival advantage for responders 
was also evident within the very poor prognostic group with NT-proBNP 
above 8500ng/L.  The responders within this group had a significantly better 
survival with median OS of 26.8 months compared to only 5 months in the 
non-responder group (p<0.001).  The median OS of those who were treated 
and those who refused chemotherapy was 12.9 months and 4.8 months 
respectively (p=0.009) within this subgroup.  There was an indication of 
better survival for patients treated with the proteasome inhibitor, bortezomib 
(median OS not reached) compared to melphalan (median OS 25.2 months) 
or thalidomide based regimens (median OS 38.9 months) (Figure 3.3c).  
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78% of patients who received bortezomib based regimen had achieved a 
haematological response with 70% achieving a VGPR or better. 65% and 
67% of those on melphalan and thalidomide based regimen achieved a 
haematological response respectively; however, the proportion achieving 
VGPR/CR was slightly higher in the thalidomide (34%) group compared to 
melphalan group (21%).  However, it is difficult to make direct comparison 
between the different regimens as both the reason for choice of 
chemotherapy and the inevitable variability in the supportive care provided 
could have easily influenced survival. 
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Figure 3.3: Kaplan-Meier analysis of overall survival based on haematological 
response to treatment  a)  Show overall survival on ITT basis by haematological 
response, median OS was 74.7 months in those achieving CR/VGPR and 52.5 
months in those achieving a PR compared to 8.8 months in non-responders (log 
rank p <0.0001); b) Shows survival by response for patient with cardiac involvement 
in the ITT cohort – median OS 55.6 months in those with CR/VGPR and 20.2 
months in those with PR and 6.4 months in NR group (log rank p<0.0001); c) Shows 
survival by treatment regimen – median OS not reached in bortezomib group 
compared to 25.2 months and 38.9 in melphalan and thalidomide groups 
respectively (log rank p=0.062); d) Shows OS for patients in 6 month land-mark 
analysis based on haematological response - median OS was 74.7 months in those 
achieving CR/VGPR and 52.5 months in those achieving a PR compared 19.4 
months for non-responders (log rank p<0.0001).200 
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Within the ITT cohort, on univariate analysis, factors adversely 
impacting survival were: poor ECOG performance status, 3 or more organ 
involvement, cardiac involvement, advanced Mayo disease stage, high NT-
proBNP levels, SBP <100mmHg, higher NYHA dyspnoea grade,  peripheral 
neuropathy, liver involvement by ICC criteria or on SAP and  dFLC 
≥180mg/L.  In particular, patients with NT-proBNP ≥8500ng/L (N=72) at 
presentation had a significantly worse outcome compared to those with NT-
proBNP <8500ng/L (Figure 3.2f and Table 3.2).  On multivariate analysis, 
independent factors adversely impacting survival were: poor ECOG status, 
presence of cardiac involvement (separate models run for each: cardiac 
involvement by either of the criteria: ICC, biomarker/echo criteria, advanced 
Mayo disease stage and NT-proBNP ≥8500ng/L), dFLC ≥180mg/L and 
achieving less than a VGPR (Table 3.2).  
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Table 3.2 The median survival of patients in relation to various baseline 
characteristics, univariate analysis and multivariate analysis at baseline, six months 
and at two years landmark analyses respectively.200 
Factor Median 
survival 
by Kaplan 
Meir 
(months) - 
with and 
without 
factor 
P value; hazard ratio (95% confidence interval) 
Multivariate at 
baseline 
Multivariate at 6 
months landmark 
analysis 
Multivariate 
for treated 
patients 
surviving at 
two years 
Cardiac 
involvement* 
45.6 vs. 
12.9 
0.040;1.47 (1.02-
2.07)  
<0.0001;2.52(1.66-
3.82) 
0.030;0.62 
(0.40-0.95) 
Mayo stage*   I: 64 Ref Ref Ref 
II: 52.5 0.21; 1.64 (0.76-
3.54) 
0.17; 1.74 (0.79-
3.83) 
0.17; 1.81 
(0.78-4.18) 
III: 9.9 <0.0001; 2.0 (1.4-
3.0) 
0.003; 3.12 (1.45-
6.69) 
0.006; 3.08 
(1.37-6.92)  
NT-proBNP 
≥8500ng/L vs. 
<8500ng/L* 
8.7 vs. 
30.0 
0.037;1.50(1.02-
2.20)  
  
SBP ≥100 vs. 
<100mmHg 
25.2 vs. 
6.1 
0.006;1.86(1.19-
2.90) 
0.030; 2.03 (1.07 – 
3.84) 
 
Liver involvement 
– SAP 
26.8 vs. 
10.6 
   
Liver – ICC 25.3 vs. 
6.4 
<0.0001;2.21(1.48-
3.30) 
 0.018; 0.55 
(0.33-0.90) 
Number of organ 
involvement (≤2 
vs. ≥3) 
30.0 vs. 
9.7 
   
ECOG 
performance 
status <2 vs. ≥2 
45.6 vs. 
9.7 
0.001;1.8(1.30-
2.60) 
 0.012; 0.60 
(0.40-0.90) 
dFLC ≥180mg/L 
vs. <180mg/L 
33.9 
vs.14.3 
 0.007;1.8(1.17-
2.74) 
0.020; 0.64 
(0.44-0.93) 
Haematological 
response: 
VGPR/CR vs PR 
  0.014;2.17(1.17-
4.03) 
0.027; 1.96 
(1.08-3.54) 
Haematological 
response: 
VGPR/CR vs NR 
  <0.0001;4.31(2.50-
7.47) 
0.000; 5.84 
(3.42-9.97) 
* Multivariate models were generated separately for each of the following cardiac 
variables: cardiac involvement, Mayo disease stage and absolute NT-proBNP < or 
≥8500ng/L.  
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A landmark analysis was carried out for patients alive at six months.  
Two hundred and thirty three of the 295 patients were alive at six months.  
The median OS for these patients was 38.9 months.  This landmark analysis 
confirmed that those achieving a VGPR or a CR had a superior outcome 
compared to those with a PR or the non-responders (median OS of patients 
achieving a VGPR or deeper response was 74.7 months compared to 52.5 
months for lesser degrees of response, log rank p<0.001; Figure 3.3d).  
Factors adversely impacting survival in this group were similar to those 
identified at presentation. 
One hundred and eight of the treated patients survived at least two 
years from diagnosis.  When compared to patients who died before two 
years (n=113), the surviving group, unsurprisingly, had better prognostic 
factors.  The characteristics of the patients surviving over two years are 
detailed in Table 3.1. 
 
Organ responses 
According to the international consensus criteria and renal response criteria, 
on an ITT basis of patients who received chemotherapy, 31/193(16%) had a 
renal response, 14/121 (12%) had a cardiac response and 5/31 (16%) had a 
liver response at six months.  Amongst the assessable patients (i.e. 
excluding those who died before response assessment), 31/104 (30%) had 
achieved a renal response; 14/55 (25%) had a cardiac response and 5/13 
(38%) had a liver response.  On assessing the impact of depth of the 
haematological response on organ response, 58% of the renal responders, 
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71% of the cardiac responders and 38% of the liver responders had attained 
a VGPR or a CR.  At 24 months, 25/193 (13%) had a renal response (of 
whom 50% attained a VGPR/CR), 15/121 (12%) had a cardiac response (of 
whom 73% attained a VGPR/CR) and 5/31 (16%) achieved a liver response 
(of whom 60% attained a VGPR/CR). 
 
Discussion 
Improved awareness of AL amyloidosis and the possibilities for its treatment 
allows for the prospect of more frequent diagnosis of AL amyloidosis in all 
age groups.  In particular, the general longevity and availability of non-
invasive investigative modalities suggest that AL will be increasingly 
recognized in older individuals especially as the prevalence of MGUS, a 
usual precursor of AL, rises with age.  There are no studies, to the best of 
our knowledge, focusing specifically on AL amyloidosis among older 
patients.  Hence little is known about its true natural history or its potential to 
respond (or not) to chemotherapy.  Chemotherapy in AL amyloidosis is 
challenging in patients of all age groups due to multisystem vital organ 
dysfunction, reducing its tolerability and increasing the likelihood of treatment 
related toxicities.  These challenges have historically led to many older 
patients being denied therapy.  In general, amongst cancer patients, 
increasing age and co-morbidities are associated with reduced use of all 
therapies including surgery, chemotherapy, and radiotherapy; consequently, 
otherwise healthy cancer patients frequently do not receive appropriate 
treatments.201  A UK Department of Health document suggested that 
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clinicians may place too much emphasis on chronological age as a proxy for 
other factors which are often but are not necessarily associated with age, 
such as co-morbidities and frailty.202  There are ongoing efforts in the 
myeloma community to define frailty in order to obtain uniformity in clinical 
trials and develop guidance for treating physicians on dose modification of 
currently used treatments.  The issues of frailty due to co-morbidities that are 
likely to worsen with treatment, and frailty caused by the illness for which 
treatment is being given, and which may be partly reversible, remains a 
difficult area to navigate.   
This study was specifically designed to assess the clinical features 
and course of AL amyloidosis in elderly patients.  The median age at 
diagnosis of patients with AL amyloidosis is ~ 60 years29, 195 and nearly a fifth 
of all patients seen at the UK National Amyloidosis Centre were aged >75 
years.  The presenting features of patients aged >75 years were, in general, 
similar to younger AL patients with a mild male predominance and similar 
patterns of organ involvement.  The majority of patients had renal 
involvement, followed by cardiac and liver amyloidosis.  Fifty four percent of 
all patients had Mayo stage III disease at presentation compared to ~40% in 
younger patients142 raising a serious concern that there may be a greater 
delay in diagnosis of amyloidosis in this elderly patient cohort where 
symptoms may well have been attributed to other co-morbidities.  Although, 
in the UK, a substantial majority of patients with amyloidosis are seen at our 
national referral centre, we acknowledge that patients who are very elderly 
with poor performance status may either not be referred or are too unfit to 
travel – a possible bias in this study.  Cardiac amyloidosis in the elderly is an 
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area of increasing interest not only in relation to AL type, but also because of 
wild type transthyretin (ATTRwt) which is increasingly being recognized as 
the cause of heart failure with preserved ejection function in older patients.203  
Therefore, it is important to acknowledge that cardiac involvement may have 
been over estimated in this aged population due to multiple factors, the 
potential overlap of ATTRwt amyloid coexisting with the AL and/or 
hypertensive heart disease.  Use of non-invasive diagnostic tests for cardiac 
amyloidosis is important given the well-recognized limitations of cardiac 
biomarkers in older individuals.204  Modalities such as cardiac magnetic 
resonance imaging205, which has a much higher sensitivity and specificity for 
cardiac amyloidosis than echocardiography may assist differentiation of AL 
and ATTRwt amyloidosis.  In addition, due to the availability of treatment 
options for the ATTRwt, early use of non-invasive radionuclide imaging with 
MRI, 99mTc-DPD206 or 18F-florbetapir207 should be considered to avoid 
diagnostic delay.  
The decisions to proceed with treatment and the type of 
chemotherapy in elderly patients may be influenced by factors including 
social situations that may not be an issue in younger individuals.  One fifth of 
patients in our cohort made an informed decision not to receive 
chemotherapy and chose supportive care only.  This was a frail group, with 
39% aged over 80 years, with poor ECOG status and advanced cardiac 
involvement.  Perhaps due to the limitations of cardiac biomarkers in the 
older patients, biomarker based staging was not always helpful in identifying 
the patients with poorest prognoses – a fifth of Mayo stage III patients 
survived for more than 2 years.  By contrast, functional markers such as 
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NYHA and ECOG, which reflect patients’ overall physiological state, 
appeared to have better discriminatory capacity, since only 10% of those 
with either NYHA 3-4 or ECOG ≥3 were alive at 2 years and had a median 
OS of 9 months.   
The chemotherapy regimens used in the study reflected those in 
practice generally in the UK during the study period.  Thalidomide based 
combinations were commonest in the last decade, with a recent move toward 
bortezomib based regimens.  Treatment was evidently challenging with only 
a third of all patients completing the planned six cycles of chemotherapy and 
three quarters of patients reporting major toxicity.  Thalidomide based 
treatments appeared to be particularly poorly tolerated in this patient group.  
There was a suggestion of better tolerance and higher responses with 
bortezomib based regimens in this cohort but further studies are needed 
before any firm conclusions can be reached.   
The overall hematologic response rate of only 44% based on this 
standard ITT analysis of the whole cohort may appear disappointingly low, 
but when the analysis is performed excluding patients who opted not be 
treated, 63% achieved a clonal response including a third achieving VGPR or 
better.  This response rate compares well to responses reported by our 
group and others using chemotherapy combinations with AL amyloidosis in 
general.135, 142  Whereas, the median OS of the whole cohort of just over two 
years (24.2 months and 13.3 months in the 75-80 and >80 year groups 
respectively) is inferior to the 3-4 year survival of the AL population in 
general 196, deeper clonal responses translated into an excellent survival 
advantage (the 5 year survival amongst haematological responders was 45% 
Chapter 3 
123 
 
with a median OS 6.2 years for those achieving a VGPR or better).  
Although, numbers were small, the estimated 5 year survival for an elderly 
patient achieving a CR was 76% in concordance with AL amyloidosis in 
general.120, 208  When compared to the UK population in general, the Office 
for National Statistics in England and Wales has projected the life 
expectancy for a 75 year old male and female to be 11 and 13 years, and 
that for an 80 year old male and female as 8.2 and 9.6 years respectively.209  
With the outcome of patients in CR approaching this figure, our data 
supports treating older patients with high efficacy regimens aiming to achieve 
deep clonal responses.       
Cardiac involvement is the most important determinant of clinical 
outcome in patients with AL amyloidosis71 in general, and was also 
associated with poor outcome in this cohort of older patients.71  Other factors 
adversely impacting outcomes at presentation on univariate analysis were 
similar to those for AL in general including advanced Mayo stage disease, 
NTproBNP >332ng/L, systolic SBP <100mmHg, dFLC ≥180mg/L, liver 
involvement, ECOG performance status of ≥2 and 3 or more organ 
involvement.  On multivariate analysis, independent factors adversely 
impacting survival were NTproBNP >332ng/L or advanced Mayo stage or 
cardiac involvement (independently analysed), liver involvement by ICC, 
SBP <100mmgHg, dFLC ≥180mg/L and ECOG ≥2.  These factors remained 
significant on the landmark analysis of the 233 (79%) patients surviving 6 
months.  On both the 6 month and two year landmark analyses, additional 
factor which independently impacted survival was achieving a 
haematological response to treatment.  In AL amyloidosis, the final aim is for 
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the haematological responses to eventually translate into organ responses, 
but the latter are often much delayed and organ function may continue to 
improve for a long period in association with a sustained clonal response.  
We attempted to define the characteristics of older patients who survive long 
enough to potentially benefit from the treatment in terms of organ response.  
We chose two years as the time point which was the median of our series 
although recent data on cardiac and renal responses suggests that earlier 
time points may also be useful.  At 2 years, on an ITT basis of patients who 
received treatment, 13% achieved a renal response, 12% had a cardiac 
response and 16% had a liver response.  A high proportion of organ 
responders had achieved a ≥VGPR to chemotherapy.  This gratifyingly 
confirms that, striving for an excellent haematological response is crucial 
since such responses translate into a high proportion of organ responses 
even in elderly patients.  The patients who survived more than two years had 
less number of organs involved, particularly less cardiac involvement (40% 
vs. 70%), lower dFLC (113mg/L vs 224mg/L), higher presenting SBP (only 
4% with SPB <100mm), markedly lower NT-proBNP (843ng/L vs. 4093ng/L) 
and lower troponin-T.  Strikingly, 95% and 72% of the 2 year survivors had a 
presenting NYHA 1-2 and ECOG 0-1 respectively.          
Younger patients with AL amyloidosis may be salvaged with second 
line treatment if response to first line treatment is poor, but the decline in 
performance status among elderly patients due to first line treatment toxicity 
and disease progression may preclude further therapy.  More knowledge is 
required to enable refined patient selection, with the dual objectives of 
avoiding toxicity from unhelpful treatment whilst permitting treated patients to 
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have the best chance of achieving a deep clonal response; thus, age alone 
should not be used as a surrogate of fitness for treatment.  Critical questions 
about the choice of initial therapy, the actual schedule of the regimen, 
especially steroid doses and dose modifications remain unanswered by this 
retrospective analysis.  Similarly, toxicity data remains limited.  Our current 
prospective ALCHemy study may answer some of these questions. 
In summary, the presentation of elderly patients with systemic AL 
amyloidosis is similar to that of AL population in general but there are a 
higher proportion of patients with advanced stage disease, perhaps reflecting 
delay in diagnosis. Outcomes of responders to treatment are good, 
especially so in those achieving a VGPR or better which translate into organ 
responses.  However, treatment toxicity impedes on the tolerability and 
consequently the possibility of achieving a deeper haematological response.  
Choosing an appropriate highly effective first line treatment appears crucial 
as patients may not remain fit for salvage therapies.  Excluding the very frail 
patients with advanced organ involvement who require careful counselling 
about risks vs. benefits of treatment, this study strongly supports the use of 
rapidly effective frontline treatment for older patients with systemic AL 
amyloidosis, striving for an early deep clonal response with good prospects 
of long term survival.  Prospective studies in older patients with novel agents 
with a better toxicity profile and ease of administration, such as oral 
proteasome inhibitors, may allow a greater proportion of this subgroup of 
patients to benefit from treatment.   
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Chapter Four: Immunoglobulin D-associated 
AL amyloidosis – the clinical profile and 
treatment outcomes 
 
This chapter is written in the context of my publication:  Clinical profile 
and treatment outcomes of immunoglobulin D associated AL 
amyloidosis. Roussel M, Sachchithanantham S, Gibbs SD, Venner CP, 
Pinney JH, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD. Br J 
Haematol. 2013 Sep;162(6):856-8. Copyright permission obtained from 
Oxford University Press, licence no. 4037321063107 for use in my thesis 
 
Introduction 
Chapter four focuses on the very rare subtype, IgD-related AL amyloidosis.    
IgD-monoclonal gammopathies are an uncommon phenomenon, 
accounting for less than five percent of patients with myeloma. IgD-
monoclonal gammopathy of uncertain significance (MGUS) is exceptionally 
rare with less than a dozen cases reported in the literature.27  Given that 
most patients with AL amyloidosis have an underlying MGUS, remarkably 
few patients with AL amyloidosis consequent to serum IgD-paraprotein have 
been reported.  IgD-related amyloidosis may be misdiagnosed as light chain 
amyloidosis if patients with a serum light chain band are not routinely 
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screened for the presence of an IgD-paraprotein.  Only 53 such patients 
were identified among the extensive experience of AL amyloidosis at the 
Mayo Clinic over a 41-year period.210  This subgroup supposedly had a 
distinct phenotype – exhibiting lower incidence of cardiac and renal 
involvement with overall survival not significantly different from the other AL 
amyloidosis patients.  This was surprising since IgD multiple myeloma is 
known to have a much worse prognosis and a greater degree of renal 
insufficiency at presentation. 
In this chapter, the experience over a 12 year period at the UK NAC is 
explored, describing the clinical profile of IgD-related AL amyloidosis and 
also the treatment outcomes in this subgroup of patients is presented.   
 
Methods 
 
Patient selection 
 
Among 2861 patients with AL amyloidosis seen between 2000 and 2012, 
serum IgD-monoclonal protein was identified in 20 (0.7 %) patients, who 
were included in this retrospective study.  At the NAC, all patients are 
routinely screened for the presence of IgD-monoclonal protein.  IgD-related 
AL amyloidosis was defined as all patients with confirmed AL amyloidosis 
with demonstrable IgD-paraprotein.  
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Outcome measures and Statistics 
Outcome measures comprised of overall patient survival (OS) and 
hematologic response to first line treatment.  The primary outcome measure 
was OS.   Statistical analysis was undertaken using the SPSS 21 
software package (SPSS, Chicago, IL).  Survival was assessed by the 
method of Kaplan and Meier and compared by log-rank test.  All P values 
were 2 sided with a significance level of 0.05.   
 
Results 
 
Patients, disease characteristics and laboratory findings 
Fifty-five percent of the patients with IgD-AL amyloidosis were male and the 
overall median age was 64 years (range 51-84).  All patients had a 
detectable IgD band on IFE. Eight patients had measurable IgD-monoclonal 
band on serum electrophoresis with a median of 1.5g/L (range 1.0 - 3.5g/L).  
All patients except one had evaluable FLC with abnormal FLC ratios.  
Eighteen (90%) were IgD lambda and 2 (10%) were IgD kappa on serum 
immunofixation.  Median serum involved free lambda and  kappa light chains 
levels were 540mg/L (range 53-6000mg/L) and 387mg/L (range 122-651), 
respectively.  Nine (45%) patients had an underlying (asymptomatic) 
myeloma with over 10% plasma cells in bone marrow and two had 
symptomatic myeloma.  As per the International Amyloidosis Consensus 
Criteria (ICC)69, kidneys were the commonest organ involved in 15 patients 
(75%) with 30% presenting with creatinine clearance less than 50 ml/min and 
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a median 24-hour proteinuria of 2.8g (range 0.5-14.8g).  The median serum 
albumin levels were 33g/L (range 19-47mg/L).  Fifteen (75%) patients had 
cardiac involvement by ICC.  Eight patients had Mayo stage II and four 
patients had Mayo stage III cardiac biomarkers with median NT-proBNP of 
376pMol/L (range 13-3558 pMol/L) and cardiac troponin T of 0.03µg/L (range 
0.01-0.19µg/L) for the whole cohort.  Four (20%) patients had neuropathic 
disease of whom one had peripheral and three had autonomic neuropathy.  
Four patients showed liver uptake on 123I labelled SAP scintigraphy but none 
had liver involvement according to the ICC (median alkaline phosphatase 
levels 110UI/L, range 44-203UI/L).  
 
Treatment 
The first line treatment regimens were as follows: seven patients received 
cyclophosphamide-thalidomide-dexamethasone (CTD), four had vincristine-
adriamycin-dexamethasone (VAD), one had cyclophosphamide-bortezomib-
dexamethasone (CVD), one had upfront autologous stem cell transplantation 
(ASCT) and three were treated with oral or intravenous melphalan.  Of note, 
two patients received consolidation ASCT (one following CTD and the other 
after VAD induction).  One patient refused treatment and three died before 
receiving any chemotherapy.   
Overall haematological response rates on an intention to treat basis 
was 50% and was 62% in the 16 patients who actually received treatment 
with 4 (25%) and 6 (37%) of evaluable patients achieving complete (CR) and 
partial (PR) responses, respectively.  The overall dFLC response rate was 
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63% including dFLC-very good partial response (defined as a greater than 
90% reduction of dFLC from baseline) or better in 7 (43%) patients.  The 
haematological responses in IgD amyloidosis to front line therapy appear 
similar to the responses noted for non-IgD patients in other studies.196  Six 
(32%) patients needed further therapies for progressive disease; this 
included one patient who relapsed with myelomatous bony lesions.  Three of 
these patients received a bortezomib-based second line therapy and the 
remaining three received a thalidomide based regimen.  
 
Clinical outcome 
Median follow-up from diagnosis was 22 months (range 2-93 months).  
Fourteen of the 20 (70%) patients have died; seven (35%) of which were 
within 12 months of diagnosis.  Of note, 3 patients died at 30, 56 and 67 
months from diagnosis, respectively, two were due to progression of multiple 
myeloma which is unusual in AL amyloidosis and the third due to prostatic 
cancer.  The estimated median overall survival (OS) was 27 months (Figure 
4.1).  Although this was not significantly different when compared to the non-
IgD patients, the estimated 5-year OS was 26% for IgD patients compared to 
37% for non-IgD patients over the same time period.   
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Figure 4.1 Overall survival of patients with IgD-associated AL amyloidosis 
compared to all non-IgD patients seen in a 12-year period showing no 
significant difference in the median survival but with a suggestion of poorer 
outcomes of IgD patients in the longer term.  
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Discussion 
In summary, IgD associated AL amyloidosis is rare and is predominantly of 
the lambda subtype.  The clinical phenotype mirrors AL amyloidosis in 
general which could be explained by the fact that the amyloidogenic light 
chains, and not the intact M-protein, lead to the amyloid phenotype.  
Compared to a previously reported series from the Mayo clinic, interestingly, 
the patients in this study had a much higher proportion of renal and cardiac 
involvement at presentation, which is similar to non-IgD associated AL 
amyloidosis.  The early outcomes of IgD-AL amyloidosis appear to be similar 
to previously reported outcomes with AL amyloidosis in general.211  In 
addition, the treatment responses in this subgroup seem to be similar to that 
of non-IgD AL amyloidosis.  
The early prognosis of amyloidosis is driven by the amyloidotic organ 
involvement rather than by the underlying plasma cell dyscrasia – however, 
the longer term prognosis may depend on the sensitivity of the plasma cell 
clone to therapy.  Patients with IgD-AL amyloidosis present with higher clonal 
burdens than AL in general.  Although the overall survival of the patients in 
this series is similar to AL in general, there is a suggestion of inferior 5 year 
survival in the IgD cohort perhaps due to factors such as the higher plasma 
cell burden and clonal resistance playing a vital role in the overall outcome.  
Interestingly, two patients progressed to symptomatic myeloma which is 
uncommon in AL amyloidosis; perhaps, suggesting that unusually for 
amyloidosis, IgD-AL patients maybe at a risk of progression to symptomatic 
myeloma.   
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In summary, IgD-associated amyloidosis is a rare disease but has a 
common AL phenotype.  The response to initial treatment and median overall 
survival are similar to AL in general although there is a suggestion of inferior 
five year survival.  Patients present with higher clonal burdens than AL in 
general and there appears to be higher risk of progression to symptomatic 
myeloma.  
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Chapter Five: Immunoglobulin M-related AL 
amyloidosis - the natural history, outcomes and 
validation of existing prognostic/response 
criteria. 
 
 
This chapter is written in the context of my publication: European 
Collaborative Study Defining Clinical Profile Outcomes and Novel 
Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light 
Chain Amyloidosis.  Sachchithanantham S, Roussel M, Palladini G, Klersy 
C, Mahmood S, Venner CP, Gibbs S, Gillmore J, Lachmann H, Hawkins PN, 
Jaccard A, Merlini G, Wechalekar AD. J Clin Oncol. 2016 Jun 
10;34(17):2037-45.  Copyright permission obtained from Oxford University 
Press, licence no. 4036751396108 for use in my thesis  
 
Introduction 
Chapter four explored the clinical features and outcomes of one of the rare 
subgroups, IgD-related AL amyloidosis.  Chapter five will explore another 
rare subgroup, IgM-related amyloidosis. 
An intact monoclonal immunoglobulin protein (M-protein) can be 
identified in about 45-55% of patient with AL amyloidosis.  The M-protein is 
usually IgG or IgA paraprotein associated with an underlying plasma cell 
disorder.  However, in 5-7% of patients, AL amyloidosis is associated with an 
underlying IgM paraprotein, described in small series by several groups.27, 
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212, 213  It has previously been suggested that IgM-AL amyloidosis should be 
classed as a distinct clinical entity with several distinguishing clinical features 
from that of non-IgM AL amyloidosis.214, 215  Given its rarity, IgM-AL remains 
poorly studied.  Since this disorder is different, as all patients have an intact 
monoclonal protein and appear to have an underlying lymphoproliferative 
disorder, criteria validated for non-IgM AL have not been formally tested in 
this disease.  The treatment paradigms designed for non-IgM AL have been 
used in IgM-AL amyloidosis, which may not always be appropriate.   
Chapter five reports the clinical characteristics, and outcomes in a 
large series of 250 patients with IgM-associated AL amyloidosis seen at 
three major European amyloidosis centres.  This chapter also seeks to 
analyse the utility of prognostic and response criteria, validated in non-IgM 
AL amyloidosis in this rare and distinct sub-group of patients.  This is the 
largest series on IgM-related AL amyloidosis.  
 
Methods 
 
Patient selection 
Two hundred and sixty one newly diagnosed patients with IgM-associated AL 
amyloidosis from amyloidosis centres in London (United Kingdom, 149 
patients), Pavia (Italy, 81 patients) and Limoges, (France, 31 patients) 
between January 1990 and December 2012 were, retrospectively, included 
in this study.  
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Outcome measures and Statistics 
Outcome measures comprised of overall patient survival (OS), hematologic 
response (HR) to first line treatment and organ response.  The primary 
outcome measure was OS.  The validity of currently published staging and 
response criteria in non-IgM AL were applied to this series to assess the 
utility of those criteria in this patient cohort including the impact of HR on the 
survival of this group of patients.  HR were assessed as per the consensus 
criteria published by Palladini et al 130 and by use of serum paraprotein (PP) 
response.   
Survival was described by its median and presented graphically 
by Kaplan-Meier curves. The association of a series of candidate predictors 
and survival were assessed by Cox models.  The proportional hazard 
assumption was tested and satisfied in all cases.  Linearity of ordinal 
predictors was verified by the likelihood ratio test to compare nested models.  
Response was treated as a time dependent variable.  The effect modification 
on the relationship of response and survival by Mayo Stage was assessed by 
including an interaction term in the model.  All non-co-linear variables with p-
value <0.1 at univariate analysis and with missing data below 20% were 
included in a multivariable Cox (time-dependent) regression model.  For all 
Cox models, clustered robust standard errors were computed to account for 
within-country correlation.  Model validation was performed by calculating the 
shrinkage coefficient/noise for calibration and the Harrell's c statistic for 
discrimination.  A 2-sided p-value <0.05 was considered statistically 
significant.  
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Results 
Two hundred and sixty one patients with isolated IgM paraprotein associated 
AL amyloidosis were identified from three European centres.  Eleven patients 
had localised amyloidosis and were, therefore, excluded from analysis.  Two 
hundred and fifty (95%) patients had systemic AL amyloidosis and were 
included in this retrospective study.  The baseline demographics are given 
on Table 5.1.  Forty five percent of those referred before 2004 were over 67 
years of age, this increased in 2004-2009 period to 51% and then to 64% in 
2010-2012.  Cardiac, renal, soft tissue and liver involvement were seen in 
45%, 68%, 35% and 17 % of patients at diagnosis.  40%, 34% and 26% of 
patients had Mayo stage (data available in 216 (86%) patients) I, II and III 
disease respectively.  Lymph node involvement was detected in 20% of 
patients at presentation. 
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Table 5.1 Patient demographics at presentation216 
 
 Median No of patients 
(%) 
Missing 
data (%) 
Age at presentation  67 (38-89) 250 0 
Sex (Male: Female ratio)  1.7:1  0 
Paraprotein concentration (g/L)   10 (IF-70)  35 (14) 
Monoclonal  light chain type    0 
 Kappa  100 (40)  
 Lambda  150 (60)  
Abnormal FLC ratio   163 / 221 (74) 30 (12) 
Evaluable FLC   147 / 221 (67) 30 (12) 
dFLC (mg/l) at presentation 122.3 (30-7762) 
100.5 (30-1343) 
155 (41-7762) 
  
 Kappa 
 Lambda 
Hemoglobin (g/L)  12.5 (7.8-17.7  32 (13) 
Total white cell count (x 109/L)  7.04 (0.56-23)  75 (30) 
Platelets (x 109/L)  294.5 (18-757)  75 (30) 
Creatinine (µmol/L)  97.2 (42-ESRD)  5 (2) 
Albumin (g/L)  35 (12–49)  28 (11) 
Alkaline phosphatase (IU/L)  129 (42-3488)  32 (13) 
24 hour proteinuria (g/24 hrs)  1.78 (0-45)  20 (8) 
Creatinine clearance (ml/min)  64 (ESRD-157)  137 (55) 
Organ involvement    3 (1) 
No of organs involved 2 (1-6)   
 1  81 (32)  
 2  89 (36)  
 3 or more  80 (32)  
Cardiac   112 (45) 2 (0.8) 
 NT-proBNP (ng/L) 609 (17-120737) 
 
19 (9%) 
 35 (14) 
 NT-proBNP >8500 ng/L 
 cTnT (ng/ml)  0.020(0.003-
0.467) 
 
0.020(0.002-
0.599) 
 55 (22) 
 cTnI (ng/ml) 
 IVS (mm)  12 (7-22) 232 (79) 50 (20) 
Mayo stage   216 (86) 35 (14) 
 Stage I  87 (40)  
 Stage II  73 (34)  
 Stage III  56 (26)  
Renal   169 (68) 0 
Liver   41 (17) 0 
Soft tissue  
 Lymph node 
 80 (35) 
50 (20) 
0 
PNS   37 (15) 0 
ANS   32 (13) 1 (0.4) 
GI   22 (9) 3 (1) 
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A total of 131 (52%) patients had a clearly identifiable 
lymphoproliferative disorder (predated the AL diagnosis in 39).  Thirty four 
(14%) had a normal BM biopsy with no detectable clonal dyscrasia.  Fifteen 
(6%) had excess plasma cells in the BM.  Details of BM were not available 
for 70 patients (28%).  Of the patients with an underlying lymphoproliferative 
disorder, 97 (39%) had lymphoplasmacytic lymphoma and 34 (14%) had a 
Non-Hodgkin’s lymphoma (NHL) not specifically classified.  Two patients had 
chronic lymphocytic lymphoma and further two patients had Follicular 
Lymphoma.   
 
Treatment and response 
Two hundred and twenty eight (91%) patients received treatment and eight 
died prior to starting chemotherapy.  Fourteen patients were excluded from 
treatment analysis as information on treatment was not available.  Twenty 
two different combination of regimen were used as first line therapies.  These 
were grouped into ten categories for ease of analysis and are shown on table 
5.2.   
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Table 5.2 Haematological response, median OS, two year survival and time 
to next treatment (TTNT) for each treatment group216  
Treatment type  N (%) Proportion 
with 
cardiac 
involveme
nt (Mayo 
stage III, 
%) 
PR or 
better 
% 
(VGPR 
or 
better, 
%) 
Median 
OS 
(Month
s)  
2 year 
surviv
al (%) 
TTNT 
(Months) 
ASCT 4 (1.8) 25 (0) 100 
(33) 
NR 100 NR 
Chlorambucil / 
Cyclophosphamide 
62 (27.1) 41 (25) 46 (7) 50.8 73 11 
CHOP/COP/VAD 14 (6.1) 21 (33) 62 (0) 49.8 79 21 
Melphalan +/-Dex 53 (23) 58 (28) 70 (26) 22.9 49 8 
FC/CLAD 12 (5) 42 (25) 40 (0) 31.4 58 10 
FCR 11 (4.8) 27 (0) 70 (30) 69.4 73 63 
RCD/RCHL/RCVP/R
CHOP/RTD 
45 (19.7) 44 (23) 63 (15) 91.9 63 20 
Bortezomib 8 (3.5) 50 (25) 57 (42) NR 88 NR 
Rituximab+Bortezom
ib 
8 (3.5) 50 (25) 86 (29) 30.2 75 19 
Thalidomide 11 (4.8) 36 (27) 63 (9) 37.9 55 5 
NR – Not reached. 
 
The median number of lines of therapies was one with a range of 1-5.  
Figure 5.1 shows the changing trend in treatment profile since the year 1990.  
The use of conventional chemotherapy, chlorambucil and melphalan, has 
diminished over time.  Purine analogues, traditional chemotherapy regimens 
and thalidomide were predominantly used between 2005 and 2009.  Since 
2010, the monoclonal antibody, rituximab, was most frequently used in 
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combination with bortezomib or combination chemotherapy (R-CD or R-
CVP/CHOP). 
 
Figure 5.1 Shows the change in treatment trend over time for the ten 
different treatment groups216; ASCT – Autologous Stem Cell Transplantation, 
Bortezomib based regimens, Chlorambucil, Conventional chemotherapy - 
CHOP/COP/VAD, PA – Purine Analogues, Melphalan, Rituximab + 
Conventional chemotherapy, RPA – Rituximab + Purine Analogues, 
RBortezomib – Rituximab + Bortezomib and Thalidomide based regimens, 
for the time period – pre 2004, 2005-2009 and after 2010.   
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Two hundred and twelve of the treated patients had evaluable 
paraprotein (81 by paraprotein alone) or dFLC (12 by dFLC alone) and 119 
by both.  HR data was available for 172 patients (78%) (M-protein data in 49 
patients as dFLC not evaluable).  On an ITT analysis, 102 (57%) patients 
achieved HR (43% partial response (PR), 9% very good partial response 
(VGPR) and 5% complete response (CR)).  Of the 49 patients evaluable for 
M-protein only response, 24 achieved PR, one CR and 24 were non-
responders.  Fifteen patients deemed as non-responders on the basis of M-
protein alone, had achieved PR (13) and VGPR (2) by dFLC response.   
Table 5.2 details treatment regimens, HR with proportion achieving VGPR or 
better, median OS as well as two year survival rates and time to next 
treatment for patients treated with the various first line therapies.  The overall 
responses appeared best with ASCT, R-bortezomib, followed by FCR/R-
Cladribine and Melphalan-Dexamethasone.  However, the numbers are too 
small in individual treatment groups for meaningful statistical comparisons.  
 
Survival analysis 
The median overall survival of IgM-related systemic AL amyloidosis patients 
was 47.9 months (figure 5.2a).  There was no improvement in survival over 
the study period, as shown in figure 5.2b:  The best outcome was seen in 
patients with no identifiable clonal infiltrate in the BM (54 months) when 
compared to those with a lymphoid infiltrate or a plasma cell predominant 
infiltrate (44 months and 23 months respectively).  Patients under the age of 
67 years (median age), had a significantly better survival rate compared to 
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those over 67 years at presentation (62 months vs. 29 months respectively, 
p<0.001).    
Survival by disease characteristics are shown on Figure 5.2c-f.  The 
presence of cardiac involvement conferred significantly worse outcomes 
(median OS 21 vs. 62.5 months for no cardiac involvement), as did advance 
Mayo disease stage (median 73, 24 and 10 months for stage I, II and III 
respectively).  Other factors associated with poorer outcomes were, 
peripheral neuropathy (PN) or autonomic neuropathy (AN), low serum 
albumin (<30g/L) (29 vs 50 months, p=0.008), higher dFLC (>180 mg/L) 
(18.9 vs 48 months, p=0.021) and liver involvement.   
 
Figure 5.2 Shows survival curves216: a) Overall survival of patients with IgM-
related AL amyloidosis with median survival of 47.9 months; b) Survival over 
time - there was no improvement in the survival over the study period.  
Median OS - 48 months before 2004, 50 months for 2005-2009 and not 
reached for 2010 -2012; Figures c-f show survival by organ involvement: c) 
Survival curves by Mayo stage - median OS for stage I, 73 months,  stage II, 
24 months and stage III, 10 months (log rank p <0.001); d) Autonomic 
nervous system  (ANS) involvement vs no involvement, median OS 15 
months and 51 months respectively (p<0.001); e) albumin <30g/l vs >30g/l, 
median OS 29 months and 50 months respectively (p=0.008); f) dFLC 
>180mg/L vs dFLC <180mg/L, median OS 19 months and 48 months 
respectively (p=0.021). 
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In this cohort, only 13% of patients with neuropathy received 
bortezomib or thalidomide.  Table 5.3 details univariate and multivariate 
analysis of factors affecting the overall survival.  Due to co-linearity of cardiac 
variables, different multivariate models of NT-proBNP and Troponin are also 
given in table 5.4.   
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Table 5.3 Factors affecting overall survival – univariate and multivariate 
analysis216 
Factor Median 
survival 
(months) 
Univariate 
HR (95%CI); p-
values 
Multivariat
e 
HR 
(95%CI); p-
values 
Noise in 
model: 
0.10 
Harrell’s C 
coef: 0.76 
Multivariate 
HR (95%CI); 
p-values 
Noise in 
model: 0.07 
Harrell’s C 
coef: 0.78 
Age (years) (<67 vs 
>67) 
62 vs 29 1.64 (1.40-1.92); 
<0.001  
1.96(1.64-
2.35); 
<0.001 
1.89(1.59-
2.24);<0.001 
Paraprotein >10 vs 
<10 
48 vs 50 1.27 (1.04-1.54); 
0.019 
1.33 (0.89-
2); 0.165 
1.34(0.88-
2.06);0.174 
dFLC (mg/l) (<180 
vs >180) 
48 vs 19 1.51 (1.07-2.15); 
0.021 
  
NHL type     
MGUS 54 Ref   
WM/LPL 38 1.43 (0.67-3.06); 
1.000 
  
Other NHL 50 1.35 (0.62-2.94); 
1.000 
  
PC 23 1.54 (0.94-2.54); 
0.131 
  
Cardiac vs Non 
Cardiac 
21 vs 62 2.34 (1.65-3.30); 
<0.001 
  
Mayo stage   p<0.001 P<0.001 
     Mayo stage I  73 Ref 1 1 
     Mayo stage II 24 2.63 (2.14-3.24); 
<0.001 
2.33(2.27-
2.39); 
<0.001 
2.31(2.15-
2.49);<0.001 
     Mayo stage III 10 4.46 (3.11-6.39); 
<0.001 
4.24(2.94-
6.11);<0.00
1 
4.1(2.52-
6.68);<0.001 
Nt-proBNP(ng/l) 
(>332 vs <332) 
19 vs 73 3.15 (2.66-3.72); 
<0.001 
 Not 
included  
Not included 
cTnT >0.035 µg/L or 
cTnI>0.1µg/L 
10 vs 57 2.79 (1.96-3.97); 
<0.001 
Not 
included 
Not included 
Soft tissue vs no 
Soft tissue 
44 vs 55 0.77 (0.49-1.20); 
0.244 
1.41(0.81-
2.46);0.222 
1.38(0.77-
2.47);0.281 
PNS vs no PNS 23 vs 50 1.54(1.21-1.95);  
<0.001 
2(1.9-
2.12);<0.00
1 
1.98(1.79-
2.19);<0.001 
ANS vs no ANS 15 vs 51 2.27 (1.53-3.37); 
<0.001 
2.04(1.77-
2.36);<0.00
1 
2.17(1.68-
2.81);<0.001 
GI vs no GI 
involvement 
24 vs 49 1.19 (0.78-1.84); 
0.420 
Not 
included 
Not included 
Renal vs non Renal 43 vs 55 1.26 (0.91-1.75); 0.86(0.62- 0.85(0.64-
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0.171 1.19);0.361 1.15);0.295 
Liver vs non Liver  21 vs 51 1.36 (1.22-1.52); 
<0.001 
1.32(1.09-
1.59);0.004 
1.36(1.07-
1.72);0.011 
Albumin (≥30g/l vs 
<30g/l) 
50 vs 29 0.64 (0.46-0.89); 
0.008 
0.56(0.25-
1.22);0.145 
0.55(0.25-
1.21);0.138 
Organ involvement     
1 69 Ref   
2 48 1.34 (0.79-2.29); 
0.563 
  
≥3 19 2.42 (1.73-3.37); 
<0.001 
  
Haematological 
response vs no 
response 
69 vs 28 0.58 (0.38-0.88); 
0.012 
Not 
included 
0.66(0.38-
1.15);0.141 
Type of haematological response  
NR 28 Ref   
PR 64 0.64 (0.40-1.04); 
0.073 
  
CR/VGPR Not 
reached 
0.36 (0.21-0.61); 
<0.001 
  
NR – Non responders 
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Table 5.4 Showing NT-proBNP and Troponin in two separate multivariate 
analyses216  
Factor Multivariate  
HR (95%CI); p-
values  
Noise in model:0.04 
Harrell’s C 
coef:0.74 
Multivariate 
HR (95%CI); p-
values 
Noise in model:0.08 
Harrell’s C coef: 
0.74 
Age (years) (<67 vs 
≥67) 
1.93 (1.58-2.36); 
<0.001 
2.03 (1.74-2.37); 
<0.001 
Paraprotein ≥10 vs 
<10 
1.23 (0.77-1.97); 
0.394 
1.50 (1.2-1.87); 
<0.001 
Cardiac vs Non 
Cardiac 
Not included Not included  
Mayo stage Not included Not included 
     Mayo stage I    
     Mayo stage II   
     Mayo stage III   
Nt-proBNP(ng/l) 
(≥332 vs <332) 
2.99 (2.66-3.37); 
<0.001 
Not included 
cTnT ≥0.035 µg/L or 
cTnI≥0.1µg/L 
Not included 3.01 (2.2-4.11); 
<0.001 
Soft tissue vs no Soft 
tissue 
1.35 (0.82-2.2); 
0.237 
1.42 (1.01-1.99); 
0.045 
PN vs no PN 1.82 (1.63-2.04); 
<0.001 
2.16 (1.84-2.53); 
<0.001 
AN vs no AN 2.06 (1.92-2.20); 
<0.001 
2.28 (1.84-2.83); 
<0.001 
GI vs no GI 
involvement 
Not included Not included 
Renal vs non Renal 0.92 (0.71-1.20); 
0.536 
0.93 (0.57-1.51); 
0.773 
Liver vs non Liver  1.20 (1.10-
1.30);<0.001 
1.68 (0.94-2.99); 
0.077 
Albumin (≥30g/l vs 
<30g/l) 
0.59 (0.26-1.32); 
0.198 
0.59 (0.32-1.07); 
0.082 
Haematological 
response vs no 
response 
Not included Not included 
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Combining factors independently predictive of survival (NT-proBNP, 
troponin T, liver involvement and presence of neuropathy), a new risk model 
is proposed.  According to this model, the median survival of patients with 
none, one or two/more abnormal was 90, 33 and 16 months respectively 
(Table 5.5) and outlined in figure 5.3a.  
 
Table 5.5 – Shows proposed new prognostic model for IgM-related AL 
amyloidosis patients216 
 
 
Factors Score 
NT-proBNP >332ng/L 1 
cTnT >0.035 µg/L or cTnI >0.1µg/L 1 
Liver involvement 1 
Involvement of PNS and / or ANS 1 
 
Stage Score Median OS 
(months) 
 1  0 90 
 2 1 33 
 3 2 or more 16 
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Figure 5.3 a-f, a) Shows the proposed new staging system216 using - BNP 
>332ng/L, cTnT >0.035 µg/L or cTnI >0.1µg/L, Liver involvement and 
Involvement of neuropathy. Stage I – no abnormal features, Stage II – one 
abnormal feature and Stage III – two or more abnormal features. The median 
OS for stage I, II and III were 90, 33 and 16 months respectively; b-f) 
Survival by response for entire cohort, by Mayo stage and type of response; 
b) Median OS for those responded to first line treatment - 69 months and for 
non-responders – 28 months (p<0.012); c) Median OS for those achieving a 
VGPR or better was not reached, PR was 64 months and for non-responders 
was 22 months;  d) Median OS for responders within Mayo stage I was 134 
months and for non-responders was 62 months  (p=0.129);  e) median OS 
for responders within Mayo stage II was 54 months and for non-responders 
was 8 months, (p<0.001) and f) Median OS for responders within Mayo 
stage III was 29 months and for non-responders was 8 months, (p=0.005).   
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Patients who responded to their first line treatment had a significantly 
better median OS (69 months) compared to the non-responders (28 months) 
(p<0.012) (figure 5.3b).  Very good partial response as defined by dFLC 
remained a predictor of outcome with median OS not reached for patients 
achieving a VGPR/CR vs. 64 months for those with a PR, (p=0.183) and 22 
months for non-responders (p<0.001) (figure 5.3c).  Amongst the patients 
with only M-protein response, median OS was not reached for responders.  
Responders within Mayo stage II and III had a significantly better outcome 
compared to the non-responders, whereas, there was no significant 
difference within Mayo stage I group, however, the median OS for the 
responders within this latter group was 134 months and only 62 months for 
the non-responders (figure 5.3d-f).  Median time to next treatment (TTNT) 
was 12 months with no significant difference when categorised by involved 
organ (the TTNT for isolated cardiac, renal and liver involvement were 7, 9 
and 9 months respectively). 
 
Organ response 
On an ITT analysis of organ response, cardiac, liver and renal responses 
were 3/57 (5%), 7/26 (27%) and 19/108 (18%).  Organ response rates are 
much lower in the IgM cohort compared to that seen in the IgA/IgG-AL cohort 
in the era of novel agents.217 
Chapter 5 
 
153 
 
 
Discussion 
Systemic AL amyloidosis associated with IgM-paraprotein is a relatively 
uncommon variant of AL amyloidosis and accounts for 6% of AL patients.27  
The National Amyloidosis Centre along with the French and Italian groups 
have previously reported on small series of IgM-AL.  These reports have 
recommended that this sub-group of AL amyloidosis needs to be clearly 
recognised as a distinct condition and considered for specific treatment 
targeting the underlying clone.212, 213, 215, 218  This large series reports the 
presenting features, response to treatment and clinical outcomes.  In 
addition, it also allowed the identification of novel prognostic factors 
(neuropathy and liver involvement) unique to this patient population.  This 
study confirms that deeper haematological responses, although still rare in 
this subgroup, translate into a significant survival advantage.  
Since AL amyloidosis is driven by the amyloidogenic light chains, the 
overall pattern of organ involvement in IgM AL remains broadly similar to that 
seen in non-IgM AL amyloidosis.219, 220  The striking difference is the less 
common cardiac involvement when compared to non-IgM AL amyloidosis 
(45% vs ~70% respectively).220  This difference may be due to the relatively 
lower proportion of lambda light chain isotype in IgM and lower light chain 
clonal burden.  There is a higher incidence of soft tissue and lymph node 
(35%) involvement, (similar to previous reports212, 213) perhaps due to co-
existent lymphoma clone at the respective site.  The prognostic impact of 
nerve involvement was unanticipated.  Only 13% of patients with nerve 
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involvement received bortezomib or thalidomide based regimens, raising the 
question about lack of exposure to novel therapies driving poorer prognosis.   
Clear and correct identification of the underlying clonal disorder is key 
to accurate treatment selection.  The underlying clonal disorder is distinctly a 
non-Hodgkin’s lymphoma in 54% of those who had bone marrow biopsy 
available in this series but plasma cell infiltration is still reported in a 
proportion (6%) as indeed is the lack of identifiable clonal infiltrate (14%).  
The latter group possibly indicates that the clone was mostly confined to the 
lymph nodes with no BM involvement, justifying a lymph node biopsy in such 
cases.  Given the considerable variability in BM reporting as evident above, 
accurate haematopathology review and use of molecular markers like 
MYD88 is crucial.  The poorer outcome in the group with excess plasma 
cells, perhaps, lends credence for the use of agents which actively target 
plasma cells, such as proteasome inhibitors, to be preferentially used in 
these cases.  Cross sectional imaging in IgM AL amyloidosis, particularly to 
assess lymph node, soft tissue and lung disease, may have an important 
role.  Particularly, in those with lymph node involvement where lymphoid 
component will respond to treatment but the amyloid may not change – 
posing a challenge in assessing “true” extent of response. Imaging is 
important in this condition and its role, including PET-CT, needs clarification.  
Contrary to clinical impression and previous publications, 74% of 
patients in this cohort had abnormal FLC.  Patients with either FLC or 
paraprotein response had improved outcomes. Since, all the patients had a 
detectable M-protein at a reasonable level, contrary to emerging literature in 
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non-IgM AL amyloidosis; it may be argued that, in IgM-AL both light chains 
and paraprotein should be used for response assessment.   
Based on previously published smaller series, treatment of patients 
with IgM-AL has evolved; patients with IgM-AL do not fare well with the 
“standard” plasma cell directed therapies, not a surprising observation as 
most cases have an underlying NHL.  This series encompasses the 
changing treatment profiles in this condition.  Although a range of regimens 
were used, rituximab now forms a backbone in most regimens and is used 
with conventional alkylators (R-CD), purine analogues, bendamustine or with 
bortezomib with possible resultant improved outcomes.  However, the 
striking paucity of VGPR/CR (14% vs 44% in bortezomib treated non-IgM 
patients (56% in Mayo stage I cases))221, highlights the difficulties of 
achieving deep clonal eradication in low grade NHL.  There is a suggestion 
in this series that patients who achieve a VGPR have much better outcomes 
than those with lesser degrees of responses – 75% alive at 5 years 
compared to just over 50% of those with PR.  This series validates that the 
goal of attaining a VGPR/CR still remains the therapeutic end point in 
patients with IgM-AL, including in those with Mayo cardiac stage II or III 
disease.  Achieving an improvement in organ function is the final goal of 
therapy.  However, the lack of deep clonal responses also translated into 
paucity in organ responses in this patient cohort compared to non-IgM AL.222, 
223 
Although the median OS in this series is similar to those in previous 
reports224, the OS of early stage disease (Mayo stage I and II) in IgM is 
poorer than non-IgM patients (75% OS at 5 years for stage I vs. >90% in 
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non-IgM AL75, 225, 226); half the expected OS in Mayo stage II patients 
compared to non-IgM cohort (2 vs ~4 years respectively).  Paradoxically, OS 
of stage 3 appears to be similar when compared to non-IgM-AL possibly due 
to a lower incidence of very advanced cardiac AL (NT-proBNP >8500 ng/L)  
in this series  and secondly, the lack of a deep clonal response allowing for 
disease progression.  This re-emphasises the need for the development of 
novel agent based, highly and rapidly effective regimens for this subgroup of 
patients.   
The factors impacting on overall survival are dominated by cardiac 
involvement, similar to the non-IgM cases.  Other poor prognostic factors 
identified were: older age (>67 yrs.) at presentation, AN or PN involvement, 
serum albumin <30g/L, dFLC >180mg/l, paraprotein >10g/L, liver 
involvement and involvement of >2 organs.  On multivariate analysis, the 
independent factors impacting survival were Mayo stage (or abnormal NT-
proBNP and troponin), age >67, neuropathy (PN/AN), and liver involvement.  
The latter two are novel prognostic markers in this group of patients.  The 
adverse impact of liver involvement has been recently demonstrated in Mayo 
stage I patients.227  The finding of PN as a significant prognostic factor has 
important therapeutic implication as proteasome inhibitor, bortezomib 
appears to be effective and PN may potentially limit its use.  A new 
prognostic staging system for IgM-AL amyloidosis that include presence of 
neuropathy and liver involvement, is proposed and presented in figure 5.3a 
(Table 5.5).  This finding requires validation with a further study including 
patients from other major centres.  
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This study has several limitations including its retrospective nature, 
small number of patients in each treatment group, lack of detailed 
haematopathology and imaging for lymphoma diagnosis.  Prospective 
studies in this subgroup of AL amyloidosis are challenging due to the rarity of 
IgM-AL and difficulty of undertaking studies across national boundaries – 
wider international collaborative efforts may help to clarify these questions.    
In summary, IgM-related AL amyloidosis is a rare and distinct clinical 
entity of AL amyloidosis.  A higher proportion of these patients have lymph 
node involvement and lower proportion have cardiac involvement.  Accurate 
characterisation of underlying clonal disorder is crucial in the diagnostic work 
up of patients with IgM-AL.  The revised staging system proposed in this 
disease requires further validation.  Striving for VGPR/CR continues to be 
the primary goal of therapy.  Currently, ASCT and bortezomib based 
regimens seem to be associated with best responses although the prolonged 
time to next treatment observed with FCR raises the important matter of 
accurately targeting the lymphoid component of the clone for longer term 
disease control.  Novel targeted therapies need to be further explored in this 
subgroup of patients. An international tissue and data registry would help to 
broaden the understanding of this disease.     
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Chapter Six: Role of 
99m
Technetium-3,3,-
diphosphono-1,2-propanodicarboxylic-acid 
scintigraphy in patients with light chain (AL) 
amyloidosis 
 
 
Introduction 
The first three results chapters of the thesis have highlighted the challenging 
subgroups of AL amyloidosis patients.  The clinical profile and treatment 
outcomes of elderly patients with AL amyloidosis, those with IgM-related and 
IgD-related amyloidosis have been explored and compared to AL 
amyloidosis in general whilst highlighting the challenges in these subgroups 
of patients.  The thesis will now focus on novel investigations and prognostic 
markers which would potentially improve the diagnostic process and help 
better risk stratify patients and formulate appropriate management plan.   
 Whilst histological demonstration of amyloid deposition is the gold 
standard for the diagnosis of amyloidosis, sampling errors, invasive nature of 
biopsies and procedure related high risk complications are impediments.  
Moreover, histology cannot provide information on amyloid distribution, 
extent and disease progression.  Conversely, non-invasive imaging offers a 
better method for assessing extent of amyloid deposition although the 
numbers of amyloid specific imaging tracers available are limited.  It is 
therefore necessary to develop non-invasive imaging modalities to evaluate 
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amyloid load, quantify and monitor disease progression and response to 
treatment.  Much progress has occurred in the development of non-invasive 
imaging methods over the last decade.  These include serum amyloid P 
component (SAP) scintigraphy, cross sectional computerised tomography 
(CT), positron emission tomography (PET) tracers, cardiac magnetic 
resonance imaging (CMR) and a number of bisphosphonate bone tracers.  
123I-SAP scintigraphy has been in routine clinical use at the National 
Amyloidosis Centre for over two decades for visceral imaging but is unable to 
image amyloid deposits in the heart, lungs, nerves or soft tissues.80  The 
bisphosphonate tracer, 99mTc-DPD has been identified as one of the most 
sensitive methods of imaging cardiac amyloid deposits in transthyretin 
(ATTR) amyloidosis.97 
 As yet, there are no reported modalities for specifically imaging soft 
tissue amyloid deposits, and hence, diagnosis is usually based on biopsy of 
the suspicious lesion if this is deemed safe. 
 18Fluorine labelled fluorodeoxyglucose-positron emission tomography 
(FDG-PET) has been reported to be positive in patients with localised AL 
amyloidosis228 – the reason for the FDG uptake remains unclear but has no 
relationship to the amyloid fibrils per se and is due to either the infiltration of 
monoclonal B cells or the cellular tissue reaction to the amyloid fibrils.   
 The utility of 99mTc-DPD for imaging soft tissue amyloid deposits has 
never been fully reported.  This chapter reports on the specific uptake of the 
bisphosphonate bone tracer, 99mTc-DPD by amyloid deposits in soft tissue, 
lymph nodes (LN) and lung parenchyma.  
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Methods 
 
Patient selection 
The study was performed at the UK National Amyloidosis Centre (NAC) and 
included all patients with localised amyloidosis who underwent 99mTc-DPD 
scintigraphy between 2010 and 2015.  All patients assessed had routine 123I-
SAP scintigraphy for assessment of visceral amyloid deposits and 99mTc-
DPD scintigraphy for cardiac amyloidosis.    
 
99mTc-DPD Scintigraphy 
Patients were scanned as previously described, using General Electric 
Medical Systems hybrid gamma cameras (Infinia Hawkeye 4 and Discovery 
670) following the intravenous injection of 700 MBq of 99mTc-DPD.206  In brief, 
whole body planar images were acquired three hours post-injection followed 
by SPECT-CT (single photon emission computed tomography with a low-
dose, non-contrast CT scan) at the site of 99mTc-DPD uptake.  
 
Results 
A total of twenty six patients were included in this study.  All 26 patients had 
extra-cardiac uptake on 99mTc-DPD scintigraphy and none had cardiac 
uptake.  These were confirmed on SPECT/CT.  Table 6.1 summarizes the 
baseline characteristics for these patients.  Using the ICC, one patient had 
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cardiac involvement, two had liver involvement and one had macroglossia.  
On cross-sectional imaging the extra-cardiac organs involved were:  LNs in 
17 (65%) (Figure 6.1a), breast in three (12%) (Figure 6.1b), 
skin/subcutaneous soft tissue in three (12%) (Figure 6.1b) and lung in five 
(19%) (Figure 6.1c).  All 26 patients had biopsy proven amyloid deposits.  
23/26 (88%) had a biopsy taken from the site of extra-cardiac uptake 
confirming amyloid deposition.  The underlying clonal dyscrasia was plasma 
cell in 14 and IgM producing lymphoma in seven patients.   
Table 6.2 shows the distribution of uptake on 99mTc-DPD scintigraphy 
for the 26 patients. Five had visceral uptake on 123I-SAP scintigraphy (liver 
and spleen in one and spleen in four), however none of these patients 
showed corresponding 99mTc-DPD uptake in the liver or spleen.   
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Table 6.1 Baseline characteristics of twenty six patients with extra-cardiac 
uptake on 99mTc-DPD scintigraphy. 
 
Variables Total number 
(%)/Median(range) (n=26) 
Male: Female ratio 1.36:1 
Age (years) 73.5 (49.2-86.9) 
Confirmation of amyloid deposition 
Breast tissue 
LN 
Lung parenchyma / Pleural 
Fat aspirate 
Orbit tissue 
26 (100%) 
3 (12%) 
17 (65%) 
5 (19%) 
1 (4%) 
1 (4%) 
Type of underlying clonal disorder   
IgA 
IgG 
IgM 
Light chain only 
21 (85%) 
1 (4%) 
10 (38%) 
7 (27%) 
3 (12%) 
Presenting paraprotein level (g/L) 12 (IF – 26) 
Involved light chain – Kappa: 
Lambda 
11:15 
Organ involvement  
Cardiac 1 (4%) 
Renal 0 
Liver 2 (8%) 
Neuropathy 2 (8%) 
Systemic vs Local AL 8 (19%) vs 18 (69%) 
NT-proBNP (pmol/L) 31.5 (4-668) 
Troponin T (µg/L) 10 (3-98) 
Mayo stage biomarkers 
1 
2 
3 
Missing 
 
12 (46%) 
9 (35%) 
1 (4%) 
4 (15%) 
Creatinine clearance (mls/min) 65.5 (22.4-166) 
Albumin (g/L) 43 (31-47) 
ALP 77 (13-193) 
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Table 6.2 Involvement by amyloid deposits and distribution of uptake on 99mTc-DPD 
scintigraphy  
No Sites Uptake on 99mTc-DPD scintigraphy 123I SAP 
uptake 
1 LN Axillary, cervical and hilar nodes Nil 
2 LN Left hilum, subcarinal and para-tracheal nodes  Nil 
3 LN Hilar and para-tracheal nodes Nil 
4 LN Mediastinal and para-tracheal nodes  Nil 
5 LN Mediastinal mass, mediastinal nodes and 
pericardial uptake 
Nil 
6 LN Bilateral axillary, right supraclavicular and 
mediastinal nodes 
Nil 
7 Lung 
parenchyma 
Diffuse parenchymal lung involvement in 
association with likely pleural involvement 
Nil 
8 LN Axillary node Nil 
9 Breast, soft 
tissue 
Bilateral breast, lower limb and pelvic girdle Nil 
10 Soft tissue Soft tissue within right leg Nil 
11 LN Right axillary node Nil 
12 Breast  Soft tissue deposits within the subcutaneous fat Nil 
13 LN Cervical, sub-pectoral, supraclavicular,  
retroperitoneal and pelvic nodes 
Nil 
14 Lung 
parenchyma  
Soft tissue masses within the thorax Nil 
15 Lung 
parenchyma 
Pulmonary nodules Nil 
16 Lung 
parenchyma 
Pulmonary nodules Nil 
17 LN Mediastinal nodes Nil 
18 Lung 
parenchyma 
Bilateral lung fields Nil 
19 LN, Liver, 
bile duct 
Axillary, mediastinal, retroperitoneal, mesentery, 
inguinal and pulmonary nodules and hepatic 
parenchyma 
Spleen 
20 LN, Breast, 
Skin 
Breast, soft tissue, lymph node Nil 
21 LN Lymph nodes above and below diaphragm  Spleen 
22 LN, Cardiac, 
Liver, PN 
Para-tracheal, pre-carinal, retrocrural and para-
oesophageal nodes 
Spleen, 
Liver 
23 LN, 
Macroglossia 
Cervical, supraclavicular, bilateral axillary and 
mediastinal nodes 
Nil 
24 LN Inguinal nodes Spleen 
25 LN Left inguinal, left external iliac, common iliac and 
retroperitoneal nodes 
Spleen 
26 LN, PN Bilateral Cervical and axillary nodes  Nil 
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The median duration of follow-up was 23.45 months (range 0.93 – 
104.8 months). One of the 17 patients with LN uptake had repeat 99mTc-DPD 
scintigraphy 25 months later which showed evidence of progressive lymph 
node involvement, demonstrating significantly increased intensity and size of 
the abnormal foci of tracer uptake in the same distribution as well as new 
nodal involvement (Figure 6.1d). 
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Figure 6.1a-d Figures demonstrate images of 99mTc-DPD uptake in four AL patients, by a) Lymph node, b) breast and skin, c) Lung 
parenchyma and d-I) Lymph nodes at baseline and d-II) 25 months later showing progression. 
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Discussion 
 
Whilst cross-sectional imaging will show abnormal tissue deposition, it lacks 
specificity for amyloidosis.   There are no imaging modalities that provide 
information on the extent of disease in localised amyloidosis. Identification of 
amyloid deposits in soft tissue and small sites such as LNs are mainly from 
biopsy confirmation of the affected sites.   
Myocardiac uptake of bone tracers, particularly DPD, and other bone 
tracers, is well known. An abundant literature exists on the subject, 
attributing such uptake to various causes, but first and foremost to cardiac 
transthyretin (TTR) amyloidosis.229, 230  In addition, sparse reports of soft 
tissue uptake in bone scans have been published along with possible 
mechanisms for the phenomenon.231-233  De Haro et al234 reported tissue 
uptake of 99mTc-DPD in a patient with biopsy proven systemic AL 
amyloidosis. Tracer uptake was seen in the heart, thyroid, parotid glands, 
uterus and intestinal tract.234  Reports have also described soft tissue uptake 
by the liver, heart, skeletal muscle, and splenic uptake by 99Tc-MDP and 
99Tc-PYP scans of AL amyloidosis patients. 235, 236 Itoh et al in 1992 reported 
a case of primary amyloidosis with calcification of systemic lymph nodes 
which were demonstrated as positive by bone scintigraphy.237 
This study reports the important findings of extraosseus and extra-
cardiac uptake of bone tracers on 99mTc-DPD scintigraphy in 26 patients with 
AL amyloidosis involving various sites.  SPECT-CT images can help 
precisely delineate the non-osseous uptake and identify calcium content of 
the site.  What was striking in these parties was the lack of cardiac uptake 
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even though all demonstrated tracer uptake in sites other than the heart. The 
sites showing increased uptake were predominantly LN but also included 
breast tissue, lung parenchyma and muscle.  
Seventeen patients had LN uptake at various sites. LN involvement 
either isolated or as part of systemic amyloidosis is currently imaged with CT 
or PET-CT scans both to document the extent of the disease and assess any 
response to treatment. 99mTc-DPD scintigraphy also may have a role in 
detecting the extent and distribution of LN amyloidosis and differentiating this 
from lymphomatous infiltration.  
Pulmonary AL amyloidosis is rare and can potentially present in five 
different forms: Diffuse interstitial or alveolar-septal disease, nodular, intra 
and extra-thoracic adenopathy, pleural disease and diaphragm deposition.238  
It is difficult to diagnose - patients often present with nodules which need 
invasive biopsy (often surgical).  Five patients with AL amyloidosis proven on 
lung parenchymal tissue had tracer uptake involving lung fields or pulmonary 
nodules on 99mTc-DPD scintigraphy. 123I-SAP scintigraphy is not able to 
provide images of amyloid deposits in diffuse organs such as the lungs. CT 
is the most frequently used imaging modality in amyloidosis confined to the 
respiratory tract, providing quantitative assessment of airway narrowing and 
extent of disease locally. Diffuse pulmonary amyloidosis is better identified 
on high-resolution CT which is also useful in monitoring the disease course 
with the help of serial pulmonary function tests.  Our findings suggest that 
99mTc-DPD would complement CT in the diagnosis of pulmonary AL 
amyloidosis involving the respiratory tract.  
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AL amyloidosis of the breast is an unusual diagnosis and has been 
reported by several groups and account for 0.5% of all patients referred to 
amyloid treatment centres.239 Amyloidosis of the breast may present as a 
distinct lesion or intermixed with breast cancer in about 50% of cases.240 
Patients rarely experience any clinical symptoms and the initial findings are 
noted on a mammogram or an ultrasound. Three of the patients from this 
study with AL amyloidosis proven on breast tissue biopsy had 99mTc-DPD 
uptake in the affected breast. One of these patients had systemic 
amyloidosis and the other two had localised form.  Whilst 99mTc-DPD 
scintigraphy is not a substitute to the current investigative modalities of 
breast lesions, it can certainly play a role in confirming the diagnosis of 
breast tissue amyloidosis in affected patients complementing the existing 
techniques. 
Pathologic conditions which may lead to a soft-tissue accumulation of 
diphosphonate and pyrophosphate have been reviewed by Brill et al.241 
However, all the reports so far have been in liver, spleen and skeletal 
muscle. This is the first series reporting uptake in LNs, breast and lung 
tissue. The mechanism of 99mTc-DPD soft tissue or LN uptake in light chain 
amyloid patients is not clear.  The binding of radionuclide labelled calcium 
seeking agents, may be explained by the high calcium content of amyloid. 
The result obtained by nuclear bone scans most likely depends on the type 
of calcium-seeking agent used and the amyloid content at the site.242 The 
failure to demonstrate 99mTc-DPD accumulation does not exclude the 
possible presence of amyloid. In order to understand this phenomenon 
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further, a directed biopsy of lesions with significant soft tissue uptake by the 
agent suggesting the presence of amyloid deposits is vital.  
Other imaging techniques such as 18F-fluorodeoxyglucose (FDG) 
positron emission tomography-CT (PET-CT) scans showing FDG avidity at 
known disease sites of some localised AL amyloidosis are also gaining 
popularity.228 Recently, a phase I study using murine IgG1 mAb 11-1F4 
labelled with 124Iodine reported 18 patients with AL amyloidosis in which fifty 
per cent of the patients showed uptake in liver, lymph nodes, bone marrow, 
intestine or spleen (but not kidneys or heart).102 
In summary, moderate to intense uptake of radiolabelled bone tracers 
by LN, lung and breast tissue amyloid have not been widely recognised. 
99mTc-DPD scintigraphy is a useful imaging modality to detect soft tissue, 
particularly, LN, breast tissue and lung parenchymal amyloid and may also 
be useful for serial imaging.  This technique is particularly useful in patients 
with IgM related AL amyloidosis in which soft tissue amyloidosis accounts for 
35% of patients of whom 20% have LN amyloidosis.216 It also has a role in 
complementing the current diagnostic modalities in patients presenting with 
localised AL amyloidosis involving soft tissue such as breast and pulmonary 
amyloidosis.    
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Chapter Seven: The prognostic role of 
multicolour flow cytometry in AL amyloidosis 
 
Introduction  
It is very well established that the prognosis of AL amyloidosis is very much 
dependent on the extent of organ damage, mostly determined by cardiac 
involvement.   In the last decade, there has been an improvement in the 
overall survival of patients with systemic AL amyloidosis following the advent 
of novel anti-plasma cell agents.  However, there continues to be a subgroup 
of patients with advanced AL amyloidosis with a dismal outlook despite the 
availability of many therapeutic agents and better supportive care.  Lately, 
the impact of plasma cell clone on outcomes has become a focus of interest 
since the treatment is to eliminate the underlying clonal PCs following the 
principles of treatment in multiple myeloma.   
The Mayo cardiac staging has remained the most widely used and 
clinically relevant prognostic system in AL.  Additionally the level of the 
amyloidogenic precursor, the serum free light chain level, has also been 
incorporated in the staging system.  However, the final determinant of 
outcomes in AL is the actual biologic characteristics of plasma cell clone 
which governs the sensitivity to treatment, duration of response after 
treatment and development of clonal resistance – all of which are well 
studied in symptomatic myeloma but remain to be fully explored and 
understood in AL amyloidosis.  The Mayo group also recently showed that 
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patients with an absolute bone marrow plasma cell (BMPC) percentage 
greater than 10% had inferior outcomes compared to those with lower 
percentages – outcomes of the former similar to symptomatic myeloma.243  
In monoclonal gammopathy and smouldering myeloma, determination of 
proportion of the ‘normal’ and clonal plasma cells in a bone marrow sample 
has prognostic significance.244  Paiva et al recently reported in a small series 
that AL patients with more than five percent ‘normal’ BMPC (defined as cells 
expressing CD38+CD138+CD19+) at diagnosis had a better prognosis.119  
Since then, a study by the Mayo group, reported on the prognostic role of 
multicolour flow cytometry (MFC) in AL amyloidosis at diagnosis and at the 
end of treatment.  They also concluded that MFC may have a role in defining 
haematological response.245 
This study explores the impact of bone marrow plasma cell burden on 
outcomes in systemic AL amyloidosis, using both standard morphological 
techniques to determine plasma cell percentages as well as proportion of 
‘normal’ plasma cells as determined by MFC. 
 
Methods 
 
Patient selection 
This study included all patients with newly diagnosed systemic AL 
amyloidosis, seen at the UK National Amyloidosis Centre between 2005 and 
2013.  All patients included in this study were required to have had both bone 
marrow trephine (BMT) and MFC performed at presentation either at the UK 
National Amyloidosis Centre or at the Haematological Malignancy diagnostic 
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service, St James’s University Hospital in Leeds during the study period.  
The plasma cell burden was morphologically estimated as previously 
described.    
 
Outcome measures and Statistics 
Primary outcome measures studied was overall survival. Statistical analysis 
was undertaken using the SPSS 21 software package (SPSS, Chicago, IL).  
Survival was assessed by the method of Kaplan and Meier and compared by 
log-rank test.  Categorical variables were compared with chi-square or 
Fisher’s exact tests as appropriate.  All P values were 2 sided with a 
significance level of 0.05.  ROC analysis was undertaken to identify cutoffs 
for proportion of ‘normal’ vs. aberrant plasma cells by MFC.  Multivariate 
analysis was by Cox or binary logistic regression as appropriate.     
  
Results 
There were 103 patients with biopsy proven systemic AL amyloidosis with 
bone marrow trephine biopsy results and MFC performed on bone marrow 
aspirates.  The median age was 64.7 years (range: 38.5-83.3) with a male-
female ratio of 1.6:1.  Sixty-three (61%) had cardiac involvement.  Table 7.1 
shows patient characteristics at presentation.  BMT was inadequate for three 
patients. The median plasma cell percentage was 15% (range 2-90%) for the 
remaining 100 patients.  Fifty five patients (55%) had ≥10% PCs on trephine 
(classed as AL-MM) and 45 (45%) had <10% (classed as AL-MGUS).  All 
patients had MFC and the median total plasma cell on MFC was 1.100% 
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(range: 0.017-12.630).  All patients had aberrant plasma cells on MFC.  The 
median neoplastic PCs were 96% (range: 9.82-100%).  The median normal 
PCs were 4.00% (range 0-72.57%).  ROC analysis identified presence of 
≥10% normal PC as a proportion of total plasma cells in a BMT sample as a 
significant cut-off for survival outcomes.  Thirty (29%) patients had ≥ 10% 
normal PCs on MFC and 73 (71%) had <10% normal PC.  21/30 (70%) of 
those with ≥10% normal PC by MFC had been reported as having AL-MGUS 
by morphology on BMT.  There was a statistically significant negative 
correlation between the plasma cell percentage of BMT and the normal PC 
percentage on MFC (Spearman correlation -0.394, p=0.004).   
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Table 7.1 Patient characteristics at presentation. 
Patient characteristics Number of patients (%) / 
Median (range) 
No. of patients 103 
Sex (Male: Female) 1.6:1 
Age at presentation (range) 64.7 (38.5-83.3) 
Monoclonal protein type  
IgG 
IgA 
IgM 
IgD 
Light chain only 
 
31 (30%) 
9 (9%) 
2 (2%) 
1 (1%) 
60 (58%) 
Paraprotein concentration 
(g/L) 
12 (IF-23) 
Involved free light chain 
type 
Kappa (mg/L) 
Lambda (mg/L) 
 
32 (31%) / 120 (21-9290) 
71 (69%) / 190 (26.8-2940) 
Baseline involved FLC 
(mg/L) 
170 (21-9290) 
Baseline dFLC (mg/L) 169 (0.20-9280) 
Organ involvement  
Cardiac  63 (61%) 
Systolic blood pressure 
(mmHg) 
100 / 118 (80-178) 
Systolic blood pressure 
<100 mm of Hg 
17 (17%) 
NT-proBNP (ng/L) 
BNP ≥332ng/L 
BNP ≥8500ng/L 
102 / 2127 (34-46373) 
79 (77%) 
21 (21%) 
TnT ng/ml 80 / 0.057 (0.005 – 0.73) 
Mayo Stage n= 80 (78%) 
I 
II 
III 
16 (20%) 
29 (36%) 
35 (44%) 
LVS (mm) 83 / 13 (7-21) 
Renal 82 (80%) 
Serum creatinine (μmol/L) 101 / 87 (36-781) 
Urinary protein (g/24hrs) 96 / 3.10 (0-18) 
Albumin  100 / 34 (16-50) 
Liver by consensus criteria 25 (24%) 
Alkaline phosphates (U/L) 101 / 85 (19-1347) 
PNS 11 (11%) 
ANS  15 (15%) 
Soft tissue  18 (18%) 
MGUS vs MM 43:57 
Alive / dead 50:53 
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There was a higher proportion of renal involvement in the ≥10% 
‘normal’ PCs group (28/30 (93%) vs. 54/73 (74%); p=0.031) whilst the 
converse was true for cardiac involvement.  There was a significant negative 
correlation between ≥10% normal PCs on MFC and cardiac involvement 
(Spearman correlation -0.454, p <0.001).  Only 8/30 (27%) patients with 
≥10% normal PC by MFC had cardiac involvement compared to 55/73 (75%) 
of those with <10% normal PCs (p <0.001).  The group with ≥10% normal 
PCs also had a significantly lower number of patients with systolic blood 
pressure (SBP) <100mmHg (1/30 vs 16/70; p=0.017) and lower NT-proBNP 
(median 589ng/L vs. 3288ng/L, p=0.001), surrogate markers of advanced 
cardiac involvement.  The median dFLC in patients with ≥10% normal-PC 
was 38 mg/L compared to 233 mg/L for those with <10% normal PC 
(p<0.001).  Of the patients with dFLC of <180mg/L, 24 had ≥10% normal PC 
and 27 had <10% normal PC; for those with dFLC ≥180mg/L, the numbers of 
patients with ≥ or < 10% normal PC were 6 and 45 (p<0.001) respectively.  
The former group therefore had lower number of patients with 
dFLC≥180mg/L (6/51, p<0.001).  
 
Survival Outcomes 
The median overall survival (OS) for the whole cohort was 36.6 months.  The 
morphological percentage of plasma cells identified by BMT had a non-
significant impact on OS:  AL-MGUS - 36 months and AL-MM - 27.7 months 
(p=0.605).  Patients with ≥10% normal PCs on MFC had a significantly better 
survival (median OS not reached) compared to those with <10% normal PCs 
(18.1 months) (p = 0.012) (figure 7.1a-c).  We assessed the impact of < or 
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≥10% normal PCs by MFC in patients with morphologically determined AL-
MGUS or AL-MM.  The median OS of patients with AL-MGUS by BMT with 
≥10% normal PC on MFC was 63.2 months and <10% normal PCs was 8.3 
months (p=0.038) with estimated five year survival 60% and 34% 
respectively.  Median OS of patients with AL-MM by BMT with ≥10% normal 
PC by MFC was not reached compared to 18.1 months for those with <10% 
normal PC (p=0.151) with estimated five year survival 75% and 37% 
respectively (Figure 7.1d).  Within the respective ≥10% and <10% normal PC 
groups on MFC, there were no significant difference in the overall survival of 
those with AL-MM and AL-MGUS by BMT (p=0.75 and p=0.81 respectively).  
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Figure 7.1a-d Shows a) Overall survival of the whole cohort (36.6 months); 
b) the median OS of patients with AL-MGUS (36 months) and AL-MM  (27.7 
months) (p=0.605), based on the morphological percentage of plasma cells 
identified by BMT; c) the median OS of patients with ≥10% normal PCs 
(median OS not reached) compared to those with <10% normal PCs (18.1 
months) (p = 0.012) on MFC; d)  the median OS of patients with AL-MGUS 
by BMT with ≥10% normal PC on MFC (63.2 months) and <10% normal PCs 
(8.3 months) (p=0.038), median OS of patients with AL-MM by BMT with 
≥10% normal PC by MFC (not reached) and those with <10% normal PC 
(18.1 months) (p=0.060)  
 
  
 
  
 
a 
d c 
b 
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The impact of organ involvement and overall survival stratified by presence 
of ≥10% normal PCs or <10% normal PCs is shown in table 7.2.   
 
Table 7.2 The impact of organ involvement and overall survival stratified by 
presence of ≥10% normal PCs or <10% normal PCs 
Organ 
involved 
No of patients 
categorised by % of PCs 
on MFC (%) 
 
Median survival by Kaplan 
Meir (months) categorised 
by % of PCs on MFC 
 - with and without factor  (P 
value) 
≥10%  <10%  P value ≥10%  <10%  
Cardiac  8/30 
(27%) 
55/73 
(75%) 
<0.001 25.6 vs NR 
(0.180) 
5.8 vs NR 
(<0.001) 
SBP 
<100mmHg 
1/30 
(3%) 
16/70 
(23%) 
0.017 5.1 vs NR 
(0.022) 
4.1 vs 25.7 
(0.193) 
NT-proBNP 
≥332ng/L 
19/30 
(63%) 
60/72 
(83%) 
0.028 37.9 vs NR 7.1 vs NR 
(0.003) 
dFLC 
≥180mg/L 
6/30 
(20%) 
45/72 
(63%) 
<0.001 13.6 vs NR 
(0.002) 
5.9 vs 82.4 
(0.030) 
Renal  28/30 
(93%) 
54/73 
(74%) 
0.027 NR vs 5.1 
(0.360) 
25.7 vs 5.2 
(0.137) 
NT-proBNP 
≥8500ng/L 
4/30 
(13%) 
17/72 
(24%) 
0.242 2.4 vs NR 
(0.048) 
3.1 vs 82.4 
(<0.001) 
Mayo Stage 
I 
II 
III 
 
9/21 
(43%) 
9/21 
(43%) 
3/21 
(14%) 
 
7/59 
(12%) 
20/59 
(34%) 
32/59 
(54%) 
 
0.001 
 
Too few 
patients for 
survival 
analysis 
 
 
5.1 vs 
NR vs 
NR (0.001) 
 
Liver  12/30 
(40%) 
16/73 
(22%) 
0.061 NR vs 63.2 
(0.336) 
4.1 vs 11.1 
(0.686) 
PNS 3/30 
(10%) 
8/73 
(11%) 
0.886 Too few 
patients for 
survival 
analysis 
3.7 vs 18.1 
(0.886) 
ANS 3/30 
(10%) 
12/73 
(16%) 
0.386 NR vs NR 
(0.856) 
3.1 vs 27.7 
(<0.001) 
Soft tissue 3/30 
(10%) 
14/73 
(19%) 
0.244 2.4 vs NR 
(<0.001) 
5.2 vs 18.1 
(0.765) 
Haematologic
al response 
13/21 
(62%) 
37/67 
(55%) 
0.590 NR vs 13.6 
(0.002) 
82.4 vs 2.3 
(<0.001) 
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The BMPC did not have any bearing on the outcome of patients with either 
cardiac or non-cardiac involvement.  Patients with cardiac involvement and 
‘normal’ PC ≥10% on MFC, had slightly superior outcome with median OS 
25.6 months compared to only 5.8 months in those with <10% ‘normal’ PCs, 
however, this was not statistically significant (p=0.291) and the number of 
patients in the former group was only eight, compared to 55 in the latter 
group.  In patients without cardiac involvement, neither BMPC burden on 
BMT by morphology nor the proportion of ‘normal’ PCs on MFC influenced 
outcome (Figure 7.2a).  Patients with dFLC≥180mg/L had median OS of 13.6 
months when ‘normal’ PC was ≥10% compared to only 5.9 months in those 
with PC <10% on MFC (p=1.00).  However, there was a noticeable impact of 
‘normal’ PCs on survival of those patients with dFLC<180mg/L at 
presentation with median OS 82.4 months in those with <10% ‘normal’ PCs 
and ‘not reached’ in those with ≥10% ‘normal’ PCs (p=0.072). 
 
Treatment 
Ninety six patients received chemotherapy and the details of the regimen 
were not available for two of these patients.  One died before receiving 
therapy and four patients chose not to receive chemotherapy.  The details of 
first line regimen used in the 94 patients are shown in table 7.3.  The 
presenting free light chains and paraprotein were too low for evaluation in 
eleven patients.  Eighty-eight patients were therefore, included in the 
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intention to treat analysis, of whom, 50 (57%) had achieved a haematological 
response (24% CR, 16% VGPR and 17% PR). 
There was no significant correlation between haematological 
response and the proportion of normal PC by MFC.  However, patients who 
had not responded to first line therapy with ≥10% ‘normal’ PCs had a 
superior survival with a median OS of 13.6 months compared to only 2.3 
months in those with <10% ‘normal’ PCs (p=0.093).  The median OS for 
patients with a haematological response and ≥10% ‘normal’ PCs was ‘not 
reached’ and that of those with <10% PCs was 82.4 months (p=0.203) 
(figure 7.2b).  The BMPC as established on trephine biopsy did not influence 
the outcome within the responders and non-responders groups. 
The factors significantly impacting on survival on univariate analysis 
were, <10% ‘normal’ PCs on MFS, cardiac involvement, advanced Mayo 
stage, autonomic nervous system involvement, SBP <100mmHg, NTproBNP 
≥332ng/L, NTproBNP ≥8500ng/L, dFLC≥180mg/L, non-renal involvement 
and haematological response to treatment.   
dFLC was excluded from multivariate models due to a correlation 
between dFLC and </≥10% normal PCs. Mayo stage alone at baseline 
(Hazard ratio (HR) 20.82 (95% CI 2.82-154.01); p=0.003) and Mayo stage 
(HR 10.17 (95% CI 1.15-90.12); p=0.037), Haematological response (HR 
6.53 (95% CI 1.62-26.36); p=0.008) and <10% normal PCs (HR 5.18 (95% 
CI 0.584-45.94); p=0.143) in landmark analysis were independent factors 
impacting survival on multivariate analysis. 
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Table 7.3 Details of first line regimen used in the 94 patients  
 
Regimen No. of 
patients (%) 
ASCT 1 (1%) 
Thalidomide 44 (47%) 
Bortezomib 33 (35%) 
Alkylating agents 
(Melphalan / 
Cyclophosphamide) 
14 (14%) 
Lenalidomide  1 (1%) 
VAD 1 (1%) 
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Figure 7.2a-b Shows a) Survival by  cardiac involvement and proportion of 
normal PC by MFC - Patients with cardiac involvement and ‘normal’ PC≥10% 
on MFC, (median OS 25.6 months), cardiac involvement and ‘normal’ 
PC<10% on MFC (5.8 months) (p=0.291, SE: 1.91, CI: 2.12-9.6), patients 
without cardiac involvement and ‘normal’ PC≥10% on MFC (median OS not 
reached) and patients without cardiac involvement and ‘normal’ PC<10% on 
MFC (median OS not reached) and b) survival by haematological response 
and proportion of normal PC by MFC – Non responders to first line therapy 
with ≥10% ‘normal’ PCs (13.6 months), <10% ‘normal’ PCs (2.3 months), 
Haematological responders with ≥10% ‘normal’ PCs (median OS not 
reached) and <10% PCs (82.4 months) (p=<0.01). 
 
 
 
a 
b 
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Discussion 
 
The management of patients with AL amyloidosis follows a risk stratified 
approach.  The end organ damage caused by the amyloid fibrils, particularly 
to the heart, dominates this algorithm.  Lately, the importance of bone 
marrow plasma cell infiltration and its clonal characteristics is being 
increasingly factored into planning therapy for patients.  This chapter 
highlights the importance of using MFC to characterise the nature of plasma 
cells in bone marrow and show that the proportion of normal to abnormal 
plasma cells is a key factor in determining prognosis; not just a 
morphological estimation of total number of plasma cells in the bone marrow 
biopsy.   
The characteristic of the patient population studied here is very similar 
to that previously reported in AL patients in general but our study consisted 
of a slightly higher proportion of patients with cardiac amyloidosis.  The level 
of plasma cell infiltration in a patient with AL amyloidosis is generally lower 
than that of multiple myeloma with a reported median percentage of plasma 
cells being ~7-10% with 38 % having a ≥10% plasma cells infiltration (AL-MM 
category).27, 117, 121, 243  The maximum percentage of total plasma cells on 
MFC was only 12.63% (compared to 90% by morphology/trephine).  Flow 
cytometry has limitations in estimation of true marrow infiltration by BMPC 
due to sample dilution effect.  
An important study from the Mayo group reported that patients with 
AL-MGUS (<10% BMPC by morphology) had significantly superior outcome 
compared to those with ≥10% BMPC by morphology even in absence of 
Chapter 7 
 
 
184 
 
symptomatic myeloma – the latter outcomes similar to that of patients with 
AL amyloidosis who had symptomatic myeloma (median OS 46, 16.2 and 
10.6 months respectively).243  This study raised important questions about 
planning therapy in patients with AL-MM category – whether to follow the AL 
guidelines (often consisting of shorter duration of therapy and autologous 
stem cell transplantation is not always considered) or use the standard 
myeloma treatment algorithms with more aggressive therapy.  The current 
study however, does not support the findings from the Mayo study, perhaps 
due to the relatively smaller cohort of patients in this study.  The median OS 
was three years for the whole cohort with no significant difference between 
the OS of those with AL-MGUS and AL-MM; although, the former had a 
slightly superior outcome.  It is possible that this may reach significance with 
larger patient numbers.    
Studies on myeloma and MGUS without amyloidosis have defined an 
important role for multiparameter flow cytometry in characterisation of the 
plasma cells in the bone marrow.  Suppression of the normal plasma cells by 
the malignant or aberrant plasma cell clone is likely to be an important 
feature of clonal “aggressiveness” in plasma cell dyscrasias.  It appears that 
there is progressive competition for overlapping bone marrow niches, which 
leads to replacement of normal BM cells by clonal plasma cells and 
associated with more advanced disease in patients with MGUS, smouldering 
and symptomatic myeloma.246  Patients with <5% normal bone marrow 
plasma cells in MGUS have significantly higher risk of progression to 
myeloma and the proportion of residual normal plasma cells was a stronger 
prognostic factor than conventional markers for progression in both SMM 
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and MGUS.244, 247  Aberrant expression of various antigens on plasma cells 
have been reported in  patients with AL amyloidosis, which, have helped in 
the identification of neoplastic PCs in AL patients with low volume disease 
burden.22, 248, 249  Most recently, the Spanish group have extended their 
method of normal vs. aberrant plasma cells in the bone marrow to patients 
with AL amyloidosis using the same (5% normal plasma cell) threshold.119  
They reported that patients with less than 5% normal BMPC had a two year 
survival rate of 88% compared to 37% in those with more than 5% 
BMPCs.119  This study confirms the previous report of the survival advantage 
of ‘normal’ PCs on MFC.  However, in this study, using ROC analysis, we 
identified 10% normal BMPC as the threshold best for defining prognosis in 
AL amyloidosis rather than the lower cut off of 5% that was used in the 
Spanish Study.  Patients with ≥10% ‘normal’ PCs on MFC had a significantly 
better survival than those with <10% ‘normal’ PCs (median OS - not reached 
vs. 18.1 months respectively, p=0.012), regardless of the BMPC burden on 
trephine.  Patients with AL-MM (with ≥10% plasma cells by morphology on 
BMT) had a better outcomes if they had ≥10% ‘normal’ PCs by flow 
cytometry.  More interestingly, this observation was true for those patients 
with a <10% plasma cell infiltration by morphology on BMT (AL-MGUS).  The 
outcome of patients with AL-MGUS with <10% ‘normal’ PC on MFC was 
significantly worse than those with ≥10% ‘normal’ PCs (median OS 8 months 
vs. ≥5 years, p=0.038) with a doubled five year survival for the latter group.  
The percentage of normal or aberrant PC in BM by flow cytometry 
also correlated with other markers of disease burden in AL amyloidosis.  
High serum free light chains (the causative culprit in AL amyloidosis) 
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correlate directly with outcomes – patients with a dFLC of ≥180mg/L have 
poorer outcomes.121  However, there has never been a formal study 
correlating bone marrow findings with the level of light chains.  In the current 
study, similar to the established criteria, patients with dFLC of <180mg/L had 
superior outcomes.  There was a significantly greater proportion of patients 
with ≥10% normal PC in the cohort with low (<180mg/L) dFLC compared to 
those with higher values.  With both cohorts (those with dFLC of <180mg/L 
and ≥180mg/L), the proportion of residual normal PC ≥10% was suggestive 
of better outcomes (but did not reach statistical significance probably due to 
small patient numbers in the subgroups) suggesting that factors in clonal 
biology other than just secretion of light chains influence clonal outcomes 
which reflect in patient survival.  There was a significantly lower number of 
patients with cardiac involvement within the ≥10% ‘normal’ PCs group (only 
eight patients).  Five year survival for those with cardiac involvement and < 
and ≥10% normal PCs were 31% and 49% respectively.  Interestingly, the 
outcome between the cardiac and non-cardiac patients was not significantly 
different when patients had ≥10% ‘normal’ PC on MFC.  The reason for this 
is unclear.  One possible explanation is the composition of the light chains in 
such cases.  The serum free light chain assay measures all light chains (both 
the normal polyclonal and abnormal monoclonal light chains).  This is 
critically important since it is only the monoclonal light chain component that 
will deposit as amyloid deposits and the polyclonal light chains may well 
interfere with the amyloid formation.  This phenomenon is well recognised in 
patients with hereditary types of amyloidosis – when patients with hereditary 
transthyretin amyloidosis get cardiac involvement and are treated with a liver 
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transplant as a curative procedure, the mixture of TTR in their blood changes 
from both mutant and wild type ATTR (each produced by the mutant and wild 
type TTR alleles respectively) to only wild type ATTR.  These patients then 
develop accelerated cardiac amyloidosis from rapid deposition of this wild 
type ATTR.  Also patients who are homozygous for hereditary amyloidosis 
variants develop rapidly progressive disease compared to heterozygotes.  
This perhaps demonstrates a protective effect of ‘normal’ PCs despite 
cardiac involvement.  The outcomes of both haematological responders and 
non-responders were superior when associated with ≥10% ‘normal’ PCs on 
MFC.  The multivariate analysis confirms that outcome in AL patients at 
baseline ultimately dependent upon extent of cardiac involvement which 
dominates the clinical outcome and patients succumb to effects of organ 
damage.  The nature of plasma cell clone does not influence early outcome.  
However, in landmark analysis, the PC clone appears significant as patients 
who had <10% normal PCs have poorer outcome along with those with 
advanced cardiac involvement and non-responders to treatment.  
In summary, when outcome was assessed according to overall BM 
burden and MFC it was clear that the presence of ≥10% ‘normal’ PCs 
conferred a favourable outcome regardless of the BMPC burden.  This study 
confirms the value of MFC in patients with AL amyloidosis.  Abnormal PC 
populations are demonstrable in all patients confirming the utility of the assay 
for diagnostic purposes.  This is particularly relevant for those patients with 
low BM burden.  Similarly the presence / absence of ‘normal’ plasma cells by 
MFC had a significant effect on outcome which was demonstrable in patients 
with both AL-MGUS and AL-MM.  There was a negative correlation between 
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the amount of ‘normal’ PCs and cardiac involvement.  As a result perhaps, 
the proportion of ‘normal’ PCs could not uphold as significant factors on a 
multivariate model along with cardiac involvement.  The exact mechanism by 
which the proportion of ‘normal’ PCs impact survival needs to be further 
explored but it appears that patients with low levels of ‘normal’ PCs are 
predisposed to develop cardiac amyloidosis, a well-established poor 
prognostic marker in the AL population.  It is therefore recommended, that 
MFC be included in the diagnostic work up of all patients with AL.  Further 
studies are required to determine how this additional prognostic data can be 
incorporated into existing prognostic models. 
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Chapter Eight: The prognostic role of Heavy 
and Light chain suppression in systemic AL 
amyloidosis 
 
Introduction 
A substantial proportion of patients (up to 30% in some series) succumb 
prematurely to disease related complications.73  The value of current 
amyloidosis staging systems in assessing longer term prognosis of patients 
surviving past the initial few months remains unclear and appears to be 
limited.   
 Monoclonal intact immunoglobulins (M-Igs) are measurable only in 
about a quarter of patients for monitoring purposes.83  The prognostic value 
of an intact M-Ig in systemic AL amyloidosis is unclear, with some series 
reporting poorer outcomes for patients expressing intact immunoglobulins.211, 
250  Recently available serum heavy/light chains (HLC) immunoassays not 
only allow quantification of Ig’κ and Ig’λ HLC from which Ig’κ / Ig’λ HLC ratios 
can be derived, giving an indication of clonality but also appear to be 
sensitive in identifying and quantifying levels of M-Ig in plasma cell 
dyscrasias.251-254  The particular advantage of this assay over traditional 
methods of immunoglobulin measurements are that the former, for the first 
time, allows the quantification of the uninvolved (polyclonal) member of the 
pair as well as of the other immunoglobulin classes (e.g. in an IgGκ 
monoclonal protein expressing patient, levels of IgGλ, IgAκ, IgAλ, IgMκ and 
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IgMλ may be measured)– thus providing an accurate measurement of 
isotype and non-isotype specific immunoglobulin values as well as pair 
immunosuppression.  The clinical and prognostic significance of 
immunoparesis in plasma cell dyscrasias remains a topic of ongoing debate.  
There are few studies evaluating the role of HLC suppression for 
prognostication in plasma cell dyscrasias.  In myeloma, HLC suppression 
appears to predict for poorer outcomes.255-257  This chapter describes the 
significance of immunoparesis as determined by HLC suppression in a 
population of newly diagnosed patients with systemic AL amyloidosis.   
 
Methods 
 
 
Patient selection 
The study included unselected patients with AL amyloidosis seen at the 
National Amyloidosis Centre, with serum samples collected at the time of 
presentation, prior to any therapy, and stored at -80°C.  A total of 170 
patients with systemic AL amyloidosis were included.  Patients fulfilling 
criteria for symptomatic myeloma were excluded.  For survival studies 
cardiac involvement was defined in methods chapter and/or NT-proBNP 
≥332ng/L. 
Serum samples were tested for FLC concentrations (κ SFLC and λ 
SFLC), HLC concentrations (IgGκ, IgGλ, IgAκ, IgAλ, IgMκ and IgMλ) and 
total immunoglobulins (IgG, IgA and IgM) as described in the methods 
chapter.  Immunoparesis was defined either by total immunoglobulin (Ig) 
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measurements as the concentration of any Ig class below the lower limit of 
normal (i.e. IgG<6g/L, IgA<0.8g/L, IgM<0.5g/L; total Ig suppression), or by 
HLC immunoassays as levels of any IgGκ, IgGλ, IgAκ, IgAλ, IgMκ and/or 
IgMλ below the lower limit of their respective reference range (HLC 
suppression).  Severe immunoparesis was defined as levels of two or more 
isotypes suppressed by ≥50% below the lower limit of normal.  
 
Outcome measures and Statistics 
Survival studies were performed on 163 patients with available follow-up 
data (median follow up 35 months (2.4 – 85.3 months).  Differences in overall 
survival (OS) between patient groups were analysed using Kaplan-Meier 
survival curves with the log rank test used to indicate significance.  The 
association of variables with OS was carried out with Cox proportional 
hazard model.  A landmark analysis was carried out in patients surviving 6 
months from study entry.  P values were two-tailed with a significance level 
of 0.05. Statistical analyses were performed using SPSS 21 (IBM, Chicago, 
USA).  Statistical differences for categorical values were calculated using the 
chi-square (χ2) test.  Survival graphs were generated using GraphPad/Prism 
5 software. 
 
Results 
Baseline characteristics including demographics, clinical features and serum 
biomarkers for 170 AL amyloidosis patients are presented in Table 8.1.  HLC 
measurements identified immunosuppression in 145/170 (85%) patients 
Chapter 8 
 
 
192 
 
(Suppression of HLC IgG isotypes in 118(70%), IgA and IgM in 60 (35%) and 
91 (54%)) (Table 8.2).  80 (47%) had ≥2 HLC isotype immunoparesis.  
Severe immunoparesis was identified in 29/170 (17%) patients (Table 8.2).  
None of the patients had symptomatic myeloma but 21% had greater than 
10% bone marrow plasma cell infiltration.   
 
 
 
Table 8.1 Patients characteristics (n=170) 
 
Median (range) or n/N (%) 
Age years 68 (34 – 85) 
Age≥65 96/170 (56) 
Male 104/170 (61) 
Cardiac involvement 124/170 (73) 
Kidney involvement 104/166 (63) 
Liver involvement 45/165 (27) 
PNS involvement 5/164 (3) 
GI tract involvement 16/167 (10) 
>1 organ involved 66/170 (39) 
NT-proBNP  (ng/L) 1894 (9 – 69999) 
Creatinine (mmol/L) 96 (19-851) 
24h proteinuria (g) 3.1 (0.1-104.0) 
Albumin (g/L) 35 (12-52) 
Alkaline phosphatase (IU/L) 103 (27-3891) 
Abnormal κ/λ SFLC ratio 134/170 (79) 
kappa patients 48/134 (36) 
lambda patients 86/134 (64) 
dFLC ≥180mg/L 83/134 (62) 
dFLC (mg/L) 237.9 (9.9 – 5026.8) 
Abnormal HLC ratio 110/170 (65) 
Intact M-Ig (by IFE) 87/170 (51) 
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115/166 (69%) had immunoparesis detected by total Ig 
measurements (IgG in 73(44%), IgA in 48(29%) and IgM in 66(40%)), all of 
which were identified by HLC suppression (p<0.001).  56 (34%) had 
suppression of ≥2 immunoglobulins, of whom 18(11%) were severe (Table 
8.2).   
 
 
Table 8.2 Frequency of immunoparesis by method 
Method n 
≥1 Ig 
suppressed 
n (%) 
≥2 Ig 
suppressed 
n (%) 
≥2 Ig 
suppressed 
>50%  
n (%) 
HLC suppression 170 145 (85) 80 (47) 29 (17) 
Total Ig 
suppression 
166 115 (69) 56 (34) 18 (11) 
  
  
HLC (≥1 Ig suppressed)* 
No Yes Total 
Total Ig No 25 26 51 
(≥1 Ig 
suppressed)* 
Yes 0 115 115 
  Total 25 141 166 
*p<0.001 (χ2 test) 
 
Survival 
There were 108 deaths of which 8 were due to infection and 89 due to 
progressive amyloidosis or amyloidosis. Median survival was 26.2 months 
(14.8 months for those with cardiac involvement).  Factors adversely 
affecting outcome on univariate analysis were cardiac involvement, abnormal 
NT-proBNP and dFLC≥180mg/L (Table 8.3).  
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Table 8.3 Univariate analysis of risk factors for overall survival 
  
All patients Patients with cardiac disease/ NT-proBNP≥332ng/L 
OS 6-month landmark OS OS 6-month landmark OS 
(n=163) (n=127) (n=121) (n=89) 
n (%) HR (CI) p n (%) HR (CI) p n (%) HR (CI) p n (%) HR (CI) p 
Cardiac disease 61(37) 
2.2 (1.5-
3.4) 
<0.001 40 (32) 
1.8 (1.1-
3.0) 
0.02 - - - - - - 
NT-proBNP ≥332ng/L 115(71) 
2.3 (1.3-
4.2) 
0.006 83 (65) 
1.8 (0.9-
3.6) 
0.08 - - - - - - 
IFE positive 85(52) 
1.1 (0.7-
1.5) 
0.81 70(55) 
1.4 (0.9-
2.3) 
0.19 60(49) 
1.1 (0.7-
1.7) 
0.67 45(50) 
1.3 (0.7-
2.3) 
0.36 
Abnormal FLC ratio 131(80) 
1.2 (0.7-
2.0) 
0.49 98(77) 
0.9 (0.5-
1.5) 
0.66 101(83) 
1.2 (0.7-
2.2) 
0.49 72(80) 
0.9 (0.5-
1.9) 
0.85 
dFLC ≥180mg/L
1
 82(63) 
1.6 (1.0-
2.4) 
0.05 88(69) 
1.3 (0.8-
2.3) 
0.34 65(64) 
1.7 (1.0-
2.9) 
0.04 43(60) 
1.5 (0.8-
2.8) 
0.23 
Abnormal HLC ratio 106(65) 
0.9 (0.6-
1.3) 
0.48 74(58) 
1.2 (0.7-
2.0) 
0.54 75(62) 
0.9 (0.6-
1.4) 
0.7 59(66) 
1.3 (0.7-
2.4) 
0.4 
HLC suppression 140(86) 
1.0 (0.6-
1.7) 
0.96 110(87) 
0.9 (0.5-
1.8) 
0.77 104(85) 
1.1 (0.6-
2.1) 
0.73 77(86) 
1.1 (0.5-
2.4) 
0.83 
HLC suppression (at least 2 
Ig) 
80(49) 
1.0 (0.7-
1.4) 
0.92 64(50) 
1.1 (0.7-
1.7) 
0.74 59(48) 
1.0 (0.6-
1.5) 
0.85 45(50) 
1.1 (0.6-
1.9) 
0.83 
 >50% HLC suppression (at 
least 2 Ig) 
28(17) 
1.4 (0.9-
2.3) 
0.16 22(17) 
1.6 (1.0-
2.9) 
0.1 20(16) 
1.7 (1.0-
2.9) 
0.06 15(17) 
2.4 (1.2-
4.6) 
0.009 
Total Ig suppression 
2
 112(70) 
1.1 (0.7-
1.6) 
0.8 87(70) 
1.0 (0.6-
1.6) 
0.91 85(71) 
1.2 (0.7-
2.0) 
0.44 63(72) 
1.3 (0.7-
2.4) 
0.42 
Total Ig suppression (at least 
2 Ig)
 
 
54(34) 
1.2 (0.8-
1.8) 
0.39 40(32) 
1.1 (0.7-
1.8) 
0.77 45(38) 
1.3 (0.8-
2.0) 
0.33 32(36) 
1.2 (0.7-
2.2) 
0.48 
>50% total Ig suppression (at 
least 2 Ig) 
17(11) 
0.9 (0.5-
1.6) 
0.65 14(11) 
0.9 (0.4-
1.9) 
0.78 13(11) 
0.9 (0.5-
1.8) 
0.81 10(11) 
1.0 (0.4-
2.3) 
0.93 
1 
Patients with abnormal FLC ratio only (n=134). 
2
4 patients missing data 
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Median OS for patients with dFLC levels above or below 180mg/L was 
14.8 vs. 43.1 months, respectively (Hazard Ratio (HR) (95%CI): 1.6 (1.0-
2.4); p=0.05), whereas median survival for patients with severe HLC 
suppression was 14.8 months compared to 28.0 months for all other patients 
(HR: 1.6 (1.0-2.9); p=0.09) (Figure 8.1a-c).  Factors adversely impacting 
survival of patients with cardiac amyloidosis were dFLC ≥180mg/L and 
severe HLC suppression (Table 8.3). The median OS for dFLC ≥180mg/L vs. 
dFLC <180mg/L was 12.6 and 35.1 months, respectively (HR: 1.7 (1.0-2.9); 
p=0.04) and severe HLC suppression vs. without severe HLC suppression 
was 8.8 and 21 months respectively (HR: 1.7 (1.0-2.9); p=0.06) (Figure 8.1d-
f) in this subgroup.  
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Figure 8.1a-f Survival outcomes in intention-to-treat (ITT) cohort. a) Median 
overall survival (OS) for the whole cohort (n=163); b) for patients stratified by 
baseline dFLC ≥180mg/L; c) severe HLC suppression (≥50% suppression in 
≥2 Ig isotypes); d) Median OS for patients with cardiac involvement at 
diagnosis (n=121); e) stratified by baseline dFLC ≥180mg/L and f) severe 
HLC suppression. Number of patients (deaths) for each arm is shown. 
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The median OS for the 127 patients surviving ≥6 months at landmark 
analysis (Table 8.3 and Figure 8.2) was 40.9 months. Interestingly, dFLC 
≥180mg/L did not have significant prognostic impact in this cohort (p=0.33), 
however, severe HLC suppression had a trend towards poorer survival 
(p=0.09). The latter was significantly associated with poorer outcome in 
patients with cardiac involvement within the 6 month landmark analysis, (HR: 
2.4 (1.2-4.6); p=0.007). Similar observations were made at nine and twelve 
months landmark analysis (Figure 8.3).  
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Figure 8.2 Survival outcomes in 6-month landmark analysis, a) Median 
overall survival (OS) for all patients alive at six months (n=127); b) based on 
baseline dFLC ≥180mg/L; c) severe HLC suppression (≥50% suppression in 
≥2 Ig isotypes); d) Median OS in the 6-month landmark analysis for patients 
with cardiac involvement (n=89); e) stratified by baseline dFLC ≥180mg/L 
and f) severe HLC suppression. Number of patients (deaths) for each arm is 
shown. 
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Figure 8.3 Survival outcomes at 9 and 12 month landmark analysis. Median 
OS in the a) 9-month (n=77) and b) 12-month (n=68) landmark analysis for 
patients with cardiac involvement and severe HLC suppression (≥50% 
suppression in ≥2 Ig isotypes). Number of patients (deaths) for each arm is 
shown. 
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A tentative survival model including dFLC ≥180mg/L and severe HLC 
suppression as risk factors in patients with cardiac involvement stratified the 
population into three categories with none (n=49), one (n=59) and two (n=13) 
risk factors and median survival times of 35.1, 12.7 and 8.8 months, 
respectively (p=0.023) (Figure 8.4).  
 
 
Figure 8.4 OS survival for patients with cardiac involvement stratified by 
baseline risk factors (dFLC ≥180mg/L and severe HLC suppression). In 121 
patients with cardiac involvement (cardiac disease and/or NT-proBNP 
≥332ng/L) presence of none, one or two risk factors identified three groups 
with median survival times of 35.1, 12.7 and 8.8 months, respectively 
(p=0.02).  
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Discussion 
The impact of immunoparesis on outcomes in plasma cell dyscrasias has 
been studied and debated for many years.  This study specifically assesses 
immunoparesis and its impact in AL amyloidosis. Immunoparesis is common 
in systemic AL amyloidosis by both standard nephelometric immunoglobulin 
measurements and as determined by HLC immunoassays.  Severe 
immunoparesis measured by HLC immunoassay, but not by total Ig 
measurement, is a marker of poor prognosis, particularly in patients with 
cardiac amyloidosis in a landmark analysis.  
Impact of M-Ig on outcomes in AL amyloidosis is unclear.  In this 
cohort the presence of an M-Ig by IFE had no prognostic value.  Traditional 
electrophoretic methods lack sensitivity for detecting M-Ig and cannot 
accurately quantify the low levels typically encountered in patients with 
systemic AL amyloidosis.83, 252  HLC immunoassays have a greater 
sensitivity for detection of M-Ig’s and may aid the monitoring and 
prognostication of monoclonal gammopathies.253, 256, 258  
Unlike myeloma, extreme HLC ratios are rarely seen in AL 
amyloidosis.  By contrast, immunoparesis is nearly universal in myeloma and 
seen in a proportion of patients with monoclonal gammopathy of 
undetermined significance (MGUS).256  An increased frequency of HLC 
suppression was also reported in a study in MGUS, in which 27% and 11% 
of 999 patients displayed immunoparesis as determined by HLC and total Ig 
measurements, respectively.256  However systemic immunoparesis as 
determined by total Ig measurements remains an inconsistent risk factor both 
in MGUS and MM.247, 257, 259-263  This cohort, demonstrated a greater 
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incidence of HLC suppression (85%) over total Ig immunoparesis (69%) in 
AL amyloidosis.  Differences may partly be due to the ability of HLC 
immunoassays to separately identify kappa and lambda isotypes of each Ig 
class, unlike total Ig measurements.  There was no correlation between 
immunoglobulin suppression and NT-proBNP or monoclonal FLC levels, 
indicating that polyclonal immunoglobulin levels do not associate with other 
risk factors or stage of disease in AL amyloidosis.264 
Baseline level of dFLC was prognostic in this cohort as previously 
reported in other studies in AL amyloidosis.130, 265  However, in the six 
months landmark analysis, the dFLC lacked prognostic power.  The biggest 
challenge in AL amyloidosis is early deaths due to disease related 
complications.  Patients surviving beyond six months have demonstrated 
resilience of organ function and have much better outcomes.74  Baseline 
biomarkers don’t have the same prognostic impact on the six month 
survivors.266  The impact of baseline dFLC on survivors has (or indeed the 
lack of prognostic impact of baseline dFLC on survivors as seen here), to the 
best of our knowledge, never been previously reported.  The striking 
observation in this series was the impact of severe immunoparesis on 
survivors in a landmark analysis.  Patients with cardiac AL and severe HLC 
immunoparesis had a median survival of 8 months.  By contrast 
immunoparesis by total Ig measurement (even severe immunoparesis), had 
no impact on prognosis in this study.   
The mechanism of suppression of normal immunoglobulin 
components in plasma cell dyscrasias remains poorly understood but is likely 
to be directly related to the characteristics of the bone marrow plasma cell 
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clone.  The group from Salamanca had reported that the presence of <5% 
normal plasma cells defined by multiparameter flow cytometry conferred a 
poor prognosis.119  Similarly, as discussed in previous chapter, the presence 
of ≥10% normal PCs in the marrow by flow cytometry, irrespective of 
absolute PC percentage by morphology (also a prognostic factor as reported 
by the Mayo group), predicted for better outcomes.267  Since normal 
immunoglobulin production is from persisting normal PCs in the bone 
marrow, the suppression of normal immunoglobulins as determined by HLC 
possibly represents the serum manifestation of this phenomenon.  
Whilst this study shows the important prognostic impact of HLC 
immunoparesis on outcomes in AL amyloidosis, the reason for this 
prognostic impact is far more challenging to understand.  Infections and 
worsening heart failure are the commonest causes of serious adverse events 
in patients with AL amyloidosis undergoing chemotherapy.268  Drugs 
commonly used in treatment of AL amyloidosis such as dexamethasone or 
cyclophosphamide are excellent immunosuppressive agents, and are likely 
to eliminate normal plasma cells in addition to achieving the desired impact 
of clonal eradication.  Since HLC immunoparesis of the “normal” uninvolved 
immunoglobulin is most likely to be directly linked to greater 
suppression/depletion of normal plasma cells, it is tempting to speculate that 
such patients with severe HLC immunoparesis will have worsening 
immunoparesis during treatment; which could tip these patients into a longer 
term state of immunodeficiency.  The prognostic impact of HLC 
immunosuppression is greatest soon after completing therapy (i.e. in the six 
month landmark analysis) compared to patients alive at 9 or 12 months 
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suggesting, perhaps, that there may be immune recovery in the survivors; 
thereby mitigating the prognostic impact of immunoparesis.  This 
immunoparesis may not only predispose to infective complication but may be 
a marker for poorer immune surveillance which may impact the longer term 
outcomes in plasma cell dyscrasia.  An alternative, or even concurrent, 
reason may be that the suppression of normal plasma cells is a direct marker 
for the aggressiveness of the plasma cell clone as impacting on treatment 
responsiveness and possible persistence of minimal residual disease (MRD) 
with the attendant longer term consequences.  We recently reported the 
persistence of MRD in AL amyloidosis patients in a serological CR,269 
highlighting the difficulty of eradicating even a small clone.   
This study has limitations and these observations need to be validated 
in a larger patient population.  The availability of baseline sera stored at the 
requisite temperatures dictated patient inclusion in this study.  Baseline 
troponin measurement was not part of standard patient assessment at the 
UK NAC at time of this study and hence we are unable to present this data.  
The retrospective nature of the data limits the ability to assess cause of 
death and impact, if any, of infections due to immunoparesis; particularly 
worsened after chemotherapy.  This study should be expanded to include 
HLC as part of baseline assessments in patients included in the ongoing 
observational study (ALCHemy) to validate these findings in a series of 
prospectively observed patient cohort.  We hope that an ongoing serial study 
of HLC monitoring in AL patients during and after treatment may address 
some of these questions.     
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In summary, hypogammaglobulinemia (or immunoparesis) as defined 
by HLC suppression and total Ig immunoparesis is a relatively common 
occurrence in AL amyloidosis.  Severe immunoparesis appears to be a 
marker of poor prognosis in patients with cardiac amyloidosis and is a 
particularly powerful marker in survivors beyond the first six months from 
diagnosis.  The clinical benefit of routine HLC measurements in patients with 
AL amyloidosis warrants further exploration in larger longitudinal studies.  
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Chapter Nine: The role of bortezomib as front 
line treatment in patients with systemic AL 
amyloidosis 
 
 
This chapter is written in the context of my publication:  
A European collaborative study of cyclophosphamide, bortezomib, and 
dexamethasone in upfront treatment of systemic AL amyloidosis. 
Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, 
Basset M, Hawkins P, Merlini G, Wechalekar AD. Blood. 2015 Jul 
30;126(5):612-5. Copyright permission obtained from Blood office for use in 
my thesis.  
 
Introduction 
 
This final chapter will focus on the treatment of AL amyloidosis with particular 
attention to the currently, widely used first line, bortezomib based therapy 
and explore its effectiveness in patients within the different Mayo cardiac 
stages. 
The introduction of bortezomib, the first-in-class proteasome inhibitor, 
represented a major advancement in the treatment of AL amyloidosis.220, 270  
Since the amyloidogenic clonal plasma cell is believed to rely on the 
proteasome to cope with the proteotoxicity caused by the misfolded light 
chain, bortezomib is expected to be particularly effective and a potential 
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targeted therapy in this disease.152, 271  Early reports supported this 
expectation, showing a high response rate and rapid responses, particularly 
when this drug was used frontline.153, 157, 158  A prospective clinical trial in 
relapsed/refractory patients showed that single-agent bortezomib, was 
rapidly effective, tolerable, and gave rise to durable responses.155, 162, 272  
After autologous stem cell transplant, bortezomib increases the rate and 
improves the quality of response.175  Even more promising results were 
obtained when bortezomib was used frontline in combination with an 
alkylating agent and dexamethasone.273  Moreover, two independent studies 
including a total of 30 patients receiving cyclophosphamide, bortezomib, and 
dexamethasone (CyBorD) frontline, reported a haematologic response in 
90% of cases, with almost two thirds of patients reaching complete response 
(CR).154, 274  This led to the perception that CyBorD was superior to other 
treatment alternatives, and this combination has become one of the 
regimens most commonly prescribed to patients with AL amyloidosis.  
However, this enthusiasm was soon tempered by the observation that 
CyBorD is not able to improve the outcome of patients with advanced cardiac 
involvement.275  In a series of 60 patients with stage III cardiac AL 
amyloidosis the overall haematologic response rate was 68%, with CR in 
17% of cases.276  In this study, the overall median survival was almost one 
year, but patients who presented with NT-proBNP above 9500 ng/L had a 
median survival of only 4 months.276  Moreover, two parallel matched case-
control studies comparing bortezomib combinations with alkylating agents 
(CyBorD and BMDex) with the standards of care CTD and MDex, showed 
that the higher rates of good quality haematologic response obtained with 
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bortezomib-based regimens did not result in an improvement of overall 
survival.225, 226  In these series, survival was driven by the high rate of early 
deaths in patients with advanced cardiac involvement identified by very high 
NT-proBNP concentrations and severe heart failure (>8500ng/L) who could 
not be rescued by bortezomib.225, 226  However, a survival advantage was 
observed for lower-risk patients treated with BMDex.226  These findings 
indicate that there is the need of large, collaborative studies to identify the 
patients who benefit most from these powerful combinations.277  In this last 
results chapter, the outcome of 230 newly diagnosed patients with AL 
amyloidosis treated with CyBorD at two referral centres, the National 
Amyloidosis Centre (NAC, London, United Kingdom) and the Amyloidosis 
Research and Treatment Centre (ARTC, Pavia, Italy) are described . 
 
Methods 
 
Patient selection 
The prospectively maintained databases of the ARTC and of the NAC were 
systematically searched for newly-diagnosed patients with AL amyloidosis 
treated with CyBorD between August 2006 and March 2013.  
 
Outcome measures and Statistics 
The primary outcome measures were the haematologic and cardiac 
responses.  Secondary outcome measure was the time to next line therapy.  
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Data are presented as medians and interquartile ranges. Differences 
in response rates between subgroups were tested for significance by the 2 
test or by Fisher’s exact test as appropriate.  Multiple logistic regression was 
used to compare response rates in various subgroups while adjusting for 
potential confounders. Response rates were reported by intent-to-treat.  
Survival curves were plotted according to Kaplan-Meier.  Survival was 
calculated from the date of diagnosis to the date of last contact or death.  
Differences in survival were tested for significance by the log-rank test.  Cox 
models were fitted to compute hazard ratios (HR) and 95% confidence 
intervals (CI) for survival.  Multivariate models were fitted including non-
collinear variables.  The impact of response on survival was assessed in a 
three-month landmark analysis.  
 
Results 
A total of 230 patients (118 from the ARTC and 112 from the NAC), 
diagnosed between August 2006 and March 2013, were included in the 
study.  Their clinical characteristics are reported in Table 9.1.  
Cyclophosphamide was administered at a dosage of 300mg/m2 on days 1, 8, 
and 15 in all patients.  The dosage of bortezomib ranged from 1.0mg/m2 
once weekly to 1.3mg/m2 twice weekly.  The maximum dosages of 1.6mg/m2 
weekly or 1.3mg/m2 twice weekly were used in 60 patients (26%), and 79 
subjects (34%) were treated with bortezomib 1.3mg/m2 weekly.  Bortezomib 
route of administration was intravenous in 154 patients (67%) and the 
remaining had subcutaneous injections.  Most patients (184, 80%) received 
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at least 80mg dexamethasone per week.  The median number of cycles 
performed was 4 (range 1-8 cycles). 
 
 
 
Table 9.1 Characteristics of 230 patients with AL amyloidosis treated with 
cyclophosphamide, bortezomib and dexamethasone 
 
Patients’ characteristics N (%) or median (IQR) 
Male sex 134 (58) 
Age, years 60 (53-66) 
Organ involvement 
   heart 
   kidney 
   soft tissues 
   liver 
   peripheral nervous system 
 
169 (73) 
157 (68) 
35 (15) 
25 (11) 
6 (3) 
Cardiac stage 
   I 
   II 
   III 
 
41 (18) 
77 (33) 
112 (49) 
Stage III patients with NT-proBNP >8500 ng/L 45 (20) 
NT-proBNP, ng/L 2839 (567-7018) 
Renal stage 
   I 
   II 
   III 
   dialysis 
 
115 (50) 
90 (39) 
17 (8) 
8 (3) 
eGFR, mL/min per 1.73m2 82 (61->90) 
Proteinuria, g/24h 2.8 (0.4-6.9) 
Bone marrow plasma cell infiltrate, % 12 (8-15) 
dFLC (mg/L) 248 (96-567) 
dFLC >180mg/L 135 (59) 
 
   IQR, interquartile range. 
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Treatment toxicity 
Twenty-three patients experienced severe adverse events. The most 
common severe (grade 3-4) adverse event occurring during treatment was 
worsening heart failure (8 patients, 3%). Five of these patients were cardiac 
stage III, and the remaining were stage II.  New York Heart Association 
(NYHA) class was III in 5 cases and class II in 3.  Bortezomib was 
administered in 1.3mg/m2 infusions in these patients, twice weekly in two 
cases and once weekly in six.  All received dexamethasone at a weekly dose 
of 20mg.  Two of these subjects are alive at 19 and 25 months, and the 
remaining died between 1 to 18 months.  Other severe adverse events were 
hypotension (5 patients), renal failure (3), neuropathic pain (2), 
thrombocytopenia (2), lethargy (1), neutropenia (1) and psychosis (1).  
Additionally, 29 patients (13%) died within three months from diagnosis.  
Twenty-four of whom had Mayo stage III biomarkers, and NT-proBNP was 
>8500ng/L in 18 subjects. 
 
Response to therapy 
A total of 201 patients had measurable clonal disease, including 40 subjects 
who died before evaluation of response.  By intent-to-treat, haematologic 
response was achieved in 138 of 230 patients (60%), with CR in 54 cases 
(23%).  Of the evaluable patients, 125 (62%) reached haematologic 
response, that was CR in 42 cases (21%) and VGPR in 45 (22%).  The 
response rate was significantly lower in cardiac stage III patients with NT-
proBNP >8500ng/L (stage IIIb) (Table 9.2).  
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Table 9.2 Haematologic response rate by intent-to-treat according to cardiac 
stage in 201 patients with measurable disease.221 
 
Response category Stage I 
(30 
patients) 
Stage II 
(67 
patients) 
Stage IIIa 
(61 
patients) 
Stage IIIb 
(43 
patients) 
Overall response 23 (77%) 43 (64%) 42 (69%) 18 (42%)* 
Complete response 10 (33%) 12 (18%) 14 (23%) 6 (14%) 
Very good partial 
response 
7 (23%) 18 (27%) 16 (26%) 4 (9%) 
Partial response 6 (20%) 13 (19%) 12 (20%) 8 (19%) 
 
*P<0.05 compared to stages I, II, and IIIa. 
 
 
In a landmark analysis excluding patients who died within three 
months from diagnosis, 126 of 174 patients (72%) responded, with 42 CRs 
(24%) and 45 VGPRs (26%).  Haematologic response rate was not 
significantly different in patients who received twice weekly and once weekly 
bortezomib (67% vs. 62%, P=0.549; ≥VGPR in 38% vs. 45%, P=0.446).  
However, patients who received less than 1.0mg/m2 twice weekly or 
1.3mg/m2 once weekly bortezomib or less than 80mg per cycle of 
dexamethasone were less likely to achieve haematologic response (Table 
9.3).  In a multiple logistic regression analysis only cardiac stage IIIb 
(P=0.008), and not low doses of bortezomib (P=0.191) and dexamethasone 
(P=0.353), was an independent  predictor of haematologic response. 
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Table 9.3 Haematologic response rate by intent-to-treat according to 
bortezomib and dexamethasone dosage in 201 patients with measurable 
disease.221 
 
Response category 
Bortezomib dosage 
Full dose 
(35 
patients) 
Intermediate 
dose 
(82 patients) 
Low dose 
(79 
patients) 
Overall response 29 (83%) 57 (69%) 42 (53%)* 
Complete response 12 (34%) 20 (24%) 11 (14%)* 
Very good partial 
response 
7 (20%) 21 (26%) 17 (21%) 
Partial response 10 (29%) 16 (19%) 14 (18%) 
Response category 
Dexamethasone dosage 
Full dose 
(58 patients) 
Intermediate dose 
(102 patients) 
Low dose 
(41 patients) 
Overall response 45 (78%) 62 (61%) 20 (49%)* 
Complete response 15 (26%) 21 (21%) 6 (15%)* 
Very good partial 
response 
17 (29%) 23 (22%) 5 (12%)* 
Partial response 12 (21%) 18 (18%) 9 (22%) 
 
*P<0.05 compared to full dose 
Bortezomib dosage: full dose, 1.3mg/m2 twice weekly or 1.6mg/m2 once 
weekly; intermediate dose, 1.0mg/m2 twice weekly or 1.3mg/m2 once weekly; 
low dose, less than 1.0mg/m2 twice weekly or 1.3mg/m2 once weekly. 
Dexamethasone dosage: full dose, at least 160mg per cycle; intermediate 
dose, <160 and ≥80mg per cycle; low dose, less than 80mg per cycle. 
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By intent-to-treat, 29 (17%) of the 167 patients with cardiac 
involvement achieved a cardiac response.  Sixteen of 56 cardiac stage II 
(29%), 11 of 66 stage IIIa (17%, P=0.124 compared to stage II), and 2 out of 
45 stage IIIb patients (4%) responded. Overall, 40 of the 157 patients (25%) 
with renal involvement achieved renal response, which was observed in 16 
out of 59 evaluable renal stage I (27%), 21 of 81 in stage II (26%), and 3 of 
17 stage III subjects (18%).  The difference in renal response rate between 
renal stages was not statistically significant.  Of the 25 patients with liver 
involvement 8 (32%) responded.  
 
Survival 
The median follow-up was 25 months.  Overall, more than 50% of patients 
are projected to survive 5 years (Figure 9.1a).  Median time to second-line 
therapy or death was 13 months (Figure 9.1b).  Cardiac stage was a major 
determinant of patients’ survival (Figure 9.1c): there were no deaths amongst 
stage I subjects, while the median survival of stage IIIb patients was only 7 
months.  Interestingly, there was no difference in outcome between stage II 
and stage IIIa subjects.  In a 3-month landmark analysis, achievement of a 
haematologic response resulted in a significant survival advantage in stage II 
and IIIa patients (Figure 9.1d), as well as in stage IIIb subjects (Figure 9.2).  
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Figure 9.1a-d a) Overall survival of 230 patients with AL amyloidosis treated 
with CyBorD; b) Time to second-line therapy or death (median 13 months) of 
230 patients with AL amyloidosis treated with CyBorD; c) Survival of 230 
patients with AL amyloidosis treated with CyBorD according to cardiac stage; 
d) Survival of 118 cardiac stage II and IIIa patients according to 
haematologic response (3 month landmark analysis).221  
 
 
 
 
 
 
 
 
 
a b 
c d 
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Stage I, II, IIIa, and IIIb patients were 41, 77, 67, and 45, respectively.  There 
were no deaths among stage I patients, and the median survival of stage II 
patients was not reached.  Survival of stage II subjects was significantly 
shorter than that of stage I patients (P<0.001).  The median survival of stage 
IIIa patients was 43 months, but their outcome was not significantly different 
from that of stage II subjects (P=0.613).  The median survival of stage IIIb 
patients was 7 months (P<0.001 compared to stage IIIa). 
Median survival was not reached for patients achieving at least PR, 
but subjects who obtained VGPR or better survived longer than those 
attaining PR (P=0.042).  The median survival of non-responders was 10 
months (P<0.001 compared to those in PR). 
 
Figure 9.2 Survival of 31 cardiac stage IIIb patients according to 
haematologic response (3 month landmark analysis).221 
  
 
The small number of patients did not allow discrimination between response 
categories. Median survival was 26 months for responders and 6 months for 
non-responders (P<0.001). 
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On a multivariate analysis, stage IIIb was the only variable retaining 
independent prognostic significance (Table 9.4).  However, in the 
multivariable model based on the 3-month landmark, haematologic response 
also independently predicted the outcome (Table 9.4).  Haematologic 
response had a major impact also on time to second-line therapy or death.  
In the overall population, median time to second-line therapy or death was 51 
months in patients achieving at least VGPR, 13 months in patients attaining 
PR (P<0.001 compared to VGPR or CR), and 6 months in non-responders 
(P<0.001 compared to PR). 
 
Table 9.4 Cox analysis of survival 
Univariate analysis 
Variables HR (95% CI) P 
Male sex 1.26 (0.83-1.91) 0.279 
Age >60 years 1.21 (0.81-1.81) 0.361 
eGFR <30 mL/min per 1.73 m2 1.22 (0.63-2.34) 0.560 
dFLC >180mg/L 1.99 (1.28-3.10) 0.002 
BMPC >10% 1.85 (0.96-3.58) 0.069 
NYHA class III or IV 3.18 (2.10-4.82) <0.001 
Stage IIIb 3.74 (2.45-5.71) <0.001 
Haematologic response* 0.17 (0.10-0.29) <0.001 
Multivariate model based on baseline variables 
dFLC >180mg/L 0.97 (0.47-2.08) 0.968 
BMPC >10% 1.65 (0.80-3.41) 0.181 
Stage IIIb 4.77 (2.38-9.59) <0.001 
Multivariate model including response (3-month landmark) 
dFLC >180mg/L 0.81 (0.33-1.99) 0.815 
BMPC >10% 1.98 (0.78-5.05) 0.154 
Stage IIIb 4.11 (1.74-9.71) 0.001 
Haematologic response 0.25 (0.11-0.53) <0.001 
 
*Three-month landmark. 
Stage IIIb patients are defined by NT-proBNP >8500 ng/L and cTnT >0.035 
ng/mL or cTnI >0.1ng/mL. 
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Second line therapy 
A total of 98 patients required second-line therapy.  The combination of 
lenalidomide and dexamethasone was the most common rescue treatment, 
being used in 20 patients.  Fourteen patients (70%), including 3 refractory to 
CyBorD, responded to lenalidomide, 2 achieved CR, and 5 VGPR. 
Seventeen patients underwent second-line autologous stem cell 
transplantation (ASCT).  Seven of whom were refractory to CyBorD, 2 had 
achieved a PR and 8 VGPR.  Eleven patients (65%) responded to ASCT, 
with 8 CRs (47%) and 1 (6%) VGPR.  Four of the nine patients with cardiac 
involvement achieved cardiac response before transplant.  There was no 
transplant-related mortality. 
Eleven relapsing patients received second-line bortezomib-based 
treatment.  Four had relapsed after achieving at least VGPR with first line 
CyBorD, 2 had achieved PR and 2 were non-responders.  In 3 patients 
VGPR was restored by second-line CyBorD.  The remaining 8 patients had 
an immune modulatory drug (thalidomide in 6 subjects and lenalidomide in 2) 
added to bortezomib and dexamethasone, and 7 of whom responded (2 
CRs, 3 VGPRs, and 2 PRs). 
Fifteen patients received different combinations including 
pomalidomide, thalidomide, bendamustine, and MDex.  In the remaining 
patients second-line therapy was deemed necessary but had not been 
commenced at the time of analysis. 
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Discussion 
The regimens that are more widely used in AL amyloidosis, such as 
autologous stem cell transplant and MDex, tend to share a common fate: 
after early enthusiastic reports of high activity in small series,135, 278  other 
studies, in different settings with higher proportion of patients with advanced 
disease, had worse, quite disappointing results.85, 136  Controlled studies, 
which are difficult to conduct in AL amyloidosis, or large series of unselected 
patients are required to establish the ideal setting for each treatment 
approach.  This has eventually been done with stem cell transplant223  and 
MDex,222  which emphasize the need for a risk-adapted approach to the 
treatment of AL amyloidosis. 
In this study of unselected subjects, overall response rates, 
particularly organ response, were lower than previously reported, and 
comparable to that observed with other regimens, such as MDex,222, 226  
CTD.142, 225  This was due to the inability of CyBorD to reduce early mortality 
in high-risk (stage IIIb) patients.  However, the CyBorD combination proved 
extremely effective in patients without heart involvement (stage I).  In this 
group, 56% of patients achieved at least VGPR, with no mortality recorded, 
indicating that these subjects can achieve prolonged survival if they are 
treated frontline with a safe regimen that is able to induce deep responses 
and closely followed to promptly treat any relapse.  In patients with 
potentially reversible heart involvement (stage II and stage IIIa), CyBorD was 
also very effective, with almost 50% of subjects reaching VGPR or better.  
Importantly, there was no difference in the survival between stage II and 
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stage IIIa subjects (the latter representing almost two thirds of stage III 
patients), identifying an “intermediate-risk” group comprising the “old” stage II 
and stage IIIa patients and indicating the impact of treatment regimens in 
redefining staging systems.  Amongst patients treated with CyBorD, the 
major determinant of survival was the presence of very advanced cardiac 
dysfunction at diagnosis, defined as cardiac stage IIIb, with very high (>8500 
ng/L) NT-proBNP.  In a recent study, the median survival of 62 stage IIIb 
patients treated with risk-adapted MDex was 7 months.222  In the present 
series there was no improvement in survival in this group of patients (median 
7 months).  This is in agreement with the observation that the addition of 
bortezomib to MDex does not improve the outcome of patients with NT-
proBNP >8500 ng/L.226  However, in the present study, stage IIIb subjects 
who survived at least three months from diagnosis had a significant 
improvement in survival if they responded to CyBorD (median exceeding 2 
years).  In the multivariate analysis, stage IIIb and haematologic response 
were independent determinants of prognosis.  This supports the case for 
haematologic response to extend survival by preventing further worsening of 
cardiac damage.  Timing of cardiac responses in stage IIIb remains unclear 
(low in our series at an early assessment time point) and may well be 
delayed in this advanced setting.  This emphasizes the importance of striving 
for a good and rapid response even in this poor-risk group.  
In the present study CyBorD was well tolerated.  However, despite 
rigorous prospectively maintained databases, the retrospective nature of this 
study might result in underestimating treatment toxicity.  Close monitoring 
and careful supportive therapy of patients with NYHA class ≥II is warranted 
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during treatment with CyBorD, and cardiac toxicity may be managed by 
reduction of the dose of bortezomib. 
The present study also allowed some observation on second-line 
therapy after CyBorD.  Transplant eligible candidates who fail to achieve CR 
with frontline CyBorD can be transplanted and to improve the quality of their 
haematologic response.  Also, patients who attain cardiac response but not 
CR with CyBorD may become eligible for autologous stem cell 
transplantation and be transplanted safely.  In agreement with a previous 
observation,279  immune modulatory drugs, particularly lenalidomide, are 
effective rescue agents after CyBorD, and can be combined with 
dexamethasone alone or added to a bortezomib-based regimen, granting a 
haematologic response. 
In conclusion, Mayo stage I patients, without cardiac involvement, 
seem to benefit most from CyBorD and can be considered for autologous 
stem cell transplant if they fail to achieve CR.  For patients with potentially 
reversible cardiac involvement (stages II and IIIa) who cannot be enrolled in 
clinical trials, CyBorD is a useful, highly effective upfront option.  This study 
suggests, bortezomib combinations are not superior to the standard 
regimens in patients with advanced cardiac disease (stage IIIb).  
Nevertheless, these subjects should still receive chemotherapy with close 
monitoring and supportive care, since response can result in substantially 
improved survival in a minority of patients. 
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Chapter 10: General Conclusions 
 
The studies in this thesis reveal a number of novel findings relating to the 
phenotype, investigations, prognosis and management of AL amyloidosis.  
 The proportion of elderly patients seen at the National Amyloidosis 
Centre is steadily increasing, mirroring general longevity and improved 
awareness of AL amyloidosis.  The overall presenting features of the elderly 
patients with systemic AL amyloidosis are comparable to that of the general 
AL population.  Perhaps due to multiple co-morbidities obscuring timely 
accurate diagnosis, a higher proportion of patients present with advanced 
stage disease.  These two factors together means that the treatment of these 
frail elderly patients is challenging.  Often both patients and clinicians may 
choose to avoid treatment altogether in view of the potential treatment 
related toxicity.  This very first study focusing specifically on AL amyloidosis 
among older patients supports the treatment of cautiously selected patients.  
Clinical outcome is affected by patient selection as much as the specifics of 
therapy.  As patients may not remain fit for salvage therapies, the first line 
treatment needs to be carefully chosen and should be highly effective with 
minimal toxicity profile.  Patients without cardiac involvement and with good 
performance status are most likely to benefit.  As previous studies have 
shown, a deep clonal response translates into better outcome and this holds 
true even in the elderly population as those with a VGPR or better had an 
excellent survival and organ responses.   
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 IgD and IgM-related AL amyloidoses are rare subgroups of this 
condition with distinct clinical features and treatment outcomes and in need 
of better understanding.  IgD AL patients have similar phenotype to the 
general AL population but the disease appears to have poorer long term 
prognosis, which, may be due to the relatively higher clonal burden and risk 
of progression to multiple myeloma which is unusual in AL amyloidosis.  The 
condition is extremely rare and attention needs to be given to exclude IgD AL 
amyloidosis in those who appear to have an underlying light chain only 
secreting plasma cell dyscrasia. 
 The largest series of patients with IgM related AL amyloidosis 
reported here confirms that this is a distinct clinical entity.  The key feature is 
that the underlying B cell clone is predominantly a Non-Hodgkin’s lymphoma; 
consequently, perhaps, lymph node involvement is more frequent in this 
subgroup of patients.  Although IgM-AL patients have less frequent cardiac 
involvement, compared to non-IgM AL population, the rate of deep 
haematological response are relatively low in the IgM patients.  This maybe 
attributable to the higher frequency of neuropathic involvement precluding 
the use of effective novel therapeutic agents such as bortezomib and 
thalidomide, that can cause neurotoxicity.  The scarcity of deep response 
may also be due to the use of anti-plasma cell agents in those with an 
underlying lymphoma.  This study emphasises the need for individualised 
therapeutic approach taking into consideration, both the clinical features and 
the underlying clone being targeted in the current era of novel therapies.  
Deep clonal response remains the therapeutic aim.  Notably, this study 
highlighted that dFLC is evaluable in only a small proportion of patients with 
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IgM but these patients have a  significant IgM paraprotein, thus, 
haematological response should possibly be assessed using both the FLC 
and M-protein so to prevent patients mislabelled as non-responders.  In 
addition to the widely used and accepted prognostic criteria, the Mayo 
staging system, liver and neuropathic involvements were found to determine 
survival of IgM-AL patients.  Subsequently, a better risk model combining the 
cardiac biomarkers with liver involvement and presence of neuropathy is 
proposed and requires further validation.  
One of the diagnostic challenges in amyloidosis patients in general is 
the lack of non-invasive diagnostic tools.  This is particularly so in patients 
with amyloid deposits at rare sites such as lymph nodes, lungs, and breast.  
The study on 99mTc-DPD scintigraphy as a tool for identifying and monitoring 
extra-cardiac AL amyloid deposits is the first of its kind. Albeit the study 
utilises small numbers of patients, the outcome of this study gives scopes for 
the use of the radiolabelled bisphosphonate bone tracers as a non-invasive 
aid to the confirmation of soft tissue AL amyloid deposits. It may also be 
useful for serial imaging to monitor response to therapy and disease 
progression of soft tissue amyloidosis.  This imaging modality is most likely 
to benefit patients with IgM-related AL amyloidosis who have a relatively high 
frequency of lymph node involvement; treatment response or progression in 
these sites can often become difficult - particularly in distinguishing amyloid 
from the underlying lymphoma in the majority of these patients.   
 Multicolour flow cytometry is valuable in patients with AL amyloidosis.  
It is useful in determining the proportion of normal and aberrant plasma cells 
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in a condition that is known to have a low tumour burden.  The presence of 
normal plasma cells as determined by MFC has a favourable outcome 
despite the overall plasma cell burden estimated on bone marrow trephines.  
The exact mechanism for this positive outcome is not clear but it is 
noteworthy, that the proportion of normal plasma cells negatively correlated 
with the presence of cardiac involvement and dFLC – both are well known 
determinant of survival outcomes in AL patients.  Therefore, it maybe that 
patients with low levels of normal plasma cells have a predisposition to 
developing cardiac amyloidosis.  The outcome of the multicolour flow 
cytometry study provides an argument for including this technique in the 
regular diagnostic work-up of all patients with AL amyloidosis.  This study did 
not find the overall bone marrow plasma cell burden determined on bone 
marrow trephine, to significantly affect survival. 
Another possible prognostic marker arising from this thesis is the 
severity of immunoparesis as determined by heavy light chain measurement.  
This study showed that the majority of AL patients have some degree of 
immunoparesis that is not demonstrable by conventional methods.  The 
study also highlighted that the prognostic markers at diagnosis do not 
necessarily govern the long term outcome in AL patients.  Severe degrees of 
immunoparesis were associated with poorer outcome following treatment, in 
particular, severe immunoparesis significantly impacted the survival of 
patients with cardiac amyloidosis following treatment; suggesting that the 
aggressiveness of the plasma cell clone, determines the long term outcome 
in AL patients.  Therefore, the measurement of degree of 
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immunosuppression by HLC method at presentation may help risk stratify 
patients and guide choice of therapy and management strategy. 
The combination of cyclophosphamide, bortezomib and 
dexamethasone (CyBorD) is currently the most commonly prescribed 
regimens in the UK for AL amyloidosis patients.  As a novel agent, 
bortezomib does provide high rates of hematologic response but this does 
not overcome the poor prognosis of advanced cardiac amyloidosis.  The 
study on the use of bortezomib as first line therapy in AL patients confirmed 
the reasonably high levels of haematological response and subsequent 
much desired organ responses that are possible with this regimen.  The 
study did however, highlight that it is those without cardiac involvement who 
most benefited from this regimen.  There was also evidence that CyBorD can 
rescue subjects with reversible heart damage.  Conversely, cardiac stage III 
patients with a high NT-proBNP had lower response rates translating into 
poorer median survival.  Nevertheless, hematologic response also improved 
survival in these subjects, emphasizing the importance of striving for a good 
response even in those with advanced cardiac disease.  The high clonal 
response and excellent outcome in early-stage AL amyloidosis with CyBorD 
confirm its place as a regimen of choice for this group. 
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Future studies 
 
 
In the study of elderly patients, achieving a response with first line regimen 
was particularly important as outcomes for non-responders were similar to 
those not treated.  Therefore, prospective trials with lower toxicity outpatient 
treatment regimens are needed.  Prospective studies in older patients with 
novel agents with a better toxicity profile and ease of administration, such as 
oral proteasome inhibitors, may allow a greater proportion of patients to 
benefit from treatment.   
 As prospective studies are challenging due to the rarity of IgM-AL and 
IgD-related amyloidosis, international tissue and data registry would help to 
broaden the understanding of these rare subtypes.  The revised staging 
system proposed in the IgM study requires further validation.  Moreover, the 
roles of novel targeted therapies need to be further explored in this condition 
with predominantly underlying non-Hodgkin’s lymphoma.  
 The findings of chapter six on the role of 99mTc-DPD scintigraphy 
requires further validation in a large group of patients with soft tissue 
amyloidosis, in particular, lymph nodes and amyloid deposits at sites such as 
the lung and breast which are rare.  Moreover, the benefits of serial 99mTc-
DPD scintigraphy also needs to be further explored in AL patients with soft 
tissue amyloidosis.  
 Further studies are required to explore the role of MFC and 
immunoparesis as determined by HLC, in existing prognostic models.  The 
exact mechanism by which the proportion of ‘normal’ PCs impact survival 
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also needs to be further evaluated.  The pathophysiological significance of 
the findings in the MFC study and the HLC study needs further exploration.  
Another study of particular interest would be the significance of minimal 
residual disease as determined by MFC and immunoparesis as determined 
by HLC method post-treatment. 
 Despite the availability of several novel agents and wider therapeutic 
options, there is a general lack of head-to-head evaluation of the treatments 
in AL amyloidosis and as such most of our knowledge comes from single-
arm trials or retrospective studies such as that reported in chapter nine.  
Thus, large prospective studies are needed to identify patients who benefit 
most from novel agents such as bortezomib in order to guide management 
strategy. 
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